Select Medical (SEM) 10-K 25 Feb 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 01, 2014	Jun. 28, 2013
Document and Entity Information	'	'	'
Entity Registrant Name	'SELECT MEDICAL HOLDINGS CORP	'	'
Entity Central Index Key	'0001320414	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Public Float	'	'	$518,721,725
Entity Common Stock, Shares Outstanding	'	140,286,867	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
In Thousands, unless otherwise specified
Current Assets:	'	'	'	'
Cash and cash equivalents	$4,319	$40,144	$12,043	$4,365
Accounts receivable, net of allowance for doubtful accounts of $41,854 and $40,815 in 2012 and 2013, respectively	391,319	359,929	'	'
Current deferred tax asset	17,624	17,877	'	'
Prepaid income taxes	'	3,895	'	'
Other current assets	41,140	31,818	'	'
Total Current Assets	454,402	453,663	'	'
Property and equipment, net	509,102	501,552	'	'
Goodwill	1,642,633	1,640,534	1,631,716	'
Other identifiable intangibles	71,907	71,745	'	'
Other assets	139,578	93,867	'	'
Total Assets	2,817,622	2,761,361	2,772,147	'
Current Liabilities:	'	'	'	'
Bank overdrafts	12,506	17,836	'	'
Current portion of long-term debt and notes payable	17,565	11,646	'	'
Accounts payable	88,285	89,547	'	'
Accrued payroll	90,011	88,586	'	'
Accrued vacation	59,730	55,714	'	'
Accrued interest	12,297	22,016	'	'
Accrued other	90,471	86,843	'	'
Income taxes payable	622	'	'	'
Due to third party payors	37	1,078	'	'
Total Current Liabilities	371,524	373,266	'	'
Long-term debt, net of current portion	1,427,710	1,458,597	'	'
Non-current deferred tax liability	96,287	89,510	'	'
Other non-current liabilities	91,875	83,699	'	'
Total Liabilities	1,987,396	2,005,072	'	'
Redeemable non-controlling interests	11,584	10,811	'	'
Stockholders' Equity:	'	'	'	'
Common stock	140	141	'	'
Capital in excess of par	474,729	473,697	'	'
Retained earnings (accumulated deficit)	311,365	243,210	'	'
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	786,234	717,048	'	'
Non-controlling interests	32,408	28,430	'	'
Total Equity	818,642	745,478	846,338	807,176
Total Liabilities and Equity	2,817,622	2,761,361	'	'
Select	'	'	'	'
Current Assets:	'	'	'	'
Cash and cash equivalents	4,319	40,144	12,043	4,365
Accounts receivable, net of allowance for doubtful accounts of $41,854 and $40,815 in 2012 and 2013, respectively	391,319	359,929	'	'
Current deferred tax asset	17,624	17,877	'	'
Prepaid income taxes	'	3,895	'	'
Other current assets	41,140	31,818	'	'
Total Current Assets	454,402	453,663	'	'
Property and equipment, net	509,102	501,552	'	'
Goodwill	1,642,633	1,640,534	'	'
Other identifiable intangibles	71,907	71,745	'	'
Other assets	139,578	92,819	'	'
Total Assets	2,817,622	2,760,313	2,770,738	'
Current Liabilities:	'	'	'	'
Bank overdrafts	12,506	17,836	'	'
Current portion of long-term debt and notes payable	17,565	11,646	'	'
Accounts payable	88,285	89,547	'	'
Accrued payroll	90,011	88,586	'	'
Accrued vacation	59,730	55,714	'	'
Accrued interest	12,297	18,759	'	'
Accrued other	90,471	92,083	'	'
Income taxes payable	622	'	'	'
Due to third party payors	37	1,078	'	'
Total Current Liabilities	371,524	375,249	'	'
Long-term debt, net of current portion	1,427,710	1,291,297	'	'
Non-current deferred tax liability	96,287	89,510	'	'
Other non-current liabilities	91,875	83,699	'	'
Total Liabilities	1,987,396	1,839,755	'	'
Redeemable non-controlling interests	11,584	10,811	'	'
Stockholders' Equity:	'	'	'	'
Common stock	0	0	'	'
Capital in excess of par	869,576	859,839	'	'
Retained earnings (accumulated deficit)	-83,342	21,478	'	'
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	786,234	881,317	'	'
Non-controlling interests	32,408	28,430	'	'
Total Equity	818,642	909,747	1,010,105	1,107,890
Total Liabilities and Equity	$2,817,622	$2,760,313	'	'

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Accounts receivable, allowance for doubtful accounts (in dollars)	$40,815	$41,854
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	700,000,000	700,000,000
Common stock, shares issued	140,260,968	140,589,256
Common stock, shares outstanding	140,260,968	140,589,256
Select	'	'
Accounts receivable, allowance for doubtful accounts (in dollars)	$40,815	$41,854
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares issued	100	100
Common stock, shares outstanding	100	100

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Income (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net operating revenues	$746,175	$722,845	$756,673	$749,955	$741,086	$713,669	$750,193	$744,021	$2,975,648	$2,948,969	$2,804,507
Costs and expenses:	'	'	'	'	'	'	'	'	'	'	'
Cost of services	'	'	'	'	'	'	'	'	2,495,476	2,443,550	2,308,570
General and administrative	'	'	'	'	'	'	'	'	76,921	66,194	62,354
Bad debt expense	'	'	'	'	'	'	'	'	37,423	39,055	51,347
Depreciation and amortization	'	'	'	'	'	'	'	'	64,392	63,311	71,517
Total costs and expenses	'	'	'	'	'	'	'	'	2,674,212	2,612,110	2,493,788
Income from operations	68,244	62,399	88,263	82,530	80,923	70,819	93,513	91,604	301,436	336,859	310,719
Other income and expense:	'	'	'	'	'	'	'	'	'	'	'
Loss on early retirement of debt	'	'	'	'	'	'	'	'	-18,747	-6,064	-31,018
Equity in earnings of unconsolidated subsidiaries	'	'	'	'	'	'	'	'	2,476	7,705	2,923
Interest income	'	'	'	'	'	'	'	'	'	'	322
Interest expense	'	'	'	'	'	'	'	'	-87,364	-94,950	-99,216
Income before income taxes	'	'	'	'	'	'	'	'	197,801	243,550	183,730
Income tax expense	'	'	'	'	'	'	'	'	74,792	89,657	70,968
Net income	'	'	'	'	'	'	'	'	123,009	153,893	112,762
Less: Net income attributable to non-controlling interests	'	'	'	'	'	'	'	'	8,619	5,663	4,916
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	28,920	23,272	27,780	34,418	39,406	24,110	43,172	41,542	114,390	148,230	107,846
Income per common share:	'	'	'	'	'	'	'	'	'	'	'
Basic (in dollars per share)	$0.21	$0.17	$0.20	$0.25	$0.28	$0.17	$0.31	$0.29	$0.82	$1.05	$0.71
Diluted (in dollars per share)	$0.21	$0.17	$0.20	$0.24	$0.28	$0.17	$0.31	$0.29	$0.82	$1.05	$0.71
Select	'	'	'	'	'	'	'	'	'	'	'
Net operating revenues	746,175	722,845	756,673	749,955	741,086	713,669	750,193	744,021	2,975,648	2,948,969	2,804,507
Costs and expenses:	'	'	'	'	'	'	'	'	'	'	'
Cost of services	'	'	'	'	'	'	'	'	2,495,476	2,443,550	2,308,570
General and administrative	'	'	'	'	'	'	'	'	76,921	66,194	62,354
Bad debt expense	'	'	'	'	'	'	'	'	37,423	39,055	51,347
Depreciation and amortization	'	'	'	'	'	'	'	'	64,392	63,311	71,517
Total costs and expenses	'	'	'	'	'	'	'	'	2,674,212	2,612,110	2,493,788
Income from operations	68,244	62,399	88,263	82,530	80,923	70,819	93,513	91,604	301,436	336,859	310,719
Other income and expense:	'	'	'	'	'	'	'	'	'	'	'
Loss on early retirement of debt	'	'	'	'	'	'	'	'	-17,788	-6,064	-20,385
Equity in earnings of unconsolidated subsidiaries	'	'	'	'	'	'	'	'	2,476	7,705	2,923
Interest income	'	'	'	'	'	'	'	'	'	'	322
Interest expense	'	'	'	'	'	'	'	'	-84,954	-83,759	-81,232
Income before income taxes	'	'	'	'	'	'	'	'	201,170	254,741	212,347
Income tax expense	'	'	'	'	'	'	'	'	75,971	93,574	80,984
Net income	'	'	'	'	'	'	'	'	125,199	161,167	131,363
Less: Net income attributable to non-controlling interests	'	'	'	'	'	'	'	'	8,619	5,663	4,916
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$28,920	$23,272	$27,780	$36,608	$41,254	$25,953	$45,018	$43,279	$116,580	$155,504	$126,447

Consolidated_Statement_of_Chan

Consolidated Statement of Changes in Equity and Income (USD $)

Total

Select

Comprehensive Income

Comprehensive Income

Common Stock

Common Stock

Capital in Excess of Par

Capital in Excess of Par

Retained Earnings (Accumulated Deficit)

Retained Earnings (Accumulated Deficit)

Non-controlling Interests

Non-controlling Interests

In Thousands, except Share data, unless otherwise specified

Select

Select

Select

Select

Select

Balance at Dec. 31, 2010

$807,176

$1,107,890

'

'

$155

$0

$535,628

$834,894

$245,164

$246,767

$26,229

$26,229

Balance (in shares) at Dec. 31, 2010

'

'

'

'

154,519,000

0

'

'

'

'

'

'

Increase (Decrease) in Stockholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

Net income

111,197

129,798

111,197

129,798

'

'

'

'

107,846

126,447

3,351

3,351

Net income - attributable to redeemable non-controlling interests

'

'

1,565

1,565

'

'

'

'

'

'

'

'

Total comprehensive income

111,197

129,798

112,762

131,363

'

'

'

'

'

'

'

'

Issuance and vesting of restricted stock

2,527

'

'

'

0

'

2,527

'

'

'

'

'

Issuance and vesting of restricted stock (in shares)

565,000

'

'

'

565,000

'

'

'

'

'

'

'

Repurchase of common shares

-72,804

'

'

'

-10

'

-45,733

'

-27,061

'

'

'

Repurchase of common shares (in shares)

'

'

'

'

-9,870,000

'

'

'

'

'

'

'

Stock option expense

1,198

'

'

'

'

'

1,198

'

'

'

'

'

Exercise of stock options

208

'

'

'

0

'

208

'

'

'

'

'

Exercise of stock options (in shares)

53,932

'

'

'

54,000

'

'

'

'

'

'

'

Federal tax benefit of losses contributed by Holdings

'

10,016

'

'

'

'

'

10,016

'

'

'

'

Additional investment by Holdings

'

208

'

'

'

'

'

208

'

'

'

'

Net change in dividends payable to Holdings

'

7,360

'

'

'

'

'

'

'

7,360

'

'

Dividends declared and paid

'

-245,729

'

'

'

'

'

'

'

-245,729

'

'

Contribution related to restricted stock awards and stock option issuances by Holdings

'

3,726

'

'

'

'

'

3,726

'

'

'

'

Distributions to non-controlling interests

-2,688

-2,688

'

'

'

'

'

'

'

'

-2,688

-2,688

Other

-476

-476

'

'

'

'

'

'

-243

-243

-233

-233

Balance at Dec. 31, 2011

846,338

1,010,105

'

'

145

0

493,828

848,844

325,706

134,602

26,659

26,659

Balance (in shares) at Dec. 31, 2011

'

'

'

'

145,268,000

0

'

'

'

'

'

'

Increase (Decrease) in Stockholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

Net income

151,948

159,222

151,948

159,222

'

'

'

'

148,230

155,504

3,718

3,718

Net income - attributable to redeemable non-controlling interests

'

'

1,945

1,945

'

'

'

'

'

'

'

'

Total comprehensive income

151,948

159,222

153,893

161,167

'

'

'

'

'

'

'

'

Issuance and vesting of restricted stock

4,472

'

'

'

'

'

4,472

'

'

'

'

'

Issuance and vesting of restricted stock (in shares)

761,500

'

'

'

746,000

'

'

'

'

'

'

'

Repurchase of common shares

-46,902

'

'

'

-5

'

-27,208

'

-19,689

'

'

'

Repurchase of common shares (in shares)

'

'

'

'

-5,726,000

'

'

'

'

'

'

'

Stock option expense

1,205

'

'

'

'

'

1,205

'

'

'

'

'

Exercise of stock options

1,817

'

'

'

1

'

1,816

'

'

'

'

'

Exercise of stock options (in shares)

301,208

'

'

'

301,000

'

'

'

'

'

'

'

Federal tax benefit of losses contributed by Holdings

'

3,917

'

'

'

'

'

3,917

'

'

'

'

Additional investment by Holdings

'

1,817

'

'

'

'

'

1,817

'

'

'

'

Dividends declared and paid

-210,888

-268,479

'

'

'

'

'

'

-210,888

-268,479

'

'

Contribution related to restricted stock awards and stock option issuances by Holdings

'

5,677

'

'

'

'

'

5,677

'

'

'

'

Distributions to non-controlling interests

-1,884

-1,884

'

'

'

'

'

'

'

'

-1,884

-1,884

Purchase of non-controlling interests

-479

-479

'

'

'

'

-416

-416

'

'

-63

-63

Other

-149

-149

'

'

'

'

'

'

-149

-149

'

'

Balance at Dec. 31, 2012

745,478

909,747

'

'

141

0

473,697

859,839

243,210

21,478

28,430

28,430

Balance (in shares) at Dec. 31, 2012

'

'

'

'

140,589,000

0

'

'

'

'

'

'

Increase (Decrease) in Stockholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

Net income

119,946

122,136

119,946

122,136

'

'

'

'

114,390

116,580

5,556

5,556

Net income - attributable to redeemable non-controlling interests

'

'

3,063

3,063

'

'

'

'

'

'

'

'

Total comprehensive income

'

122,136

123,009

125,199

'

'

'

'

'

'

'

'

Issuance and vesting of restricted stock

6,220

'

'

'

'

'

6,220

'

'

'

'

'

Issuance and vesting of restricted stock (in shares)

952,500

'

'

'

953,000

'

'

'

'

'

'

'

Repurchase of common shares

-11,781

'

'

'

-1

'

-7,524

'

-4,256

'

'

'

Repurchase of common shares (in shares)

'

'

'

'

-1,447,000

'

'

'

'

'

'

'

Stock option expense

811

'

'

'

'

'

811

'

'

'

'

'

Exercise of stock options

1,525

'

'

'

'

'

1,525

'

'

'

'

'

Exercise of stock options (in shares)

166,600

'

'

'

166,000

'

'

'

'

'

'

'

Federal tax benefit of losses contributed by Holdings

'

1,179

'

'

'

'

'

1,179

'

'

'

'

Additional investment by Holdings

'

1,525

'

'

'

'

'

1,525

'

'

'

'

Net change in dividends payable to Holdings

'

5,239

'

'

'

'

'

'

'

5,239

'

'

Dividends declared and paid

-41,961

-226,621

'

'

'

'

'

'

-41,961

-226,621

'

'

Contribution related to restricted stock awards and stock option issuances by Holdings

'

7,033

'

'

'

'

'

7,033

'

'

'

'

Distributions to non-controlling interests

-1,839

-1,839

'

'

'

'

'

'

'

'

-1,839

-1,839

Purchase of non-controlling interests

261

261

'

'

'

'

'

'

'

'

261

261

Other

-18

-18

'

'

'

'

'

'

-18

-18

'

'

Balance at Dec. 31, 2013

$818,642

$818,642

'

'

$140

$0

$474,729

$869,576

$311,365

($83,342)

$32,408

$32,408

Balance (in shares) at Dec. 31, 2013

'

'

'

'

140,261,000

0

'

'

'

'

'

'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Operating activities	'	'	'
Net income	$123,009	$153,893	$112,762
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Depreciation and amortization	64,392	63,311	71,517
Provision for bad debts	37,423	39,055	51,347
Equity in earnings of unconsolidated subsidiaries	-2,476	-7,705	-2,923
Loss on early retirement of debt	18,747	6,064	31,018
Gain from disposal or sale of assets	-581	-5,906	-4,966
Non-cash stock compensation expense	7,033	5,677	3,725
Amortization of debt discount and issuance costs	8,433	7,566	8,007
Deferred income taxes	7,032	7,909	35,305
Changes in operating assets and liabilities, net of effects from acquisition of businesses:	'	'	'
Accounts receivable	-67,145	15,158	-111,126
Other current assets	-8,167	-1,607	-1,201
Other assets	-3,484	5,862	-2,081
Accounts payable	-1,283	-6,117	20,629
Due to third-party payors	-1,041	-4,448	227
Accrued expenses	10,631	19,970	4,888
Net cash provided by operating activities	192,523	298,682	217,128
Investing activities	'	'	'
Purchases of property and equipment	-73,660	-68,185	-46,016
Investment in businesses, net of distributions	-34,893	-14,689	-15,699
Acquisition of businesses, net of cash acquired	-1,665	-6,043	-899
Proceeds from sale of assets	2,912	16,511	7,879
Net cash used in investing activities	-107,306	-72,406	-54,735
Financing activities	'	'	'
Borrowings on revolving credit facilities	690,000	495,000	735,000
Payments on revolving credit facilities	-800,000	-405,000	-720,000
Borrowings on 2011 credit facility term loans, net of discount	298,500	266,750	841,500
Payments on 2011 credit facility term loans	-596,720	-9,875	-4,250
Issuance of 6.375% senior subordinated notes	600,000	'	'
Payments on 2005 credit facility term loans, net of premium	'	'	-484,633
Repurchase of 10% senior subordinated notes	'	'	-150,000
Repurchase of senior floating rate notes	-167,300	'	'
Repurchase of 7 5/8% senior subordinated notes, net of premiums	-70,000	-278,495	-273,941
Borrowings of other debt	15,310	8,281	7,055
Principal payments on other debt	-10,834	-10,295	-7,499
Debt issuance costs	-18,914	-6,527	-18,556
Proceeds from (repayment of) bank overdrafts	-5,330	1,227	-2,183
Dividends paid	-41,961	-210,888	'
Repurchase of common stock	-11,781	-46,902	-72,804
Proceeds from issuance of common stock	1,525	1,817	208
Distributions to non-controlling interests	-3,537	-3,268	-4,612
Net cash used in financing activities	-121,042	-198,175	-154,715
Net increase (decrease) in cash and cash equivalents	-35,825	28,101	7,678
Cash and cash equivalents at beginning of period	40,144	12,043	4,365
Cash and cash equivalents at end of period	4,319	40,144	12,043
Supplemental Cash Flow Information	'	'	'
Cash paid for interest	89,061	80,722	107,488
Cash paid for taxes	64,963	77,614	39,000
Select	'	'	'
Operating activities	'	'	'
Net income	125,199	161,167	131,363
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Depreciation and amortization	64,392	63,311	71,517
Provision for bad debts	37,423	39,055	51,347
Equity in earnings of unconsolidated subsidiaries	-2,476	-7,705	-2,923
Loss on early retirement of debt	17,788	6,064	20,385
Gain from disposal or sale of assets	-581	-5,906	-4,966
Non-cash stock compensation expense	7,033	5,677	3,725
Amortization of debt discount and issuance costs	8,344	7,190	6,700
Deferred income taxes	7,032	7,909	35,305
Changes in operating assets and liabilities, net of effects from acquisition of businesses:	'	'	'
Accounts receivable	-67,145	15,158	-111,126
Other current assets	-8,167	-1,607	-1,201
Other assets	-3,484	5,877	-2,068
Accounts payable	-1,283	-6,117	20,629
Due to third-party payors	-1,041	-4,448	227
Accrued expenses	15,068	23,746	21,139
Net cash provided by operating activities	198,102	309,371	240,053
Investing activities	'	'	'
Purchases of property and equipment	-73,660	-68,185	-46,016
Investment in businesses, net of distributions	-34,893	-14,689	-15,699
Acquisition of businesses, net of cash acquired	-1,665	-6,043	-899
Proceeds from sale of assets	2,912	16,511	7,879
Net cash used in investing activities	-107,306	-72,406	-54,735
Financing activities	'	'	'
Borrowings on revolving credit facilities	690,000	495,000	735,000
Payments on revolving credit facilities	-800,000	-405,000	-720,000
Borrowings on 2011 credit facility term loans, net of discount	298,500	266,750	841,500
Payments on 2011 credit facility term loans	-596,720	-9,875	-4,250
Issuance of 6.375% senior subordinated notes	600,000	'	'
Payments on 2005 credit facility term loans, net of premium	'	'	-484,633
Repurchase of 7 5/8% senior subordinated notes, net of premiums	-70,000	-278,495	-273,941
Borrowings of other debt	15,310	8,281	7,055
Principal payments on other debt	-10,834	-10,295	-7,499
Debt issuance costs	-18,914	-6,527	-18,556
Proceeds from (repayment of) bank overdrafts	-5,330	1,227	-2,183
Equity investment by Holdings	1,525	1,817	208
Dividends paid	-226,621	-268,479	-245,729
Distributions to non-controlling interests	-3,537	-3,268	-4,612
Net cash used in financing activities	-126,621	-208,864	-177,640
Net increase (decrease) in cash and cash equivalents	-35,825	28,101	7,678
Cash and cash equivalents at beginning of period	40,144	12,043	4,365
Cash and cash equivalents at end of period	4,319	40,144	12,043
Supplemental Cash Flow Information	'	'	'
Cash paid for interest	83,482	70,047	84,575
Cash paid for taxes	$64,963	$77,614	$39,000

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
6.375% senior subordinated notes	'	'	'
Long-term debt and notes payable	'	'	'
Interest rate of debt (as a percent)	6.38%	'	'
10% senior subordinated notes	'	'	'
Long-term debt and notes payable	'	'	'
Interest rate of debt (as a percent)	10.00%	10.00%	10.00%
7 5/8% senior subordinated notes	'	'	'
Long-term debt and notes payable	'	'	'
Interest rate of debt (as a percent)	'	7.63%	7.63%

Organization_and_Significant_A

Organization and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Organization and Significant Accounting Policies	'
Organization and Significant Accounting Policies	'
	1.     Organization and Significant Accounting Policies
	Business Description
	Select Medical Corporation ("Select") was formed in December 1996 and commenced operations during February 1997 upon the completion of its first acquisition. Select Medical Holdings Corporation ("Holdings") was formed in October 2004 for the purpose of affecting a leveraged buyout of Select, which was a publicly traded entity. On February 24, 2005, Select merged with a subsidiary of Holdings, which resulted in Select becoming a wholly-owned subsidiary of Holdings (the "Merger"). On September 30, 2009 Holdings completed its initial public offering of common stock. Generally accepted accounting principles ("GAAP") require that any amounts recorded or incurred (such as goodwill and compensation expense) by the parent as a result of the Merger or for the benefit of the subsidiary be "pushed down" and recorded in Select's consolidated financial statements. Holdings and Select and their subsidiaries are collectively referred to as the "Company." The consolidated financial statements of Holdings include the accounts of its wholly-owned subsidiary Select. Holdings conducts substantially all of its business through Select and its subsidiaries.
	The Company provides long term acute care hospital services and inpatient acute rehabilitative hospital care through its specialty hospital segment and provides physical, occupational and speech rehabilitation services through its outpatient rehabilitation segment. The Company's specialty hospital segment consists of hospitals designed to serve the needs of long term stay acute patients and hospitals designed to serve patients that require intensive medical rehabilitation care. Patients are typically admitted to the Company's specialty hospitals from general acute care hospitals. These patients have specialized needs, and serious and often complex medical conditions such as respiratory failure, neuromuscular disorders, traumatic brain and spinal cord injuries, strokes, non-healing wounds, cardiac disorders, renal disorders and cancer. The Company's outpatient rehabilitation segment consists of clinics and contract services that provide physical, occupational and speech rehabilitation services. The Company's outpatient rehabilitation patients are typically diagnosed with musculoskeletal impairments that restrict their ability to perform normal activities of daily living. The Company operated 119, 122 and 123 specialty hospitals at December 31, 2011, 2012 and 2013, respectively. At December 31, 2011, 2012 and 2013, the Company operated 954, 979, and 1,006 outpatient clinics, respectively. At December 31, 2011, 2012 and 2013, the Company had facilities in the District of Columbia and 39 states.
	Reclassifications
	Certain reclassifications have been made to prior-year amounts in order to conform to the current-year presentation.
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company, its majority owned subsidiaries, limited liability companies and limited partnerships the Company and its subsidiaries control through ownership of general and limited partnership or membership interests. All significant intercompany balances and transactions are eliminated in consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at cost which approximates market value.
	Accounts Receivable and Allowance for Doubtful Accounts
	The Company reports accounts receivable at estimated net realizable values. Substantially all of the Company's accounts receivable are related to providing healthcare services to patients whose costs are primarily paid by federal and state governmental authorities, managed care health plans, commercial insurance companies and workers' compensation programs. Collection of these accounts receivable is the Company's primary source of cash and is critical to its operating performance. The Company's primary collection risks relate to non-governmental payors who insure these patients and deductibles, co-payments and amounts owed by the patient. Deductibles, co-payments and amounts owed by the patient are an immaterial portion of the Company's net accounts receivable balance and accounted for approximately 0.2% and 0.3% of the net accounts receivable balance before doubtful accounts at December 31, 2012 and 2013, respectively. The Company's general policy is to verify insurance coverage prior to the date of admission for a patient admitted to the Company's hospitals or in the case of the Company's outpatient rehabilitation clinics, the Company verifies insurance coverage prior to their first therapy visit. The Company's estimate for the allowance for doubtful accounts is calculated by providing a reserve allowance based upon the age of an account balance. Generally the Company has reserved as uncollectible all governmental accounts over 365 days and non-governmental accounts over 180 days from discharge. This method is monitored based on historical cash collections experience. Collections are impacted by the effectiveness of the Company's collection efforts with non-governmental payors and regulatory or administrative disruptions with the fiscal intermediaries that pay the Company's governmental receivables.
	The Company has historically collected substantially all of its third-party insured receivables (net of contractual allowances) which include receivables from governmental agencies. The Company reviews its overall reserve adequacy by monitoring historical cash collections as a percentage of net revenue less the provision for bad debts.
	Uncollected accounts are written off the balance sheet when they are turned over to an outside collection agency, or when management determines that the balance is uncollectible, whichever occurs first.
	Property and Equipment
	Property and equipment are stated at cost net of accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets or the term of the lease, as appropriate. The general range of useful lives is as follows:
	Leasehold improvements	5 – 15 years
	Furniture and equipment	3 – 20 years
	Buildings	40 years
	Building Improvements	5 – 25 years
	Land Improvements	2 – 25 years
	The Company reviews the realizability of long-lived assets whenever events or circumstances occur which indicate recorded costs may not be recoverable. Gains or losses related to the retirement or disposal of property and equipment are reported as a component of income from operations.
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash balances and trade receivables. The Company invests its excess cash with large financial institutions. The Company grants unsecured credit to its patients, most of who reside in the service area of the Company's facilities and are insured under third-party payor agreements. Because of the geographic diversity of the Company's facilities and non-governmental third-party payors, Medicare represents the Company's only significant concentration of credit risk.
	Income Taxes
	Deferred tax assets and liabilities are recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. As part of the process of preparing its consolidated financial statements, the Company estimates income taxes based on its actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for book and tax purposes. The Company also recognizes as deferred tax assets the future tax benefits from net operating loss carry forwards. The Company evaluates the realizability of these deferred tax assets by assessing their valuation allowances and by adjusting the amount of such allowances, if necessary. Among the factors used to assess the likelihood of realization are projections of future taxable income streams, the expected timing of the reversals of existing temporary differences, and the impact of tax planning strategies that could be implemented to avoid the potential loss of future tax benefits.
	Reserves for uncertain tax positions are established for exposure items related to various federal and state tax matters. Income tax reserves are recorded when an exposure is identified and when, in the opinion of management, it is more likely than not that a tax position will not be sustained and the amount of the liability can be estimated.
	Intangible Assets
	Goodwill and certain other indefinite-lived intangible assets are not amortized, but instead are subject to periodic impairment evaluations. In performing the quantitative periodic impairment tests, the fair value of the reporting unit is compared to its carrying value, including goodwill and other intangible assets. If the carrying value exceeds the fair value, an impairment condition exists, which results in an impairment loss equal to the excess carrying value.
	To determine the fair value of its reporting units, the Company uses a discounted cash flow approach. Included in this analysis are assumptions regarding revenue growth rate, future Adjusted EBITDA margin estimates, future general and administrative expense rates and the industry's weighted average cost of capital and industry specific market comparable Adjusted EBITDA multiples. The Company also must estimate residual values at the end of the forecast period and future capital expenditure requirements. Each of these assumptions requires the Company to use its knowledge of (1) its industry, (2) its recent transactions, and (3) reasonable performance expectations for its operations. If any one of the above assumptions changes or fails to materialize, the resulting decline in the Company's estimated fair value could result in a material impairment charge to the goodwill associated with any one of the reporting units.
	Impairment tests are required to be conducted at least annually, or when events or conditions occur that might suggest a possible impairment. These events or conditions include, but are not limited to, a significant adverse change in the business environment, regulatory environment or legal factors; a current period operating or cash flow loss combined with a history of such losses or a projection of continuing losses; or a sale or disposition of a significant portion of a reporting unit. The occurrence of one of these events or conditions could significantly impact an impairment assessment, necessitating an impairment charge. For purposes of goodwill impairment assessment, the Company has defined its reporting units as specialty hospitals, outpatient rehabilitation clinics and contract therapy with goodwill having been allocated among reporting units based on the relative fair value of those divisions when the Merger occurred in 2005 and based on subsequent acquisitions and dispositions. The Company's most recent impairment assessment was completed during the fourth quarter of 2013 utilizing financial information as of October 1, 2013 and indicated that there was no impairment with respect to goodwill or other recorded intangible assets.
	Identifiable assets and liabilities acquired in connection with business combinations accounted for under the purchase method are recorded at their respective fair values. Deferred income taxes have been recorded to the extent of differences between the fair value and the tax basis of the assets acquired and liabilities assumed. Company management has allocated the intangible assets between identifiable intangibles and goodwill. At December 31, 2013, intangible assets other than goodwill consist of the values assigned to trademarks, certificates of need and accreditations. Management believes that the estimated useful lives established are reasonable based on the economic factors applicable to each of the intangible assets.
	The approximate useful life of each class of intangible assets is as follows:
	Trademarks	Indefinite
	Certificates of need	Indefinite
	Accreditations	Indefinite
	The Company reviews the realizability of intangible assets whenever events or circumstances occur which indicate recorded amounts may not be recoverable.
	If the expected future cash flows (undiscounted) are less than the carrying amount of such assets, the Company recognizes an impairment loss for the difference between the carrying amount of the assets and their estimated fair value.
	Due to Third-Party Payors
	Due to third-party payors represents the difference between amounts received under interim payment plans from Medicare and Medicaid for services rendered and amounts estimated to be reimbursed by those third-party payors upon settlement of cost reports.
	Insurance Risk Programs
	Under a number of the Company's insurance programs, which include the Company's employee health insurance program, its workers' compensation, professional malpractice liability insurance programs and certain components under its property and casualty insurance program, the Company is liable for a portion of its losses. In these situations the Company accrues for its losses under an occurrence-based approach whereby the Company estimates the losses that will be incurred in a respective accounting period and accrues that estimated liability. Where the Company has substantial exposure, actuarial methods are utilized in estimating the losses. In cases where the Company has minimal exposure, losses are estimated by analyzing historical trends. These programs are monitored quarterly and estimates are revised as necessary to take into account additional information. Provisions for losses for professional liability risks retained by the Company at December 31, 2012 and 2013 have been discounted at 3%. At December 31, 2012 and 2013, respectively, the Company had recorded a liability of $92.5 million and $103.4 million related to these programs. If the Company did not discount the provisions for losses for professional liability risks, the aggregate liability for all of the insurance risk programs would be approximately $95.6 million and $106.8 million at December 31, 2012 and 2013, respectively.
	Equity Method Investments
	Investments in equity method investees are accounted for using the equity method based upon the level of ownership and/or the Company's ability to exercise significant influence over the operating and financial policies of the investee. Investments of this nature are recorded at original cost and adjusted periodically to recognize the Company's proportionate share of the investees' net income or losses after the date of investment. When net losses from an investment accounted for under the equity method exceeds its carrying amount, the investment balance is reduced to zero. The Company resumes accounting for the investment under the equity method if the entity subsequently reports net income and the Company's share of that net income exceeds the share of the net losses not recognized during the period the equity method was suspended. Investments are written down only when there is clear evidence that a decline in value that is other than temporary has occurred. The Company evaluates its investments in companies accounted for using the equity method for impairment when there is evidence or indicators that a decrease in value may be other than temporary.
	Non-Controlling Interests
	The interests held by other parties in subsidiaries, limited liability companies and limited partnerships owned and controlled by the Company are generally reported as a component of stockholders' equity. Some of those minority ownership interests consist of outside owners that have certain "put rights," that are currently exercisable, and that, if exercised, require the Company to purchase the minority member's interest. These redeemable non-controlling interests that are currently redeemable or considered probable of becoming redeemable have been adjusted to their approximate redemption values and are reported outside of the stockholders' equity section. As of December 31, 2012 and 2013, the Company believes the redemption values of the non-controlling ownership interests approximates the fair value of those interests classified as redeemable non-controlling interests. The redeemable non-controlling interests' balances reported on our consolidated balance sheets were $10.8 million and $11.6 million as of December 31, 2012 and 2013, respectively. The non-controlling interests' balances reported in the stockholders' equity section of our consolidated balance sheets were $28.4 million and $32.4 million as of December 31, 2012 and 2013, respectively.
	Net income attributable to non-controlling interests was $4.9 million, $5.7 million and $8.6 million for the years ended December 31, 2011, 2012, and 2013, respectively. Non-controlling interests reported in the consolidated statement of operations and comprehensive income reflect the respective interests in the income or loss of the subsidiaries, attributable to the other parties, the effect of which is removed from the Company's consolidated statement of operations and comprehensive income.
	Revenue Recognition
	Net operating revenues consists primarily of patient service revenues and revenues generated from therapy services provided to healthcare institutions under contractual arrangements and are recognized as services are rendered.
	Patient service revenue is reported net of provisions for contractual allowances from third-party payors and patients. The Company has agreements with third-party payors that provide for payments to the Company at amounts different from its established billing rates. The differences between the estimated program reimbursement rates and the standard billing rates are accounted for as contractual adjustments, which are deducted from gross revenues to arrive at net operating revenues. Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges, per diem and per visit payments. Retroactive adjustments are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods as final settlements are determined. Accounts receivable resulting from such payment arrangements are recorded net of contractual allowances.
	A significant portion of the Company's net operating revenues are generated directly from the Medicare program. Net operating revenues generated directly from the Medicare program represented approximately 48%, 47% and 46% of the Company's net operating revenues for the years ended December 31, 2011, 2012 and 2013, respectively. Approximately 29% and 32% of the Company's accounts receivable (after allowances for contractual adjustments but before doubtful accounts) at December 31, 2012 and 2013, respectively, are from Medicare. As a provider of services to the Medicare program, the Company is subject to extensive regulations. The inability of any of the Company's specialty hospitals or clinics to comply with regulations can result in significant changes in that specialty hospital's or clinic's net operating revenues generated from the Medicare program.
	Revenues generated under contractual arrangements are comprised primarily of billings for services rendered to nursing homes, hospitals, schools and other third parties.
	Stock Based Compensation
	The Company measures the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognizes the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements comprise both stock options and restricted share plans. Employee stock options are valued using the Black-Scholes option valuation method which uses assumptions that relate to the expected volatility of the Company's common stock, the expected dividend yield of the Company's stock, the expected life of the options and the risk free interest rate. Such compensation amounts, if any, are amortized over the respective vesting periods or periods of service of the option grant. The Company values restricted stock grants by using the closing market price of its stock on the date of grant.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2013
Acquisitions	'
Acquisitions	'
	2.     Acquisitions
	For the Year Ended December 31, 2011
	The Company exchanged one of its long term acute care hospitals and paid $2.0 million in cash for an entity that operates an inpatient rehabilitation hospital. The Company also paid $2.3 million in cash and issued a $1.0 million note for an outpatient rehabilitation business. In addition, the Company purchased non-controlling interests for $0.5 million in cash. The Company completed the post-closing settlement of net working capital with the seller of Regency Hospital Company, L.L.C. resulting in the receipt of $3.9 million in cash.
	For the Year Ended December 31, 2012
	The Company paid $5.9 million in cash and issued $1.8 million in notes for the purchase of several outpatient rehabilitation businesses. In addition, the Company purchased non-controlling interests for $0.1 million in cash.
	For the Year Ended December 31, 2013
	The Company paid $0.9 million in cash and issued $0.3 million in notes for the purchase of several outpatient rehabilitation businesses and paid $0.2 million in cash and issued a $3.0 million note for the purchase of an inpatient rehabilitation hospital. In addition, the Company purchased non-controlling interests for $0.6 million in cash.
	Information with respect to all businesses acquired in purchase transactions is as follows:
		For the Year Ended
		December 31,
		2011			2012			2013
		(in thousands)
	Cash paid (net of cash acquired)	$	899		$	6,043		$	1,665
	Notes issued		1,020			1,844			3,283
			1,919			7,887			4,948
	Contingent consideration		—			1,500			100
	Liabilities assumed		701			107			885
			2,620			9,494			5,933
	Fair value of assets acquired, principally accounts receivable and property and equipment		767			1,313			3,487
	Non-controlling interests		(602	)		(970	)		347
	Cost in excess of fair value of net assets acquired (goodwill)	$	2,455		$	9,151		$	2,099

Significant_Transactions

Significant Transactions	12 Months Ended
	Dec. 31, 2013
Significant Transactions	'
Significant Transactions	'
	3.     Significant Transactions
	On April 1, 2011, the Company entered into a joint venture with Baylor Health Care System. The joint venture consists of a partnership between Baylor Institute for Rehabilitation and a wholly-owned subsidiary of the Company. The Company contributed several businesses to the joint venture, including its Frisco inpatient rehabilitation hospital and certain Texas-based outpatient rehabilitation clinics. A gain of $1.2 million was recognized on this contribution and is included in the general and administrative line item on the consolidated statement of operations for the year ended December 31, 2011. In 2011, the Company invested $13.5 million in cash which consisted of the purchase of partnership units for $7.6 million and working capital investments of $5.9 million and in 2012, the Company invested an additional $7.8 million. The Company owns a 49.0% non-controlling interest in the partnership and is accounting for the investment using the equity method.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property and Equipment	'
Property and Equipment	'
	4.     Property and Equipment
	Property and equipment consists of the following:
		December 31,
		2012		2013
		(in thousands)
	Land	$	68,573	$	68,492
	Leasehold improvements		128,468		146,117
	Buildings		352,677		368,968
	Furniture and equipment		246,858		256,079
	Construction-in-progress		21,648		26,639
			818,224		866,295
	Less: accumulated depreciation		316,672		357,193
	Total property and equipment	$	501,552	$	509,102
	Depreciation expense was $69.8 million, $62.5 million and $63.9 million for the years ended December 31, 2011, 2012 and 2013, respectively.

Intangible_Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2013
Intangible Assets	'
Intangible Assets	'
	5.     Intangible Assets
	The gross carrying amounts of the Company's indefinite-lived intangible assets consist of the following:
		December 31,
		2012			2013
		(in thousands)
	Goodwill	$	1,640,534		$	1,642,633
	Trademarks		57,709			57,709
	Certificates of need		11,914			12,115
	Accreditations		2,122			2,083
	Total	$	1,712,279		$	1,714,540
	The Company's accreditations and trademarks have renewal terms. The costs to renew these intangibles are expensed as incurred. At December 31, 2013, the accreditations and trademarks have a weighted average time until next renewal of 1.5 years and 6.5 years, respectively.
	Amortization expense for intangible assets with finite lives follows:
		For the Year Ended
		December 31
		2011			2012			2013
		(in thousands)
	Amortization expense	$	1,306		$	340		$	—
	Amortization expense for the Company's intangible assets primarily relates to the amortization of the value associated with the non-compete agreements entered into in connection with the acquisitions of the outpatient rehabilitation division of HealthSouth Corporation and SemperCare Inc. During 2011 the non-compete agreement related to the acquisition of SemperCare Inc. was fully amortized and during 2012 the non-compete agreement related to the acquisition of substantially all of the outpatient rehabilitation division of HealthSouth Corporation was fully amortized.
	The changes in the carrying amount of goodwill for the Company's reportable segments for the years ended December 31, 2012 and 2013 are as follows:
		Specialty			Outpatient			Total
		Hospitals			Rehabilitation
		(in thousands)
	Balance as of January 1, 2012	$	1,333,553		$	298,163		$	1,631,716
	Goodwill acquired during year		—			9,151			9,151
	Other		(333	)		—			(333	)
	Balance as of December 31, 2012	$	1,333,220		$	307,314		$	1,640,534
	Goodwill acquired during year		1,395			837			2,232
	Purchase price adjustment		—			(133	)		(133	)
	Balance as of December 31, 2013	$	1,334,615		$	308,018		$	1,642,633

LongTerm_Debt_and_Notes_Payabl

Long-Term Debt and Notes Payable	12 Months Ended
	Dec. 31, 2013
Long-Term Debt and Notes Payable	'
Long-Term Debt and Notes Payable	'
	6.     Long-Term Debt and Notes Payable
	The components of long-term debt and notes payable are shown in the following tables:
		Holdings
		December 31,
		2012		2013
		(in thousands)
	75/8% senior subordinated notes	$	70,000	$	—
	6.375% senior notes		—		600,000
	Senior secured credit facilities:
	Revolving loan		130,000		20,000
	Term loans(1)		1,096,641		807,815
	Senior floating rate notes		167,300		—
	Other		6,302		17,460
	Total debt		1,470,243		1,445,275
	Less: current maturities		11,646		17,565
	Total long-term debt	$	1,458,597	$	1,427,710
		Select
		December 31,
		2012		2013
		(in thousands)
	75/8% senior subordinated notes	$	70,000	$	—
	6.375% senior notes		—		600,000
	Senior secured credit facilities:
	Revolving loan		130,000		20,000
	Term loans(1)		1,096,641		807,815
	Other		6,302		17,460
	Total debt		1,302,943		1,445,275
	Less: current maturities		11,646		17,565
	Total long-term debt	$	1,291,297	$	1,427,710
	-1
	Presented net of unamortized discount of $14.2 million and $6.3 million at December 31, 2012 and 2013, respectively.
	Senior Secured Credit Facilities
	On June 1, 2011, Select entered into a senior secured credit agreement that provided $1.15 billion in senior secured credit facilities. Subsequently, the Company has amended its senior secured credit agreement and at December 31, 2013, it consists of the following:
	•
	A $300.0 million revolving credit facility of which $293.3 million matures on March 1, 2018 and $6.7 million matures on June 1, 2016. Select had $237.7 million of availability under its revolving loan facility (after giving effect to $42.3 million of outstanding letters of credit) at December 31, 2013.
	•
	An aggregate $814.2 million principle amount ($807.8 million net of discounts) term loan facility consisting of a series B term loan in the amount of $295.9 million, net of discount, and a series C term loan in the amount of $511.9 million, net of discount. The term loans amortize in equal quarterly installments on the last day of each March, June, September and December in aggregate amounts equal to $2.1 million. The balance of the series B term loan and series C term loans will be payable on February 20, 2016 and June 1, 2018, respectively.
	As of December 31, 2013, borrowings under the senior secured credit facilities bear interest at a rate equal to:
	•
	in the case of the series B term loans, Adjusted LIBO plus 3.25%, or Alternate Base Rate plus 2.25%;
	•
	in the case of the series C term loans, Adjusted LIBO plus 3.00%, or Alternate Base Rate plus 2.00%; and
	•
	in the case of the revolving loans, Adjusted LIBO plus 3.75%, or Alternate Base Rate plus 2.75%,
	"Adjusted LIBO" (as defined in the senior secured credit agreement) shall at no time be less than 1.00% with respect to borrowings under the series C term loans. Adjusted LIBO and Alternate Base Rate with respect to the revolving loans may vary, in each case based on Select's leverage ratio (the ratio of indebtedness to consolidated EBITDA, as defined in the senior secured credit agreement) for the most recently reported period.
	Select will be required to prepay borrowings under the senior secured credit facilities with (1) 100% of the net cash proceeds received from non-ordinary course asset sales or other dispositions, or as a result of a casualty or condemnation, subject to reinvestment provisions and other customary carveouts and the payment of certain indebtedness secured by liens subject to a first lien intercreditor agreement, (2) 100% of the net cash proceeds received from the issuance of debt obligations other than certain permitted debt obligations, and (3) 50% of excess cash flow (as defined in the senior secured credit agreement) if Select's leverage ratio is greater than 3.75 to 1.00 and 25% of excess cash flow if Select's leverage ratio is less than or equal to 3.75 to 1.00 and greater than 3.25 to 1.00, in each case, reduced by the aggregate amount of term loans optionally prepaid during the applicable fiscal year. Select will not be required to prepay borrowings with excess cash flow if Select's leverage ratio is less than or equal to 3.25 to 1.00. At December 31, 2013, Select's leverage ratio was 3.91 to 1.00 which will require a prepayment of borrowings under the senior secured credit facilities of 50% of excess cash flow (as defined in the senior secured credit agreement), or approximately $34.0 million. Select expects to have the borrowing capacity and intends to use borrowings under its revolving credit facility to make the required prepayment during the first quarter ended March 31, 2014. Therefore, outstanding borrowings subject to required prepayment as of December 31, 2013 under the senior secured credit facilities are classified as long-term on our Consolidated Balance Sheet as of December 31, 2013.
	The senior secured credit facilities require Select to maintain a leverage ratio, which is tested quarterly and prohibits Select from making capital expenditures in excess of $125.0 million in any fiscal year (subject to a 50% carry-over provision). Failure to comply with these financial covenants would result in an event of default under the senior secured credit facilities and, absent a waiver or an amendment from the lenders, preclude Select from making further borrowings under the revolving credit facility and permit the lenders to accelerate all outstanding borrowings under the senior secured credit facilities. As of December 31, 2013, Select was in compliance with all financial covenants related to the senior secured credit facilities.
	The senior secured credit facilities also contain a number of affirmative and restrictive covenants, including limitations on mergers, consolidations and dissolutions; sales of assets; investments and acquisitions; indebtedness; liens; affiliate transactions; and dividends and restricted payments. The senior secured credit facilities contain events of default for non-payment of principal and interest when due, cross-default and cross-acceleration provisions and an event of default that would be triggered by a change of control.
	Senior Notes
	On May 28, 2013, Select issued and sold $600.0 million aggregate principal amount of its 6.375% senior notes due 2021. On May 28, 2013, Select used the proceeds of the senior notes to pay a portion of the amounts then outstanding on the original term loan and the series A term loan, and to pay related fees and expenses.
	Interest on the senior notes accrues at the rate of 6.375% per annum and is payable semi-annually in cash in arrears on June 1 and December 1 of each year, commencing on December 1, 2013. The senior notes are Select's senior unsecured obligations and rank equally in right of payment with all of its other existing and future senior unsecured indebtedness and senior in right of payment to all of its existing and future subordinated indebtedness. The senior notes are unconditionally guaranteed by all of Select's wholly-owned subsidiaries. The senior notes are guaranteed, jointly and severally, by Select's direct or indirect existing and future domestic restricted subsidiaries other than certain non-guarantor subsidiaries.
	Select may redeem some or all of the senior notes prior to June 1, 2016 by paying a "make-whole" premium. Select may redeem some or all of the senior notes on or after June 1, 2016 at specified redemption prices. In addition, prior to June 1, 2016, Select may redeem up to 35% of the senior notes with the net proceeds of certain equity offerings at a price of 106.375% plus accrued and unpaid interest, if any. Select is obligated to offer to repurchase the senior notes at a price of 101% of their principal amount plus accrued and unpaid interest, if any, as a result of certain change of control events. These restrictions and prohibitions are subject to certain qualifications and exceptions.
	The Indenture relating to the senior notes contains covenants that, among other things, limit Select's ability and the ability of certain of its subsidiaries to (i) grant liens on its assets, (ii) make dividend payments, other distributions or other restricted payments, (iii) incur restrictions on the ability of Select's restricted subsidiaries to pay dividends or make other payments, (iv) enter into sale and leaseback transactions, (v) merge, consolidate, transfer or dispose of substantially all of their assets, (vi) incur additional indebtedness, (vii) make investments, (viii) sell assets, including capital stock of subsidiaries, (ix) use the proceeds from sales of assets, including capital stock of restricted subsidiaries, and (x) enter into transactions with affiliates. In addition, the Indenture requires, among other things, Select to provide financial and current reports to holders of the senior notes or file such reports electronically with the U.S. Securities and Exchange Commission (the "SEC"). These covenants are subject to a number of exceptions, limitations and qualifications set forth in the Indenture.
	Maturities of Long-Term Debt and Notes Payable
	Maturities of the Company's long-term debt for the years after 2013 are approximately as follows and are presented net of the discount on the senior secured credit facility term loans (in thousands):
	2014	$	17,565
	2015		10,183
	2016		296,232
	2017		4,075
	2018		515,820
	2019 and beyond		601,400
	Loss on Early Retirement of Debt
	During the year ended December 31, 2011, the Company refinanced its senior secured credit facility, repurchased and retired $266.5 million principal amount of Select's 75/8% senior subordinated notes, and repurchased and retired $150.0 million principal amount of Holdings 10% senior subordinated notes. A loss on early retirement of debt of $31.0 million and $20.4 million for Holdings and Select, respectively, was recognized for the year ended December 31, 2011, which included the write-off of unamortized debt issuance costs, tender premiums and original issue discount.
During the year ended December 31, 2012, the Company repurchased and retired an aggregate of $275.0 million principal amount of Select's outstanding 75/8% senior subordinated notes. A loss on early retirement of debt of $6.1 million was recognized by Holdings and Select for the year ended December 31, 2012, which included the write-off of unamortized debt issuance costs and call premiums.
During the year ended December 31, 2013, Select entered into a credit extension amendment on February 20, 2013, the proceeds of which were used to redeem all of its outstanding 75/8% senior subordinated notes, to finance Holdings' redemption of all of its 10% senior floating rate, and to repay a portion of the balance outstanding under Select's revolving credit facility. Additionally, on May 28, 2013, Select issued and sold $600.0 million aggregate principal amount of its 6.375% senior notes due 2021, the proceeds of which were used to pay a portion of the senior secured credit facility term loans then outstanding and to pay related fees and expenses. A loss on early retirement of debt of $18.7 million and $17.8 million for Holdings and Select, respectively, was recognized for the year ended December 31, 2013, which included the write-off of unamortized debt issuance costs.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity	'
Stockholders' Equity	'
	7.     Stockholders' Equity
	Common Stock
	Holdings' board of directors has authorized a common stock repurchase program to repurchase up to $350.0 million worth of shares of its common stock. The program will remain in effect until March 31, 2015, unless extended by the board of directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Holdings deems appropriate. Holdings is funding this program with cash on hand and borrowings under its revolving credit facility. For the years ended December 31, 2011, 2012 and 2013, respectively, Holdings repurchased 9,858,907 shares at a cost of $72.7 million, 5,725,782 shares at a cost of $46.8 million and 1,115,691 shares at a cost of $10.0 million which includes transaction costs.
	Holdings granted 565,000 shares, 761,500 shares and 952,500 shares of restricted stock for the years ended December 31, 2011, 2012 and 2013, respectively and issued 53,932 shares, 301,208 shares and 166,600 shares of common stock related to the exercise of stock options and for the years ended December 31, 2011, 2012 and 2013, respectively. Also, 10,860 shares, 15,860 shares and 331,697 shares of stock were forfeited for the years ended December 31, 2011, 2012 and 2013, respectively.

Stock_Option_and_Restricted_St

Stock Option and Restricted Stock Plans	12 Months Ended
	Dec. 31, 2013
Stock Option and Restricted Stock Plans	'
Stock Option and Restricted Stock Plans	'
	8.     Stock Option and Restricted Stock Plans
	On February 25, 2005, Holdings adopted the Select Medical Holdings Corporation 2005 Equity Incentive Plan. On May 13, 2011, the Select Medical Holdings Corporation 2005 Equity Incentive Plan was frozen and Holdings adopted the 2011 Select Medical Holdings Corporation 2011 Equity Incentive Plan. The Select Medical Holdings Corporation 2005 Equity Incentive Plan and the Select Medical Holdings Corporation 2011 Equity Incentive Plan are referred to as the "Plans." The Plans provide for grants of restricted stock and stock options of Holdings. On November 8, 2005 the board of directors of Holdings adopted a director equity incentive plan ("Director Plan") and on August 12, 2009, the board of directors and stockholders of Holdings approved an amendment and restatement of the Director Plan. This amendment authorized Holdings to issue under the Director Plan options to purchase up to 75,000 shares of its common stock and restricted stock awards covering up to 150,000 shares of its common stock.
	The options under the Plans and Director Plan generally vest over five years and have an option term not to exceed ten years. The fair value of the options granted was estimated using the Black-Scholes option pricing model assuming an expected volatility of 36%, no dividend yield, an expected life of five years and a risk free rate of 3.3% for 2011. There were no options granted under the Plans or Director Plan during the years ended December 31, 2012 and 2013.
	The following is a summary of stock option grants under the Plans and Director Plan from January 1, 2011 through December 31, 2013:
			Number of Options			Exercise			Fair Value of
			Granted			Price			Common Stock
			(share amounts in thousands)
	March 3, 2011			88			7.66			7.66
	May 13, 2011			20			9			9
	August 3, 2011			10			7.14			7.14
	Stock option transactions and other information related to the Plans are as follows:
			Price Per Share			Shares			Weighted
									Average
									Exercise Price
			(share amounts in thousands)
	Balance, January 1, 2012		$	3.33 - 10.00			2,730		$	8.16
	Granted			—			—			—
	Exercised			3.33 - 10.00			(280	)		6.07
	Canceled			7.66 - 10.00			(27	)		8.18
	Balance, December 31, 2012		$	3.33 - 10.00			2,423		$	8.4
	Granted			—			—			—
	Exercised			7.14 - 10.00			(167	)		9.15
	Canceled			8.33 - 10.00			(316	)		9.13
	Balance, December 31, 2013		$	3.33 - 10.00			1,940		$	8.22
	Additional information with respect to the outstanding options as of December 31, 2013 for the Plans is as follows:
	Exercise Price		Number			Weighted Average			Number
			Outstanding			Remaining			Exercisable
						Contractual Life
			(share amounts in thousands)
	$  3.00 – 4.00			220			1.15			220
	6.00 – 7.00			9			6.61			3
	7.01 – 8.00			75			7.2			28
	8.01 – 9.00			585			3.31			557
	9.01 – 10.00			1,051			5.51			848
	The weighted average remaining contractual term for all outstanding options is 4.42 years and the weighted average remaining contractual term of exercisable options is 4.11 years.
	The total intrinsic value of options exercised for the years ended December 31, 2013, 2012, and 2011 was $0.2 million, $1.1 million and $0.2 million respectively. The aggregate intrinsic value of options outstanding and options exercisable at December 31, 2013 was $6.6 million and $5.8 million, respectively.
	Transactions and other information related to the Director Plan are as follows:
			Price Per Share			Shares			Weighted Average
									Exercise Price
			(share amounts in thousands)
	Balance, January 1, 2012		$	3.33 - 10.00			63		$	7.62
	Granted			—			—			—
	Exercised			3.33 - 8.33			(21	)		5.47
	Balance, December 31, 2012		$	3.33 - 10.00			42		$	8.69
	Granted			—			—			—
	Exercised			—			—			—
	Balance, December 31, 2013		$	3.33 - 10.00			42		$	8.69
	Additional information with respect to the outstanding options as of December 31, 2013 for the Director Plan is as follows:
	Exercise Price			Number			Weighted			Number
				Outstanding			Average			Exercisable
							Remaining
							Contractual Life
				(share amounts in thousands)
	$	3.00 – 4.00			6			1.61			6
		8.00 – 9.00			9			3.37			9
		9.01 – 10.00			27			5.12			25
	The weighted average remaining contractual term for all outstanding options is 4.24 years and the weighted average remaining contractual term of exercisable options is 4.16 years.
	The aggregate intrinsic value of options outstanding and options exercisable at December 31, 2013 was $122.7 thousand and $118.8 thousand, respectively.
	The following is a summary of restricted stock issuances from January 1, 2011 through December 31, 2013:
			Number of Shares Issued			Fair Value of Common Stock
			(share amounts in thousands)
	August 3, 2011			25			7.14
	November 3, 2011			190			8.61
December 15, 2011			350			8.57
March 26, 2012			65			8.33
May 2, 2012			129			8.67
August 7, 2012			38			11.84
October 30, 2012			530			10.75
January 2, 2013			5			9.9
February 20, 2013			35			8.8
May 1, 2013			115			8.06
August 7, 2013			38			8.89
October 30, 2013			760			8.5
Stock compensation expense for each of the next five years, based on restricted stock awards granted as of December 31, 2013, is estimated to be as follows:
		2014			2015			2016			2017		2018
		(in thousands)
Stock compensation expense		$	7,740		$	6,057		$	3,061		$	581	$	40
The Company recognized the following stock compensation expense related to restricted stock and stock option awards:
		For the Year Ended
		December 31,
		2011			2012			2013
		(in thousands)
Stock compensation expense:
Included in general and administrative		$	1,996		$	3,538		$	5,276
Included in cost of services			1,729			2,139			1,757
Total		$	3,725		$	5,677		$	7,033

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
Income Taxes	'
	9.     Income Taxes
	Significant components of the Company's tax provision for the years ended December 31, 2011, 2012, and 2013 are as follows:
		Holdings									Select
		For the Year Ended									For the Year Ended
		December 31,									December 31,
		2011			2012			2013			2011			2012			2013
		(in thousands)									(in thousands)
	Current:
	Federal	$	29,991		$	70,159		$	55,847		$	40,007		$	74,076		$	57,026
	State and local		5,672			11,589			11,913			5,672			11,589			11,913
	Total current		35,663			81,748			67,760			45,679			85,665			68,939
	Deferred		35,305			7,909			7,032			35,305			7,909			7,032
	Total income tax provision	$	70,968		$	89,657		$	74,792		$	80,984		$	93,574		$	75,971
	The differences between the expected income tax provision and income taxes computed at the federal statutory rate of 35% were as follows:
		Holdings									Select
		For the Year Ended									For the Year Ended
		December 31,									December 31,
		2011			2012			2013			2011			2012			2013
	Expected federal tax rate		35	%		35	%		35	%		35	%		35	%		35	%
	State and local taxes, net of federal benefit		4.5			4.2			4.6			3.9			4			4.5
	Other permanent differences		1			0.6			1.1			0.9			0.6			1.1
	Valuation allowance		(0.5	)		(0.6	)		(0.7	)		(0.4	)		(0.6	)		(0.6	)
	Uncertain tax positions		(3.6	)		(0.5	)		(0.6	)		(3.1	)		(0.5	)		(0.6	)
	IRS audit settlements		—			(0.6	)		—			—			(0.5	)		—
	Non-controlling interest		(1.1	)		(0.9	)		(1.7	)		(0.9	)		(0.9	)		(1.7	)
	Sale of entities		3.1			—			—			2.7			—			—
	Other		0.2			(0.4	)		0.1			—			(0.4	)		0.1
	Total		38.6	%		36.8	%		37.8	%		38.1	%		36.7	%		37.8	%
	A summary of deferred tax assets and liabilities for Holdings and Select is as follows:
		December 31, 2012											December 31, 2013
		Total			Current			Non-Current					Total			Current			Non-Current
		(in thousands)
	Deferred tax assets
	Allowance for doubtful accounts	$	1,496		$	1,496		$	—				$	1,484		$	1,484		$	—
	Compensation and benefit related accruals		45,784			38,254			7,530					45,147			35,706			9,441
	Professional malpractice liability insurance		17,005			5,003			12,002					20,333			6,382			13,951
	Restructuring reserve		679			679			—					441			441			—
	Net operating loss carryforwards		24,543			777			23,766					22,686			422			22,264
	Other		1,025			996			29					630			630			—
	Stock options		4,089			—			4,089					4,392			—			4,392
	Uncertain tax positions		2,661			—			2,661					2,107			—			2,107
	Total deferred tax assets		97,282			47,205			50,077					97,220			45,065			52,155
	Deferred tax liabilities
	Deferred income		(33,188	)		(26,253	)		(6,935	)				(31,832	)		(24,897	)		(6,935	)
	Other		(1,311	)		(118	)		(1,193	)				(2,620	)		(230	)		(2,390	)
	Depreciation and amortization		(121,075	)		—			(121,075	)				(130,884	)		—			(130,884	)
	Total deferred tax liabilities		(155,574	)		(26,371	)		(129,203	)				(165,336	)		(25,127	)		(140,209	)
	Net deferred taxes before valuation allowance		(58,292	)		20,834			(79,126	)				(68,116	)		19,938			(88,054	)
	Valuation allowance		(13,341	)		(2,957	)		(10,384	)				(10,547	)		(2,314	)		(8,233	)
	Net deferred taxes	$	(71,633	)	$	17,877		$	(89,510	)			$	(78,663	)	$	17,624		$	(96,287	)
	The valuation allowance as of December 31, 2013 is primarily attributable to the uncertainty regarding the realization of state net operating losses and other net deferred tax assets of loss entities. The net deferred tax liabilities at December 31, 2012 and 2013 of approximately $71.6 million and $78.7 million, respectively, consist of items which have been recognized for tax reporting purposes, but which will increase tax on returns to be filed in the future, and include the use of net operating loss carryforwards. The Company has performed the required assessment of positive and negative evidence regarding the realization of the deferred tax assets. This assessment included a review of legal entities with three years of cumulative losses, estimates of projected future taxable income and the impact of tax-planning strategies that management plans to implement. Although realization is not assured, based on the Company's assessment, it has concluded that it is more likely than not that such assets, net of the determined valuation allowance, will be realized.
	The total state net operating losses are approximately $512.3 million. State net operating loss carry forwards expire and are subject to gross valuation allowances as follows:
		State Net Operating Losses			Gross Valuation Allowance
		(in thousands)
	2014	$	5,427		$	5,401
	2015		8,333			7,980
	2016		11,238			9,728
	2017		12,834			11,092
	Thereafter through 2033		473,034			355,392
	Reserves for Uncertain Tax Positions:
	The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax of multiple state jurisdictions. Significant judgment is required in evaluating the Company's tax positions and determining its provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. The Company establishes reserves for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These reserves are established when it is believed that certain positions might be challenged despite the Company's belief that its tax return positions are fully supportable. The Company adjusts these reserves in light of changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate.
	The reconciliation of the Company's unrecognized tax benefits is as follows (in thousands):
	Gross tax contingencies — January 1, 2011	$	22,310
Reductions for tax positions taken in prior periods due primarily to statute expiration		(2,706	)
Reductions for tax positions taken in prior periods due to change in estimate		(7,012	)
Additions for existing tax positions taken		3,064
Gross tax contingencies — December 31, 2011		15,656
Reductions for tax positions taken in prior periods due primarily to statute expiration		(2,516	)
Additions for existing tax positions taken		750
Gross tax contingencies — December 31, 2012		13,890
Reductions for tax positions taken in prior periods due primarily to statute expiration		(2,299	)
Additions for existing tax positions taken		435
Gross tax contingencies — December 31, 2013	$	12,026
In 2011, the Company recognized $7.0 million of income tax benefits based on new information discovered by the Company which substantiates previously unrecognized tax benefits from an acquisition which occurred in 1999.
As of December 31, 2012 and 2013, the Company had $13.9 million and $12.0 million of unrecognized tax benefits, respectively, all of which, if fully recognized, would affect the Company's effective income tax rate.
As of December 31, 2013, changes to the Company's gross unrecognized tax benefits that the Company believes are reasonably possible in the next 12 months are not material. The Company's policy is to include interest related to income taxes in income tax expense. As of December 31, 2012 and December 31, 2013, the Company had accrued interest related to income taxes of $1.5 million and $1.6 million, net of federal income taxes, respectively. Interest recognized for the years ended December 31, 2011, 2012 and 2013 was $0.4 million, $0.5 million, and $0.5 million, net of federal income tax benefits, respectively.
The Company has substantially concluded all U.S. federal income tax matters for years through 2005. Substantially all material state, local and foreign income tax matters have been concluded for years through 2008.

Retirement_Savings_Plan

Retirement Savings Plan	12 Months Ended
	Dec. 31, 2013
Retirement Savings Plan	'
Retirement Savings Plan	'
	10.    Retirement Savings Plan
	The Company sponsors a defined contribution retirement savings plan for substantially all of its employees. Employees who are not classified as HCE's (highly compensated employees) may contribute up to 30% of their salary; HCE's may contribute up to 6% of their salary. The Plan provides a discretionary company match which is determined annually. Currently, the Company matches 25% of the first 6% of compensation employees contribute to the plan. The employees vest in the employer contributions over a three-year period beginning on the employee's hire date. The expense incurred by the Company related to this plan was $7.6 million, $8.2 million and $8.7 million during the years ended December 31, 2011, 2012 and 2013, respectively.

Segment_Information

Segment Information	12 Months Ended
	Dec. 31, 2013
Segment Information	'
Segment Information	'
	11.    Segment Information
	The Company's reportable segments consist of (i) specialty hospitals and (ii) outpatient rehabilitation. Other activities include the Company's corporate services and certain other non-consolidating joint ventures and minority investments in other healthcare related businesses. The outpatient rehabilitation reportable segment has two operating segments: outpatient rehabilitation clinics and contract therapy. These operating segments are aggregated for reporting purposes as they have common economic characteristics and provide a similar service to a similar patient base. The accounting policies of the segments are the same as those described in the summary of significant accounting policies. The Company evaluates performance of the segments based on Adjusted EBITDA. Adjusted EBITDA is defined as net income before interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, equity in earnings (losses) of unconsolidated subsidiaries and other income (expense).
	The following tables summarize selected financial data for the Company's reportable segments. The segment results of Holdings are identical to those of Select with the exception of total assets.
		Year Ended December 31, 2011
		Specialty			Outpatient			Other			Total
		Hospitals			Rehabilitation
		(in thousands)
	Net revenue	$	2,095,519		$	708,867		$	121		$	2,804,507
	Adjusted EBITDA		362,334			83,864			(60,237	)		385,961
	Total assets(1):
	Select		2,187,767			486,589			96,382			2,770,738
	Holdings		2,187,767			486,589			97,791			2,772,147
	Capital expenditures		30,464			12,135			3,417			46,016
		Year Ended December 31, 2012
		Specialty			Outpatient			Other			Total
		Hospitals			Rehabilitation
		(in thousands)
	Net revenue	$	2,197,529		$	751,317		$	123		$	2,948,969
	Adjusted EBITDA		381,354			87,024			(62,531	)		405,847
	Total assets(1):
	Select		2,143,906			491,920			124,487			2,760,313
	Holdings		2,143,906			491,920			125,535			2,761,361
	Capital expenditures		50,005			13,209			4,971			68,185
		Year Ended December 31, 2013
		Specialty			Outpatient			Other			Total
		Hospitals			Rehabilitation
		(in thousands)
	Net revenue	$	2,198,121		$	777,177		$	350		$	2,975,648
	Adjusted EBITDA		353,843			90,313			(71,295	)		372,861
	Total assets(1):
	Select		2,205,921			512,539			99,162			2,817,622
	Holdings		2,205,921			512,539			99,162			2,817,622
	Capital expenditures		56,523			14,113			3,024			73,660
	-1
	The specialty hospital segment includes $2.7 million in real estate assets held for sale on December 31, 2011, 2012 and 2013.
	A reconciliation of Adjusted EBITDA to income before income taxes is as follows:
		Year Ended December 31, 2011
		Specialty			Outpatient			Other
		Hospitals			Rehabilitation
								(in thousands)
	Adjusted EBITDA	$	362,334		$	83,864		$	(60,237	)
	Depreciation and amortization		(50,629	)		(16,487	)		(4,401	)
	Stock compensation expense		—			—			(3,725	)
											Holdings			Select
	Income (loss) from operations	$	311,705		$	67,377		$	(68,363	)	$	310,719		$	310,719
	Loss on early retirement of debt											(31,018	)		(20,385	)
	Equity in earnings of unconsolidated subsidiaries											2,923			2,923
	Interest expense, net											(98,894	)		(80,910	)
	Income before income taxes										$	183,730		$	212,347
		Year Ended December 31, 2012
		Specialty			Outpatient			Other
		Hospitals			Rehabilitation
								(in thousands)
	Adjusted EBITDA	$	381,354		$	87,024		$	(62,531	)
	Depreciation and amortization		(46,836	)		(13,208	)		(3,267	)
	Stock compensation expense		—			—			(5,677	)
											Holdings			Select
	Income (loss) from operations	$	334,518		$	73,816		$	(71,475	)	$	336,859		$	336,859
	Loss on early retirement of debt											(6,064	)		(6,064	)
	Equity in earnings of unconsolidated subsidiaries											7,705			7,705
	Interest expense, net											(94,950	)		(83,759	)
	Income before income taxes										$	243,550		$	254,741
		Year Ended December 31, 2013
	Specialty			Outpatient			Other
	Hospitals			Rehabilitation
							(in thousands)
Adjusted EBITDA	$	353,843		$	90,313		$	(71,295	)
Depreciation and amortization		(48,621	)		(12,024	)		(3,747	)
Stock compensation expense		—			—			(7,033	)
										Holdings			Select
Income (loss) from operations	$	305,222		$	78,289		$	(82,075	)	$	301,436		$	301,436
Loss on early retirement of debt											(18,747	)		(17,788	)
Equity in earnings of unconsolidated subsidiaries											2,476			2,476
Interest expense, net											(87,364	)		(84,954	)
Income before income taxes										$	197,801		$	201,170

Income_per_Share

Income per Share	12 Months Ended
	Dec. 31, 2013
Income per Share	'
Income per Share	'
	12.   Income per Share
	The Company applies the two-class method for calculating and presenting income per common share. The two-class method is an earnings allocation formula that determines earnings per share for each class of stock participation rights in undistributed earnings. Under the two class method:
	(a)
	Net income attributable to Select Medical Holdings Corporation is reduced by any contractual amount of dividends in the current period for each class of stock. There were no contractual dividends for the years ended December 31, 2011, 2012 and 2013.
	(b)
	The remaining income is allocated to common stock and unvested restricted stock to the extent that each security may share in income, as if all of the earnings for the period had been distributed. The total income allocated to each security is determined by adding together the amount allocated for dividends in (a) above and the amount allocated for participation features.
	(c)
	The income allocated to common stock is then divided by the weighted average number of outstanding shares to which the earnings are allocated to determine the income per share for common stock.
	In applying the two-class method, the Company determined that undistributed earnings should be allocated equally on a per share basis between the common stock and unvested restricted stock due to the equal participation rights of the common stock and unvested restricted stock (i.e., the voting conversion rights).
	The following table sets forth for the periods indicated the calculation of income per share in the Company's Consolidated Statement of Operations and the differences between basic weighted average shares outstanding and diluted weighted average shares outstanding used to compute basic and diluted earnings per share, respectively:
		For the Year Ended December 31,
		2011		2012		2013
		(in thousands, except per share amounts)
	Numerator:
	Net income attributable to Select Medical Holdings Corporation	$	107,846	$	148,230	$	114,390
	Less: Earnings allocated to unvested restricted stockholders		1,205		2,514		2,450
	Net income available to common stockholders	$	106,641	$	145,716	$	111,940
	Denominator:
	Weighted average shares — basic		150,501		138,767		136,879
	Effect of dilutive securities:
	Stock options		224		275		168
	Weighted average shares — diluted		150,725		139,042		137,047
	Basic income per common share:	$	0.71	$	1.05	$	0.82
	Diluted income per common share:	$	0.71	$	1.05	$	0.82
	The following amounts are shown here for informational and comparative purposes only since their inclusion would be anti-dilutive:
		For the Year Ended December 31,
		2011		2012		2013
		(in thousands)
	Stock options		2,414		1,654		1,474

Fair_Value

Fair Value	12 Months Ended
	Dec. 31, 2013
Fair Value	'
Fair Value	'
	13.   Fair Value
	Financial instruments include cash and cash equivalents, notes payable and long-term debt. The carrying amount of cash and cash equivalents approximates fair value because of the short-term maturity of these instruments.
	The carrying value of Select's senior secured credit facility was $1,226.6 million and $827.8 million at December 31, 2012 and 2013, respectively. The fair value of Select's senior secured credit facility was $1,216.2 million and $828.3 million at December 31, 2012 and 2013, respectively. The fair value of Select's senior secured credit facility was based on quoted market prices for this debt in the syndicated loan market.
	The carrying value of Select's 6.375% senior notes was $600.0 million at December 31, 2013. The fair value of Select's 6.375% senior notes was $586.5 million at December 31, 2013. The fair value of this debt was based on quoted market prices.
	The Company considers the inputs in the valuation process of its senior secured credit facility and 6.375% senior notes to be Level 2 in the fair value hierarchy. Level 2 in the fair value hierarchy is defined as inputs that are observable for the asset or liability, either directly or indirectly which includes quoted prices for identical assets or liabilities in markets that are not active.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions	'
Related Party Transactions	'
	14.   Related Party Transactions
	The Company rents its corporate office space from related parties affiliated through common ownership or management. The Company made payments for office rent, leasehold improvements and miscellaneous expenses aggregating $4.0 million during both the years ended December 31, 2011 and 2012 and $4.2 million during the year ended December 31, 2013 to the affiliated companies.
	As of December 31, 2013, future rental commitments under outstanding agreements with the affiliated companies are approximately as follows (in thousands):
	2014	$	3,758
	2015		3,792
	2016		3,828
	2017		3,865
	2018		3,950
	Thereafter		17,047
		$	36,240
	The Company provides contracted services, principally employee leasing services and charges management fees to related parties affiliated through its equity investments. Net operating revenues generated from the provision of contracted services and management fees to related parties through equity investments are as follows:
		For the Year Ended
		December 31,
		2011		2012		2013
		(in thousands)
	BIR JV, LLP	$	53,309	$	92,205	$	96,465
	Rehabilitation Institute of Denton, LLC		7,292		8,133		7,163
	OHRH, LLC		—		—		2,069
	Global Rehab — Scottsdale, LLC.		—		—		4,129
	Amplion Clinical Communications, Inc.		—		305		1,534
	Other		150		140		310
	Total	$	60,751	$	100,783	$	111,670

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies	'
Commitments and Contingencies	'
	15.   Commitments and Contingencies
	Leases
	The Company leases facilities and equipment from unrelated parties under operating leases. Minimum future lease obligations on long-term non-cancelable operating leases in effect at December 31, 2013 are approximately as follows (in thousands):
	2014	$	125,611
	2015		98,100
	2016		77,724
	2017		63,517
	2018		51,104
	Thereafter		364,253
		$	780,309
	Total rent expense for operating leases, including cancelable leases, for the years ended December 31, 2011, 2012 and 2013 was $163.9 million, $168.3 million and $164.6 million, respectively.
	Property rent expense to unrelated parties for the years ended December 31, 2011, 2012 and 2013 was $114.8 million, $118.1 million and $119.5 million, respectively.
	Construction Commitments
	At December 31, 2013, the Company had outstanding commitments under construction contracts related to new construction, improvements and renovations at the Company's long term acute care properties and inpatient rehabilitation facilities totaling approximately $22.8 million.
	Other
	A subsidiary of the Company has entered into a naming, promotional and sponsorship agreement with an NFL team for the team's headquarters complex that requires a payment of $2.9 million in 2014. Each successive annual payment increases by 2.3% through 2025. The naming, promotional and sponsorship agreement is in effect until 2025.
	Litigation
	The Company is a party to various legal actions, proceedings and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services ("CMS") or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company's businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company's business, financial position, results of operations and liquidity.
	To address claims arising out of the operations of the Company's specialty hospitals and outpatient rehabilitation facilities, the Company maintains professional malpractice liability insurance and general liability insurance, subject to self-insured retention of $2.0 million per medical incident for professional liability claims and $2.0 million per occurrence for general liability claims. The Company also maintains umbrella liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company's other insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company's opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations, or cash flows.
	Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.
	On January 8, 2013, a federal magistrate judge unsealed an Amended Complaint in United States of America and the State of Indiana, ex rel. Doe I, Doe II and Doe III v. Select Medical Corporation, Select Specialty Hospital-Evansville, Evansville Physician Investment Corporation, Dr. Richard Sloan and Dr. Jeffrey Selby. The Amended Complaint, which was served on the Company on February 15, 2013, is a civil action filed under seal on September 28, 2012 in the United States District Court for the Southern District of Indiana by private plaintiff-relators on behalf of the United States and the state of Indiana under the federal False Claims Act and Indiana False Claims and Whistleblower Protection Act. Although the Amended Complaint identifies the relators by fictitious pseudonyms, on March 28, 2013, the relators filed a Notice identifying themselves as the former CEO at the Company's long term acute care hospital in Evansville, Indiana ("SSH-Evansville") and two former case managers at SSH-Evansville. The named defendants include the Company, SSH-Evansville, and two physicians who have practiced at SSH-Evansville. On March 26, 2013, the defendants, relators and the United States filed a joint motion seeking a stay of the proceedings, in which the United States notified the court that its investigation has not been completed and therefore it is not yet able to decide whether or not to intervene, and on March 29, 2013, the magistrate judge granted the motion and stayed all deadlines in the case for 90 days. The court has subsequently granted additional motions filed by the United States to continue the stay, and the current stay extends until March 17, 2014.
	In January 2014, representatives of the United States Attorney's Office for the Southern District of Indiana and the Office of Attorney General for the State of Indiana informed the Company that, while they have not yet decided whether to intervene in the case, their investigation is continuing concerning allegations that SSH-Evansville admitted patients for whom long-term acute care was not medically necessary, up-coded diagnoses at admission, discharged patients too early or held patients too long, readmitted patients discharged to short-stay acute care hospitals only after nine days to enable billing for two admissions, and allowed unnecessary bronchoscopies to be performed. The Company is involved in ongoing discussions with the government regarding this matter.
	As previously disclosed, beginning in April 2012, the Company and SSH-Evansville have received various subpoenas and demands for documents relating to SSH-Evansville, including a request for information and subpoenas from the Office of Inspector General of the U.S. Department of Health and Human Services and subpoenas from the Office of Attorney General for the State of Indiana, and the Evansville (Indiana) Police Department has executed a search warrant at SSH-Evansville. The Company has produced and will continue to produce documents in response to, and intends to fully cooperate with, these governmental investigations. At this time, the Company is unable to predict the timing and outcome of this matter.

Supplemental_Disclosures_of_Ca

Supplemental Disclosures of Cash Flow Information	12 Months Ended
	Dec. 31, 2013
Supplemental Disclosures of Cash Flow Information	'
Supplemental Disclosures of Cash Flow Information	'
	16.   Supplemental Disclosures of Cash Flow Information
	Non-cash investing and financing activities are comprised of the following for the years ended December 31, 2011, 2012 and 2013:
		Holdings
		For the Year Ended
		December 31,
		2011			2012			2013
		(in thousands)
	Notes issued with acquisitions(1)	$	1,020		$	1,844		$	3,283
	Liabilities assumed with acquisitions(1)		701			107			885
	Contingent consideration related to acquisitions(1)		—			1,500			100
	Notes related to investment in business		—			—			3,399
		Select
		For the Year Ended
		December 31,
		2011			2012			2013
		(in thousands)
	Dividends declared to Holdings by Select(2)	$	(5,240	)	$	(5,240	)	$	—
	Notes issued with acquisitions(1)		1,020			1,844			3,283
	Liabilities assumed with acquisitions(1)		701			107			885
	Contingent consideration related to acquisitions(1)		—			1,500			100
	Notes related to investment in business		—			—			3,399
	-1
	Refer to Footnote 2 — Acquisitions.
	-2
	Recorded in accrued other liabilities on the consolidated balance sheet of Select.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events	'
Subsequent Events	'
	17.   Subsequent Events
	On February 19, 2014, Select Medical's board of directors declared a cash dividend of $0.10 per share. The dividend will be payable on or about March 10, 2014 to stockholders of record as of the close of business on March 3, 2014.

Financial_Information_for_Subs

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes	12 Months Ended
	Dec. 31, 2013
Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes	'
Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes	'
	18.   Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes
	Select's 6.375% senior notes are fully and unconditionally guaranteed, except for customary limitations, on a senior basis by all of Select's wholly-owned subsidiaries (the "Subsidiary Guarantors") which is defined as a subsidiary where Select or a subsidiary of Select holds all of the outstanding ownership interests. Certain of Select's subsidiaries did not guarantee the 6.375% senior notes (the "Non-Guarantor Subsidiaries").
	Select conducts a significant portion of its business through its subsidiaries. Presented below is consolidating financial information for Select, the Subsidiary Guarantors and the Non-Guarantor Subsidiaries at December 31, 2012 and 2013 and for the years ended December 31, 2011, 2012 and 2013.
	The equity method has been used by Select with respect to investments in subsidiaries. The equity method has been used by Subsidiary Guarantors with respect to investments in Non-Guarantor Subsidiaries. Separate financial statements for Subsidiary Guarantors are not presented.
	The consolidating balance sheets at December 2011 and the consolidating statement of cash flows for the year ended December 31, 2011 included in this footnote contain certain immaterial adjustments that were made to the December 31, 2011 consolidating balance sheet and the consolidating statement of cash flows for the year ended December 31, 2011 relating to the presentation of intercompany transactions. On the December 31, 2011 consolidating balance sheet, intercompany accounts that were previously reported as both asset and liability balances within the liability section of the balance sheet have been adjusted and presented separately as either an intercompany receivable within the current asset classification or as an intercompany payable within the current liability classification, based upon the account's attributes on each subsidiary's balance sheet. On the consolidating statement of cash flows for the year ended December 31, 2011, the changes in intercompany advances that were previously reported as a change in operating assets and liabilities in cash flow provided by operating activities has been adjusted as a financing activity. These adjustments had no impact on the total equity of the Guarantors, non-Guarantors or Parent Company. They did not alter the net increase or decrease in cash for the Guarantors, non-Guarantors or Parent Company.
		Select Medical Corporation
		Consolidating Balance Sheet
		December 31, 2013
		Select Medical			Subsidiary			Non-Guarantor			Eliminations			Consolidated
		Corporation (Parent			Guarantors			Subsidiaries
		Company Only)
		(in thousands)
	Assets
	Current Assets:
	Cash and cash equivalents	$	71		$	3,098		$	1,150		$	—		$	4,319
	Accounts receivable, net		—			337,517			54,452			-650	(a)		391,319
	Current deferred tax asset		7,965			5,214			4,445			—			17,624
	Intercompany receivables		—			1,079,736			105,028			-1,184,764	(b)		—
	Other current assets		9,745			26,545			4,850			—			41,140
	Total Current Assets		17,781			1,452,110			169,925			(1,185,414	)		454,402
	Property and equipment, net		15,624			434,040			59,438			—			509,102
	Investment in affiliates		3,059,581			83,012			—			-3,142,593	(c)(d)		—
	Goodwill		—			1,642,633			—			—			1,642,633
	Non-current deferred tax asset		7,662			—			—			-7,662	(e)		—
	Other identifiable intangibles		—			71,907			—			—			71,907
	Other assets		35,274			103,696			608			—			139,578
	Total Assets	$	3,135,922		$	3,787,398		$	229,971		$	(4,335,669	)	$	2,817,622
	Liabilities and Equity
	Current Liabilities:
	Bank overdrafts	$	12,506		$	—		$	—		$	—		$	12,506
	Current portion of long-term debt and notes payable		9,107			7,317			1,141			—			17,565
	Accounts payable		6,749			68,574			12,962			—			88,285
	Intercompany payables		1,184,764			—			—			-1,184,764	(b)		—
	Accrued payroll		1,167			88,599			245			—			90,011
	Accrued vacation		4,619			47,682			7,429			—			59,730
	Accrued interest		11,076			1,221			—			—			12,297
	Accrued other		59,249			23,493			7,729			—			90,471
	Income taxes payable		622			—			—			—			622
	Due to third party payors		—			1			686			-650	(a)		37
	Total Current Liabilities		1,289,859			236,887			30,192			(1,185,414	)		371,524
	Long-term debt, net of current portion		1,006,201			364,060			57,449			—			1,427,710
	Non-current deferred tax liability		—			96,111			7,838			-7,662	(e)		96,287
	Other non-current liabilities		53,628			33,123			5,124			—			91,875
	Total Liabilities		2,349,688			730,181			100,603			(1,193,076	)		1,987,396
	Redeemable non-controlling interests		—			—			11,584			—			11,584
	Stockholder's Equity:
	Common stock		0			—			—			—			0
	Capital in excess of par		869,576			—			—			—			869,576
	Retained earnings		(83,342	)		920,694			21,186			-941,880	(d)		(83,342	)
	Subsidiary investment		—			2,136,523			64,190			-2,200,713	(c)		—
	Total Select Medical Corporation Stockholder's Equity		786,234			3,057,217			85,376			(3,142,593	)		786,234
	Non-controlling interests		—			—			32,408			—			32,408
	Total Equity		786,234			3,057,217			117,784			(3,142,593	)		818,642
	Total Liabilities and Equity	$	3,135,922		$	3,787,398		$	229,971		$	(4,335,669	)	$	2,817,622
	(a)
	Reclass portion of due to third party payor to accounts receivable net in consolidation.
	(b)
	Elimination of intercompany.
	(c)
	Elimination of investments in consolidated subsidiaries.
	(d)
	Elimination of investments in consolidated subsidiaries' earnings.
	(e)
Reclass of non-current deferred tax assset to report net non-current deferred tax liability in consolidation.
	Select Medical Corporation
	Consolidating Statement of Operations
	For the Year Ended December 31, 2013
	Select Medical			Subsidiary			Non-Guarantor			Eliminations			Consolidated
	Corporation (Parent			Guarantors			Subsidiaries
	Company Only)
	(in thousands)
Net operating revenues	$	350		$	2,553,505		$	421,793		$	—		$	2,975,648
Costs and expenses:
Cost of services		1,757			2,135,754			357,965			—			2,495,476
General and administrative		76,709			212			—			—			76,921
Bad debt expense		—			31,003			6,420			—			37,423
Depreciation and amortization		3,746			50,982			9,664			—			64,392
Total costs and expenses		82,212			2,217,951			374,049			—			2,674,212
Income (loss) from operations		(81,862	)		335,554			47,744			—			301,436
Other income and expense:
Intercompany interest and royalty fees		(1,326	)		1,339			(13	)		—			—
Intercompany management fees		144,447			(125,361	)		(19,086	)		—			—
Equity in earnings of unconsolidated subsidiaries		—			2,384			92			—			2,476
Loss on early retirement of debt		(17,788	)		—			—			—			(17,788	)
Interest expense		(58,100	)		(22,760	)		(4,094	)		—			(84,954	)
Income (loss) from operations before income taxes		(14,629	)		191,156			24,643			—			201,170
Income tax expense (benefit)		(1,238	)		76,870			339			—			75,971
Equity in earnings of subsidiaries		129,971			15,716			—			-145,687	(a)		—
Net income		116,580			130,002			24,304			(145,687	)		125,199
Less: Net income attributable to non-controlling interests		—			—			8,619			—			8,619
Net income attributable to Select Medical Corporation	$	116,580		$	130,002		$	15,685		$	(145,687	)	$	116,580
(a)
Elimination of equity in earnings of subsidiaries.
Select Medical Corporation
Consolidating Statement of Cash Flows
For the Year Ended December 31, 2013
	Select Medical			Subsidiary			Non-Guarantor			Eliminations			Consolidated
	Corporation (Parent			Guarantors			Subsidiaries
	Company Only)
	(in thousands)
Operating activities
Net income	$	116,580		$	130,002		$	24,304		$	(145,687	)(a)	$	125,199
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		3,746			50,982			9,664			—			64,392
Provision for bad debts		—			31,003			6,420			—			37,423
Equity in earnings of unconsolidated subsidiaires		—			(2,384	)		(92	)		—			(2,476	)
Loss on early retirement of debt		17,788			—			—			—			17,788
Gain from disposal or sale of assets		—			(463	)		(118	)		—			(581	)
Non-cash stock compensation expense		7,033			—			—			—			7,033
Amortization of debt discount and issuance costs		8,344			—			—			—			8,344
Deferred income taxes		7,032			—			—			—			7,032
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries		(129,971	)		(15,716	)		—			145,687	(a)		—
Accounts receivable		—			(59,804	)		(7,341	)		—			(67,145	)
Other current assets		(4,145	)		(5,735	)		1,713			—			(8,167	)
Other assets		(6,594	)		3,026			84			—			(3,484	)
Accounts payable		2,075			(3,660	)		302			—			(1,283	)
Due to third-party payors		—			996			(2,037	)		—			(1,041	)
Accrued expenses		(4,929	)		20,609			(612	)		—			15,068
Net cash provided by operating activities		16,959			148,856			32,287			—			198,102
Investing activities
Purchases of property and equipment		(3,024	)		(60,532	)		(10,104	)		—			(73,660	)
Investment in businesses, net of distributions		—			(34,893	)		—			—			(34,893	)
Acquisition of businesses, net of cash acquired		—			(1,665	)		—			—			(1,665	)
Proceeds from sale of assets		—			2,456			456			—			2,912
Net cash used in investing activities		(3,024	)		(94,634	)		(9,648	)		—			(107,306	)
Financing activities
Borrowings on revolving credit facility		690,000			—			—			—			690,000
Payments on revolving credit facility		(800,000	)		—			—			—			(800,000	)
Borrowings on credit facility term loans, net of discount		298,500			—			—			—			298,500
Payments on credit facility term loans		(596,720	)		—			—			—			(596,720	)
Issuance of 6.375% senior notes		600,000			—			—			—			600,000
Repurchase of 75/8% senior subordinated notes, net of premiums		(70,000	)		—			—			—			(70,000	)
Borrowings of other debt		8,923			5,303			1,084			—			15,310
Principal payments on other debt		(7,752	)		(873	)		(2,209	)		—			(10,834	)
Debt issuance costs		(18,914	)		—			—			—			(18,914	)
Repayments of bank overdrafts		(5,330	)		—			—			—			(5,330	)
Equity investment by Holdings		1,525			—			—			—			1,525
Dividends paid to Holdings		(226,621	)		—			—			—			(226,621	)
Intercompany		77,455			(59,288	)		(18,167	)		—			—
Distributions to non-controlling interests		—			—			(3,537	)		—			(3,537	)
Net cash used in financing activities		(48,934	)		(54,858	)		(22,829	)		—			(126,621	)
Net decrease in cash and cash equivalents		(34,999	)		(636	)		(190	)		—			(35,825	)
Cash and cash equivalents at beginning of period		35,070			3,734			1,340			—			40,144
Cash and cash equivalents at end of period	$	71		$	3,098		$	1,150		$	—		$	4,319
(a)
Elimination of equity in earnings of consolidated subsidiaries.
Select Medical Corporation
Consolidating Balance Sheet
December 31, 2012
	Select Medical			Subsidiary			Non-Guarantor			Eliminations			Consolidated
	Corporation (Parent			Guarantors			Subsidiaries
	Company Only)
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	35,070		$	3,734		$	1,340		$	—		$	40,144
Accounts receivable, net		—			308,043			53,531			-1,645	(a)		359,929
Current deferred tax asset		12,383			1,060			4,434			—			17,877
Prepaid income taxes		3,895			—			—			—			3,895
Intercompany receivables		—			1,021,479			102,694			(1,124,173	)(b)		—
Other current assets		5,600			19,655			6,563			—			31,818
Total Current Assets		56,948			1,353,971			168,562			(1,125,818	)		453,663
Property and equipment, net		16,344			425,677			59,531			—			501,552
Investment in affiliates		2,930,022			82,475			—			(3,012,497	)(c)(d)		—
Goodwill		—			1,640,534			—			—			1,640,534
Other identifiable intangibles		—			71,745			—			—			71,745
Non-current deferred tax asset		5,107			—			—			-5,107	(e)		—
Other assets		28,680			63,447			692			—			92,819
Total Assets	$	3,037,101		$	3,637,849		$	228,785		$	(4,143,422	)	$	2,760,313
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	17,836		$	—		$	—		$	—		$	17,836
Current portion of long-term debt and notes payable		8,916			1,059			1,671			—			11,646
Accounts payable		4,674			72,213			12,660			—			89,547
Intercompany payables		1,124,173			—			—			-1,124,173	(b)		—
Accrued payroll		186			88,096			304			—			88,586
Accrued vacation		4,249			44,508			6,957			—			55,714
Accrued interest		17,955			804			—			—			18,759
Accrued other		55,206			31,343			5,534			—			92,083
Due to third party payors		—			—			2,723			-1,645	(a)		1,078
Total Current Liabilities		1,233,195			238,023			29,849			(1,125,818	)		375,249
Long-term debt, net of current portion		872,671			358,104			60,522			—			1,291,297
Non-current deferred tax liability		—			85,287			9,330			-5,107	(e)		89,510
Other non-current liabilities		49,918			28,808			4,973			—			83,699
Total Liabilities		2,155,784			710,222			104,674			(1,130,925	)		1,839,755
Redeemable non-controlling interests		—			—			10,811			—			10,811
Stockholder's Equity:
Common stock		0			—			—			—			0
Capital in excess of par		859,839			—			—			—			859,839
Retained earnings		21,478			790,692			21,197			-811,889	(d)		21,478
Subsidiary investment		—			2,136,935			63,673			-2,200,608	(c)		—
Total Select Medical Corporation Stockholder's Equity		881,317			2,927,627			84,870			(3,012,497	)		881,317
Non-controlling interests		—			—			28,430			—			28,430
Total Equity		881,317			2,927,627			113,300			(3,012,497	)		909,747
Total Liabilities and Equity	$	3,037,101		$	3,637,849		$	228,785		$	(4,143,422	)	$	2,760,313
(a)
Reclass portion of due to third party payor to accounts receivable net in consolidation.
(b)
Elimination of intercompany.
(c)
Elimination of investments in consolidated subsidiaries.
(d)
Elimination of investments in consolidated subsidiaries' earnings.
(e)
Reclass of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.
Select Medical Corporation
Consolidating Statement of Operations
For the Year Ended December 31, 2012
	Select Medical			Subsidiary			Non-Guarantor			Eliminations			Consolidated
	Corporation (Parent			Guarantors			Subsidiaries
	Company Only)
	(in thousands)
Net operating revenues	$	123		$	2,549,896		$	398,950		$	—		$	2,948,969
Costs and expenses:
Cost of services		2,139			2,099,734			341,677			—			2,443,550
General and administrative		67,402			(1,208	)		—			—			66,194
Bad debt expense		—			33,595			5,460			—			39,055
Depreciation and amortization		3,267			50,734			9,310			—			63,311
Total costs and expenses		72,808			2,182,855			356,447			—			2,612,110
Income (loss) from operations		(72,685	)		367,041			42,503			—			336,859
Other income and expense:
Intercompany interest and royalty fees		(2,532	)		2,494			38			—			—
Intercompany management fees		120,276			(102,096	)		(18,180	)		—			—
Loss on early retirement of debt		(6,064	)		—			—			—			(6,064	)
Equity in earnings of unconsolidated subsidiaries		—			7,637			68			—			7,705
Interest expense		(54,167	)		(25,348	)		(4,244	)		—			(83,759	)
Income (loss) from operations before income taxes		(15,172	)		249,728			20,185			—			254,741
Income tax expense (benefit)		(8,206	)		101,795			(15	)		—			93,574
Equity in earnings of subsidiaries		162,470			15,639			—			(178,109	)(a)		—
Net income		155,504			163,572			20,200			(178,109	)		161,167
Less: Net income attributable to non-controlling interests		—			—			5,663			—			5,663
Net income attributable to Select Medical Corporation	$	155,504		$	163,572		$	14,537		$	(178,109	)	$	155,504
(a)
Elimination of equity in earnings of subsidiaries.
Select Medical Corporation
Consolidating Statement of Cash Flows
For the Year Ended December 31, 2012
	Select Medical			Subsidiary			Non-Guarantor			Eliminations			Consolidated
	Corporation (Parent			Guarantors			Subsidiaries
	Company Only)
	(in thousands)
Operating activities
Net income	$	155,504		$	163,572		$	20,200		$	-178,109	(a)	$	161,167
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		3,267			50,734			9,310			—			63,311
Provision for bad debts		—			33,595			5,460			—			39,055
Equity in earnings of unconsolidated subsidiaires		—			(7,637	)		(68	)		—			(7,705	)
Loss on early retirement of debt		6,064			—			—			—			6,064
Loss (gain) from disposal or sale of assets		—			(6,002	)		96			—			(5,906	)
Non-cash stock compensation expense		5,677			—			—			—			5,677
Amortization of debt discount and issuance costs		7,190			—			—			—			7,190
Deferred income taxes		7,909			—			—			—			7,909
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries		(162,470	)		(15,639	)		—			178,109	(a)		—
Accounts receivable		—			29,727			(14,569	)		—			15,158
Other current assets		740			141			(2,488	)		—			(1,607	)
Other assets		2,448			3,268			161			—			5,877
Accounts payable		(2,679	)		(4,040	)		602			—			(6,117	)
Due to third-party payors		—			(15,278	)		10,830			—			(4,448	)
Accrued expenses		25,350			(3,835	)		2,231			—			23,746
Net cash provided by operating activities		49,000			228,606			31,765			—			309,371
Investing activities
Purchases of property and equipment		(5,150	)		(49,160	)		(13,875	)		—			(68,185	)
Investment in businesses, net of distributions		—			(14,689	)		—			—			(14,689	)
Acquisition of businesses, net of cash acquired		—			(6,043	)		—			—			(6,043	)
Proceeds from sale of assets		—			16,511			—			—			16,511
Net cash used in investing activities		(5,150	)		(53,381	)		(13,875	)		—			(72,406	)
Financing activities
Borrowings on revolving credit facility		495,000			—			—			—			495,000
Payments on revolving credit facility		(405,000	)		—			—			—			(405,000	)
Borrowings on 2011 credit facility term loans, net of discount		266,750			—			—			—			266,750
Payments on 2011 credit facility term loans		(9,875	)		—			—			—			(9,875	)
Repurchase of 75/8% senior subordinated notes, net of premiums		(278,495	)		—			—			—			(278,495	)
Borrowings of other debt		8,003			—			278			—			8,281
Principal payments on other debt		(8,049	)		(433	)		(1,813	)		—			(10,295	)
Debt issuance costs		(6,527	)		—			—			—			(6,527	)
Proceeds from bank overdrafts		1,227			—			—			—			1,227
Equity investment by Holdings		1,817			—			—			—			1,817
Dividends paid to Holdings		(268,479	)		—			—			—			(268,479	)
Intercompany		183,421			(171,058	)		(12,363	)		—			—
Distributions to non-controlling interests		—			—			(3,268	)		—			(3,268	)
Net cash used in financing activities		(20,207	)		(171,491	)		(17,166	)		—			(208,864	)
Net increase in cash and cash equivalents		23,643			3,734			724			—			28,101
Cash and cash equivalents at beginning of period		11,427			—			616			—			12,043
Cash and cash equivalents at end of period	$	35,070		$	3,734		$	1,340		$	—		$	40,144
(a)
Elimination of equity in earnings of consolidated subsidiaries.
Select Medical Corporation
Consolidating Statement of Operations
For the Year Ended December 31, 2011
	Select Medical			Subsidiary			Non-Guarantor			Eliminations			Consolidated
	Corporation (Parent			Guarantors			Subsidiaries
	Company Only)
	(in thousands)
Net operating revenues	$	121		$	2,436,177		$	368,209		$	—		$	2,804,507
Costs and expenses:
Cost of services		1,729			1,996,671			310,170			—			2,308,570
General and administrative		61,995			359			—			—			62,354
Bad debt expense		—			44,300			7,047			—			51,347
Depreciation and amortization		4,115			58,064			9,338			—			71,517
Total costs and expenses		67,839			2,099,394			326,555			—			2,493,788
Income (loss) from operations		(67,718	)		336,783			41,654			—			310,719
Other income and expense:
Intercompany interest and royalty fees		(3,408	)		3,382			26			—			—
Intercompany management fees		120,013			(102,970	)		(17,043	)		—			—
Loss on early retirement of debt		(20,385	)		—			—			—			(20,385	)
Equity in earnings of unconsolidated subsidiaries		—			2,870			53			—			2,923
Interest income		132			122			68			—			322
Interest expense		(41,817	)		(34,612	)		(4,803	)		—			(81,232	)
Income (loss) before income taxes		(13,183	)		205,575			19,955			—			212,347
Income tax expense (benefit)		(12,821	)		92,561			1,244			—			80,984
Equity in earnings of subsidiaries		126,809			13,406			—			-140,215	(a)		—
Net income		126,447			126,420			18,711			(140,215	)		131,363
Less: Net income attributable to non-controlling interests		—			—			4,916			—			4,916
Net income attributable to Select Medical Corporation	$	126,447		$	126,420		$	13,795		$	(140,215	)	$	126,447
(a)
Elimination of equity in earnings of subsidiaries.
Select Medical Corporation
Consolidating Statement of Cash Flows
For the Year Ended December 31, 2011
	Select Medical			Subsidiary			Non-Guarantor			Eliminations			Consolidated
	Corporation (Parent			Guarantors			Subsidiaries
	Company Only)
	(in thousands)
Operating activities
Net income	$	126,447		$	126,420		$	18,711		$	-140,215	(a)	$	131,363
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		4,115			58,064			9,338			—			71,517
Provision for bad debts		—			44,300			7,047			—			51,347
Equity in earnings of unconsolidated subsidiaries		—			(2,870	)		(53	)		—			(2,923	)
Loss on early retirement of debt		20,385			—			—			—			20,385
Loss (gain) from disposal or sale of assets		13			(5,024	)		45			—			(4,966	)
Non-cash stock compensation expense		3,725			—			—			—			3,725
Amortization of debt discount and issuance costs		6,700			—			—			—			6,700
Deferred income taxes		35,305			—			—			—			35,305
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries		(126,809	)		(13,406	)		—			140,215	(a)		—
Accounts receivable		—			(98,966	)		(12,160	)		—			(111,126	)
Other current assets		(1,780	)		1,165			(586	)		—			(1,201	)
Other assets		(12,069	)		9,683			318			—			(2,068	)
Accounts payable		1,326			16,247			3,056			—			20,629
Due to third-party payors		—			1,408			(1,181	)		—			227
Accrued expenses		14,823			5,522			794			—			21,139
Net cash provided by operating activities		72,181			142,543			25,329			—			240,053
Investing activities
Purchases of property and equipment		(3,413	)		(37,759	)		(4,844	)		—			(46,016	)
Investment in businesses, net of distributions		—			(15,699	)		—			—			(15,699	)
Acquisition of businesses, net of cash acquired		—			(899	)		—			—			(899	)
Proceeds from sale of assets		—			7,879			—			—			7,879
Net cash used in investing activities		(3,413	)		(46,478	)		(4,844	)		—			(54,735	)
Financing activities
Borrowings on revolving credit facility		735,000			—			—			—			735,000
Payments on revolving credit facility		(720,000	)		—			—			—			(720,000	)
Borrowings on 2011 credit facility term loans, net of discount		841,500			—			—			—			841,500
Payments on 2011 credit facility term loans		(4,250	)		—			—			—			(4,250	)
Payments on 2005 credit facility term loans, net of call premium		(484,633	)		—			—			—			(484,633	)
Repurchase of 75/8% senior subordinated notes, net of premiums		(273,941	)		—			—			—			(273,941	)
Borrowings of other debt		6,100			955			—			—			7,055
Principal payments on other debt		(5,662	)		(755	)		(1,082	)		—			(7,499	)
Debt issuance costs		(18,556	)		—			—			—			(18,556	)
Repayments of bank overdrafts		(2,183	)		—			—			—			(2,183	)
Equity investment by Holdings		208			—			—			—			208
Dividends paid to Holdings		(245,729	)		—			—			—			(245,729	)
Intercompany		114,656			(99,832	)		(14,824	)		—			—
Distributions to non-controlling interests		—			—			(4,612	)		—			(4,612	)
Net cash used in financing activities		(57,490	)		(99,632	)		(20,518	)		—			(177,640	)
Net increase (decrease) in cash and cash equivalents		11,278			(3,567	)		(33	)		—			7,678
Cash and cash equivalents at beginning of period		149			3,567			649			—			4,365
Cash and cash equivalents at end of period	$	11,427		$	—		$	616		$	—		$	12,043
(a)
Elimination of equity in earnings of consolidated subsidiaries.

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2013
Selected Quarterly Financial Data (Unaudited)	'
Selected Quarterly Financial Data (Unaudited)	'
	19.   Selected Quarterly Financial Data (Unaudited)
	The table below sets forth selected unaudited financial data for each quarter of the last two years.
		Holdings
		First		Second		Third		Fourth
		Quarter		Quarter		Quarter		Quarter
		(in thousands, except per share amounts)
	Year ended December 31, 2012
	Net operating revenues	$	744,021	$	750,193	$	713,669	$	741,086
	Income from operations		91,604		93,513		70,819		80,923
	Net income attributable to Select Medical Holdings Corporation	$	41,542	$	43,172	$	24,110	$	39,406
	Income per common share:
	Basic	$	0.29	$	0.31	$	0.17	$	0.28
	Diluted	$	0.29	$	0.31	$	0.17	$	0.28
		Select
		First		Second		Third		Fourth
		Quarter		Quarter		Quarter		Quarter
		(in thousands)
	Year ended December 31, 2012
	Net operating revenues	$	744,021	$	750,193	$	713,669	$	741,086
	Income from operations		91,604		93,513		70,819		80,923
	Net income attributable to Select Medical Corporation	$	43,279	$	45,018	$	25,953	$	41,254
		Holdings
		First		Second		Third		Fourth
		Quarter		Quarter		Quarter		Quarter
		(in thousands, except per share amounts)
	Year ended December 31, 2013
	Net operating revenues	$	749,955	$	756,673	$	722,845	$	746,175
	Income from operations		82,530		88,263		62,399		68,244
	Net income attributable to Select Medical Holdings Corporation	$	34,418	$	27,780	$	23,272	$	28,920
	Income per common share:
	Basic	$	0.25	$	0.2	$	0.17	$	0.21
	Diluted	$	0.24	$	0.2	$	0.17	$	0.21
		Select
		First		Second		Third		Fourth
		Quarter		Quarter		Quarter		Quarter
		(in thousands)
	Year ended December 31, 2013
	Net operating revenues	$	749,955	$	756,673	$	722,845	$	746,175
	Income from operations		82,530		88,263		62,399		68,244
	Net income attributable to Select Medical Corporation	$	36,608	$	27,780	$	23,272	$	28,920

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2013
Schedule II - Valuation and Qualifying Accounts	'
Schedule II - Valuation and Qualifying Accounts	'
	Select Medical Holdings Corporation
	Select Medical Corporation
	Schedule II — Valuation and Qualifying Accounts
	Description	Balance at		Charged to			Acquisitions		Deductions			Balance at
		Beginning		Cost and			(A)		(B)			End of Year
		of Year		Expenses
		(in thousands)
	Allowance for Doubtful Accounts
	Year ended December 31, 2013	$	41,854	$	37,423		$	—	$	(38,462	)	$	40,815
	Year ended December 31, 2012	$	47,469	$	39,055		$	—	$	(44,670	)	$	41,854
	Year ended December 31, 2011	$	44,416	$	51,347		$	108	$	(48,402	)	$	47,469
	Income Tax Valuation Allowance
	Year ended December 31, 2013	$	13,341	$	(2,794	)	$	—	$	—		$	10,547
	Year ended December 31, 2012	$	15,733	$	(2,392	)	$	—	$	—		$	13,341
	Year ended December 31, 2011	$	16,622	$	(889	)	$	—	$	—		$	15,733
	(A)
	Represents opening balance sheet reserves resulting from purchase accounting entries.
	(B)
	Allowance for doubtful accounts deductions represent write-offs against the reserve for 2011, 2012 and 2013.

Organization_and_Significant_A1

Organization and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Organization and Significant Accounting Policies	'
Reclassifications	'
	Reclassifications
	Certain reclassifications have been made to prior-year amounts in order to conform to the current-year presentation.
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company, its majority owned subsidiaries, limited liability companies and limited partnerships the Company and its subsidiaries control through ownership of general and limited partnership or membership interests. All significant intercompany balances and transactions are eliminated in consolidation.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at cost which approximates market value.
Accounts Receivable and Allowance for Doubtful Accounts	'
	Accounts Receivable and Allowance for Doubtful Accounts
	The Company reports accounts receivable at estimated net realizable values. Substantially all of the Company's accounts receivable are related to providing healthcare services to patients whose costs are primarily paid by federal and state governmental authorities, managed care health plans, commercial insurance companies and workers' compensation programs. Collection of these accounts receivable is the Company's primary source of cash and is critical to its operating performance. The Company's primary collection risks relate to non-governmental payors who insure these patients and deductibles, co-payments and amounts owed by the patient. Deductibles, co-payments and amounts owed by the patient are an immaterial portion of the Company's net accounts receivable balance and accounted for approximately 0.2% and 0.3% of the net accounts receivable balance before doubtful accounts at December 31, 2012 and 2013, respectively. The Company's general policy is to verify insurance coverage prior to the date of admission for a patient admitted to the Company's hospitals or in the case of the Company's outpatient rehabilitation clinics, the Company verifies insurance coverage prior to their first therapy visit. The Company's estimate for the allowance for doubtful accounts is calculated by providing a reserve allowance based upon the age of an account balance. Generally the Company has reserved as uncollectible all governmental accounts over 365 days and non-governmental accounts over 180 days from discharge. This method is monitored based on historical cash collections experience. Collections are impacted by the effectiveness of the Company's collection efforts with non-governmental payors and regulatory or administrative disruptions with the fiscal intermediaries that pay the Company's governmental receivables.
	The Company has historically collected substantially all of its third-party insured receivables (net of contractual allowances) which include receivables from governmental agencies. The Company reviews its overall reserve adequacy by monitoring historical cash collections as a percentage of net revenue less the provision for bad debts.
	Uncollected accounts are written off the balance sheet when they are turned over to an outside collection agency, or when management determines that the balance is uncollectible, whichever occurs first.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost net of accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets or the term of the lease, as appropriate. The general range of useful lives is as follows:
	Leasehold improvements	5 – 15 years
	Furniture and equipment	3 – 20 years
	Buildings	40 years
	Building Improvements	5 – 25 years
	Land Improvements	2 – 25 years
	The Company reviews the realizability of long-lived assets whenever events or circumstances occur which indicate recorded costs may not be recoverable. Gains or losses related to the retirement or disposal of property and equipment are reported as a component of income from operations.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash balances and trade receivables. The Company invests its excess cash with large financial institutions. The Company grants unsecured credit to its patients, most of who reside in the service area of the Company's facilities and are insured under third-party payor agreements. Because of the geographic diversity of the Company's facilities and non-governmental third-party payors, Medicare represents the Company's only significant concentration of credit risk.
Income Taxes	'
	Income Taxes
	Deferred tax assets and liabilities are recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. As part of the process of preparing its consolidated financial statements, the Company estimates income taxes based on its actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for book and tax purposes. The Company also recognizes as deferred tax assets the future tax benefits from net operating loss carry forwards. The Company evaluates the realizability of these deferred tax assets by assessing their valuation allowances and by adjusting the amount of such allowances, if necessary. Among the factors used to assess the likelihood of realization are projections of future taxable income streams, the expected timing of the reversals of existing temporary differences, and the impact of tax planning strategies that could be implemented to avoid the potential loss of future tax benefits.
	Reserves for uncertain tax positions are established for exposure items related to various federal and state tax matters. Income tax reserves are recorded when an exposure is identified and when, in the opinion of management, it is more likely than not that a tax position will not be sustained and the amount of the liability can be estimated.
Intangible Assets	'
	Intangible Assets
	Goodwill and certain other indefinite-lived intangible assets are not amortized, but instead are subject to periodic impairment evaluations. In performing the quantitative periodic impairment tests, the fair value of the reporting unit is compared to its carrying value, including goodwill and other intangible assets. If the carrying value exceeds the fair value, an impairment condition exists, which results in an impairment loss equal to the excess carrying value.
	To determine the fair value of its reporting units, the Company uses a discounted cash flow approach. Included in this analysis are assumptions regarding revenue growth rate, future Adjusted EBITDA margin estimates, future general and administrative expense rates and the industry's weighted average cost of capital and industry specific market comparable Adjusted EBITDA multiples. The Company also must estimate residual values at the end of the forecast period and future capital expenditure requirements. Each of these assumptions requires the Company to use its knowledge of (1) its industry, (2) its recent transactions, and (3) reasonable performance expectations for its operations. If any one of the above assumptions changes or fails to materialize, the resulting decline in the Company's estimated fair value could result in a material impairment charge to the goodwill associated with any one of the reporting units.
	Impairment tests are required to be conducted at least annually, or when events or conditions occur that might suggest a possible impairment. These events or conditions include, but are not limited to, a significant adverse change in the business environment, regulatory environment or legal factors; a current period operating or cash flow loss combined with a history of such losses or a projection of continuing losses; or a sale or disposition of a significant portion of a reporting unit. The occurrence of one of these events or conditions could significantly impact an impairment assessment, necessitating an impairment charge. For purposes of goodwill impairment assessment, the Company has defined its reporting units as specialty hospitals, outpatient rehabilitation clinics and contract therapy with goodwill having been allocated among reporting units based on the relative fair value of those divisions when the Merger occurred in 2005 and based on subsequent acquisitions and dispositions. The Company's most recent impairment assessment was completed during the fourth quarter of 2013 utilizing financial information as of October 1, 2013 and indicated that there was no impairment with respect to goodwill or other recorded intangible assets.
	Identifiable assets and liabilities acquired in connection with business combinations accounted for under the purchase method are recorded at their respective fair values. Deferred income taxes have been recorded to the extent of differences between the fair value and the tax basis of the assets acquired and liabilities assumed. Company management has allocated the intangible assets between identifiable intangibles and goodwill. At December 31, 2013, intangible assets other than goodwill consist of the values assigned to trademarks, certificates of need and accreditations. Management believes that the estimated useful lives established are reasonable based on the economic factors applicable to each of the intangible assets.
	The approximate useful life of each class of intangible assets is as follows:
	Trademarks	Indefinite
	Certificates of need	Indefinite
	Accreditations	Indefinite
	The Company reviews the realizability of intangible assets whenever events or circumstances occur which indicate recorded amounts may not be recoverable.
	If the expected future cash flows (undiscounted) are less than the carrying amount of such assets, the Company recognizes an impairment loss for the difference between the carrying amount of the assets and their estimated fair value.
Due to Third-Party Payors	'
	Due to Third-Party Payors
	Due to third-party payors represents the difference between amounts received under interim payment plans from Medicare and Medicaid for services rendered and amounts estimated to be reimbursed by those third-party payors upon settlement of cost reports.
Insurance Risk Programs	'
	Insurance Risk Programs
	Under a number of the Company's insurance programs, which include the Company's employee health insurance program, its workers' compensation, professional malpractice liability insurance programs and certain components under its property and casualty insurance program, the Company is liable for a portion of its losses. In these situations the Company accrues for its losses under an occurrence-based approach whereby the Company estimates the losses that will be incurred in a respective accounting period and accrues that estimated liability. Where the Company has substantial exposure, actuarial methods are utilized in estimating the losses. In cases where the Company has minimal exposure, losses are estimated by analyzing historical trends. These programs are monitored quarterly and estimates are revised as necessary to take into account additional information. Provisions for losses for professional liability risks retained by the Company at December 31, 2012 and 2013 have been discounted at 3%. At December 31, 2012 and 2013, respectively, the Company had recorded a liability of $92.5 million and $103.4 million related to these programs. If the Company did not discount the provisions for losses for professional liability risks, the aggregate liability for all of the insurance risk programs would be approximately $95.6 million and $106.8 million at December 31, 2012 and 2013, respectively.
Equity Method Investments	'
	Equity Method Investments
	Investments in equity method investees are accounted for using the equity method based upon the level of ownership and/or the Company's ability to exercise significant influence over the operating and financial policies of the investee. Investments of this nature are recorded at original cost and adjusted periodically to recognize the Company's proportionate share of the investees' net income or losses after the date of investment. When net losses from an investment accounted for under the equity method exceeds its carrying amount, the investment balance is reduced to zero. The Company resumes accounting for the investment under the equity method if the entity subsequently reports net income and the Company's share of that net income exceeds the share of the net losses not recognized during the period the equity method was suspended. Investments are written down only when there is clear evidence that a decline in value that is other than temporary has occurred. The Company evaluates its investments in companies accounted for using the equity method for impairment when there is evidence or indicators that a decrease in value may be other than temporary.
Non-Controlling Interests	'
	Non-Controlling Interests
	The interests held by other parties in subsidiaries, limited liability companies and limited partnerships owned and controlled by the Company are generally reported as a component of stockholders' equity. Some of those minority ownership interests consist of outside owners that have certain "put rights," that are currently exercisable, and that, if exercised, require the Company to purchase the minority member's interest. These redeemable non-controlling interests that are currently redeemable or considered probable of becoming redeemable have been adjusted to their approximate redemption values and are reported outside of the stockholders' equity section. As of December 31, 2012 and 2013, the Company believes the redemption values of the non-controlling ownership interests approximates the fair value of those interests classified as redeemable non-controlling interests. The redeemable non-controlling interests' balances reported on our consolidated balance sheets were $10.8 million and $11.6 million as of December 31, 2012 and 2013, respectively. The non-controlling interests' balances reported in the stockholders' equity section of our consolidated balance sheets were $28.4 million and $32.4 million as of December 31, 2012 and 2013, respectively.
	Net income attributable to non-controlling interests was $4.9 million, $5.7 million and $8.6 million for the years ended December 31, 2011, 2012, and 2013, respectively. Non-controlling interests reported in the consolidated statement of operations and comprehensive income reflect the respective interests in the income or loss of the subsidiaries, attributable to the other parties, the effect of which is removed from the Company's consolidated statement of operations and comprehensive income.
Revenue Recognition	'
	Revenue Recognition
	Net operating revenues consists primarily of patient service revenues and revenues generated from therapy services provided to healthcare institutions under contractual arrangements and are recognized as services are rendered.
	Patient service revenue is reported net of provisions for contractual allowances from third-party payors and patients. The Company has agreements with third-party payors that provide for payments to the Company at amounts different from its established billing rates. The differences between the estimated program reimbursement rates and the standard billing rates are accounted for as contractual adjustments, which are deducted from gross revenues to arrive at net operating revenues. Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges, per diem and per visit payments. Retroactive adjustments are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods as final settlements are determined. Accounts receivable resulting from such payment arrangements are recorded net of contractual allowances.
	A significant portion of the Company's net operating revenues are generated directly from the Medicare program. Net operating revenues generated directly from the Medicare program represented approximately 48%, 47% and 46% of the Company's net operating revenues for the years ended December 31, 2011, 2012 and 2013, respectively. Approximately 29% and 32% of the Company's accounts receivable (after allowances for contractual adjustments but before doubtful accounts) at December 31, 2012 and 2013, respectively, are from Medicare. As a provider of services to the Medicare program, the Company is subject to extensive regulations. The inability of any of the Company's specialty hospitals or clinics to comply with regulations can result in significant changes in that specialty hospital's or clinic's net operating revenues generated from the Medicare program.
	Revenues generated under contractual arrangements are comprised primarily of billings for services rendered to nursing homes, hospitals, schools and other third parties.
Stock Based Compensation	'
	Stock Based Compensation
	The Company measures the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognizes the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements comprise both stock options and restricted share plans. Employee stock options are valued using the Black-Scholes option valuation method which uses assumptions that relate to the expected volatility of the Company's common stock, the expected dividend yield of the Company's stock, the expected life of the options and the risk free interest rate. Such compensation amounts, if any, are amortized over the respective vesting periods or periods of service of the option grant. The Company values restricted stock grants by using the closing market price of its stock on the date of grant.

Organization_and_Significant_A2

Organization and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Organization and Significant Accounting Policies	'
Schedule of general range of useful lives of property and equipment	'
	Leasehold improvements	5 – 15 years
	Furniture and equipment	3 – 20 years
	Buildings	40 years
	Building Improvements	5 – 25 years
	Land Improvements	2 – 25 years
Schedule of approximate useful life of each class of intangible assets	'
	Trademarks	Indefinite
	Certificates of need	Indefinite
	Accreditations	Indefinite

Acquisitions_Tables

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2013
Acquisitions	'
Schedule of all businesses acquired in purchase transactions	'
		For the Year Ended
		December 31,
		2011			2012			2013
		(in thousands)
	Cash paid (net of cash acquired)	$	899		$	6,043		$	1,665
	Notes issued		1,020			1,844			3,283
			1,919			7,887			4,948
	Contingent consideration		—			1,500			100
	Liabilities assumed		701			107			885
			2,620			9,494			5,933
	Fair value of assets acquired, principally accounts receivable and property and equipment		767			1,313			3,487
	Non-controlling interests		(602	)		(970	)		347
	Cost in excess of fair value of net assets acquired (goodwill)	$	2,455		$	9,151		$	2,099

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property and Equipment	'
Schedule of components of property and equipment	'
		December 31,
		2012		2013
		(in thousands)
	Land	$	68,573	$	68,492
	Leasehold improvements		128,468		146,117
	Buildings		352,677		368,968
	Furniture and equipment		246,858		256,079
	Construction-in-progress		21,648		26,639
			818,224		866,295
	Less: accumulated depreciation		316,672		357,193
	Total property and equipment	$	501,552	$	509,102

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Intangible Assets	'
Schedule of gross carrying amounts of the Company's indefinite-lived intangible assets	'
		December 31,
		2012			2013
		(in thousands)
	Goodwill	$	1,640,534		$	1,642,633
	Trademarks		57,709			57,709
	Certificates of need		11,914			12,115
	Accreditations		2,122			2,083
	Total	$	1,712,279		$	1,714,540
Schedule of amortization expenses for intangible assets with finite lives	'
		For the Year Ended
		December 31
		2011			2012			2013
		(in thousands)
	Amortization expense	$	1,306		$	340		$	—
Schedule of changes in the carrying amount of goodwill for the Company's reportable segments	'
		Specialty			Outpatient			Total
		Hospitals			Rehabilitation
		(in thousands)
	Balance as of January 1, 2012	$	1,333,553		$	298,163		$	1,631,716
	Goodwill acquired during year		—			9,151			9,151
	Other		(333	)		—			(333	)
	Balance as of December 31, 2012	$	1,333,220		$	307,314		$	1,640,534
	Goodwill acquired during year		1,395			837			2,232
	Purchase price adjustment		—			(133	)		(133	)
	Balance as of December 31, 2013	$	1,334,615		$	308,018		$	1,642,633

LongTerm_Debt_and_Notes_Payabl1

Long-Term Debt and Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of components of long-term debt and notes payable	'
		Holdings
		December 31,
		2012		2013
		(in thousands)
	75/8% senior subordinated notes	$	70,000	$	—
	6.375% senior notes		—		600,000
	Senior secured credit facilities:
	Revolving loan		130,000		20,000
	Term loans(1)		1,096,641		807,815
	Senior floating rate notes		167,300		—
	Other		6,302		17,460
	Total debt		1,470,243		1,445,275
	Less: current maturities		11,646		17,565
	Total long-term debt	$	1,458,597	$	1,427,710
Schedule of maturities of the Company's long-term debt	'
	Maturities of the Company's long-term debt for the years after 2013 are approximately as follows and are presented net of the discount on the senior secured credit facility term loans (in thousands):
	2014	$	17,565
	2015		10,183
	2016		296,232
	2017		4,075
	2018		515,820
	2019 and beyond		601,400
Select	'
Schedule of components of long-term debt and notes payable	'
		Select
		December 31,
		2012		2013
		(in thousands)
	75/8% senior subordinated notes	$	70,000	$	—
	6.375% senior notes		—		600,000
	Senior secured credit facilities:
	Revolving loan		130,000		20,000
	Term loans(1)		1,096,641		807,815
	Other		6,302		17,460
	Total debt		1,302,943		1,445,275
	Less: current maturities		11,646		17,565
	Total long-term debt	$	1,291,297	$	1,427,710
	-1
	Presented net of unamortized discount of $14.2 million and $6.3 million at December 31, 2012 and 2013, respectively.

Stock_Option_and_Restricted_St1

Stock Option and Restricted Stock Plans (Tables)	12 Months Ended
	Dec. 31, 2013
Stock option and restricted stock plans	'
Summary of stock option grants	'
	The following is a summary of stock option grants under the Plans and Director Plan from January 1, 2011 through December 31, 2013:
			Number of Options			Exercise			Fair Value of
			Granted			Price			Common Stock
			(share amounts in thousands)
	March 3, 2011			88			7.66			7.66
	May 13, 2011			20			9			9
	August 3, 2011			10			7.14			7.14
Summary of restricted stock issuances	'
	The following is a summary of restricted stock issuances from January 1, 2011 through December 31, 2013:
			Number of Shares Issued			Fair Value of Common Stock
			(share amounts in thousands)
	August 3, 2011			25			7.14
	November 3, 2011			190			8.61
	December 15, 2011			350			8.57
	March 26, 2012			65			8.33
	May 2, 2012			129			8.67
	August 7, 2012			38			11.84
	October 30, 2012			530			10.75
	January 2, 2013			5			9.9
	February 20, 2013			35			8.8
	May 1, 2013			115			8.06
	August 7, 2013			38			8.89
	October 30, 2013			760			8.5
Schedule of stock compensation expense for each of the next five years	'
	Stock compensation expense for each of the next five years, based on restricted stock awards granted as of December 31, 2013, is estimated to be as follows:
			2014			2015			2016			2017		2018
			(in thousands)
	Stock compensation expense		$	7,740		$	6,057		$	3,061		$	581	$	40
Schedule of stock compensation expense recognized related to restricted stock and stock option awards	'
			For the Year Ended
			December 31,
			2011			2012			2013
			(in thousands)
	Stock compensation expense:
	Included in general and administrative		$	1,996		$	3,538		$	5,276
	Included in cost of services			1,729			2,139			1,757
	Total		$	3,725		$	5,677		$	7,033
Plans	'
Stock option and restricted stock plans	'
Schedule of stock option transactions and other information	'
			Price Per Share			Shares			Weighted
									Average
									Exercise Price
			(share amounts in thousands)
	Balance, January 1, 2012		$	3.33 - 10.00			2,730		$	8.16
	Granted			—			—			—
	Exercised			3.33 - 10.00			(280	)		6.07
	Canceled			7.66 - 10.00			(27	)		8.18
	Balance, December 31, 2012		$	3.33 - 10.00			2,423		$	8.4
	Granted			—			—			—
	Exercised			7.14 - 10.00			(167	)		9.15
	Canceled			8.33 - 10.00			(316	)		9.13
	Balance, December 31, 2013		$	3.33 - 10.00			1,940		$	8.22
Schedule of additional information with respect to the outstanding options	'
	Additional information with respect to the outstanding options as of December 31, 2013 for the Plans is as follows:
	Exercise Price		Number			Weighted Average			Number
			Outstanding			Remaining			Exercisable
						Contractual Life
			(share amounts in thousands)
	$  3.00 – 4.00			220			1.15			220
	6.00 – 7.00			9			6.61			3
	7.01 – 8.00			75			7.2			28
	8.01 – 9.00			585			3.31			557
	9.01 – 10.00			1,051			5.51			848
Director Plan	'
Stock option and restricted stock plans	'
Schedule of stock option transactions and other information	'
			Price Per Share			Shares			Weighted Average
									Exercise Price
			(share amounts in thousands)
	Balance, January 1, 2012		$	3.33 - 10.00			63		$	7.62
	Granted			—			—			—
	Exercised			3.33 - 8.33			(21	)		5.47
	Balance, December 31, 2012		$	3.33 - 10.00			42		$	8.69
	Granted			—			—			—
	Exercised			—			—			—
	Balance, December 31, 2013		$	3.33 - 10.00			42		$	8.69
Schedule of additional information with respect to the outstanding options	'
	Additional information with respect to the outstanding options as of December 31, 2013 for the Director Plan is as follows:
	Exercise Price			Number			Weighted			Number
				Outstanding			Average			Exercisable
							Remaining
							Contractual Life
				(share amounts in thousands)
	$	3.00 – 4.00			6			1.61			6
		8.00 – 9.00			9			3.37			9
		9.01 – 10.00			27			5.12			25

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
Schedule of significant components of the Company's tax provision	'
		Holdings									Select
		For the Year Ended									For the Year Ended
		December 31,									December 31,
		2011			2012			2013			2011			2012			2013
		(in thousands)									(in thousands)
	Current:
	Federal	$	29,991		$	70,159		$	55,847		$	40,007		$	74,076		$	57,026
	State and local		5,672			11,589			11,913			5,672			11,589			11,913
	Total current		35,663			81,748			67,760			45,679			85,665			68,939
	Deferred		35,305			7,909			7,032			35,305			7,909			7,032
	Total income tax provision	$	70,968		$	89,657		$	74,792		$	80,984		$	93,574		$	75,971
Schedule of differences between the expected income tax provision and income taxes computed at the federal statutory rate	'
		Holdings									Select
		For the Year Ended									For the Year Ended
		December 31,									December 31,
		2011			2012			2013			2011			2012			2013
	Expected federal tax rate		35	%		35	%		35	%		35	%		35	%		35	%
	State and local taxes, net of federal benefit		4.5			4.2			4.6			3.9			4			4.5
	Other permanent differences		1			0.6			1.1			0.9			0.6			1.1
	Valuation allowance		(0.5	)		(0.6	)		(0.7	)		(0.4	)		(0.6	)		(0.6	)
	Uncertain tax positions		(3.6	)		(0.5	)		(0.6	)		(3.1	)		(0.5	)		(0.6	)
	IRS audit settlements		—			(0.6	)		—			—			(0.5	)		—
	Non-controlling interest		(1.1	)		(0.9	)		(1.7	)		(0.9	)		(0.9	)		(1.7	)
	Sale of entities		3.1			—			—			2.7			—			—
	Other		0.2			(0.4	)		0.1			—			(0.4	)		0.1
	Total		38.6	%		36.8	%		37.8	%		38.1	%		36.7	%		37.8	%
Summary of deferred tax assets and liabilities for Holdings and Select	'
		December 31, 2012											December 31, 2013
		Total			Current			Non-Current					Total			Current			Non-Current
		(in thousands)
	Deferred tax assets
	Allowance for doubtful accounts	$	1,496		$	1,496		$	—				$	1,484		$	1,484		$	—
	Compensation and benefit related accruals		45,784			38,254			7,530					45,147			35,706			9,441
	Professional malpractice liability insurance		17,005			5,003			12,002					20,333			6,382			13,951
	Restructuring reserve		679			679			—					441			441			—
	Net operating loss carryforwards		24,543			777			23,766					22,686			422			22,264
	Other		1,025			996			29					630			630			—
	Stock options		4,089			—			4,089					4,392			—			4,392
	Uncertain tax positions		2,661			—			2,661					2,107			—			2,107
	Total deferred tax assets		97,282			47,205			50,077					97,220			45,065			52,155
	Deferred tax liabilities
	Deferred income		(33,188	)		(26,253	)		(6,935	)				(31,832	)		(24,897	)		(6,935	)
	Other		(1,311	)		(118	)		(1,193	)				(2,620	)		(230	)		(2,390	)
	Depreciation and amortization		(121,075	)		—			(121,075	)				(130,884	)		—			(130,884	)
	Total deferred tax liabilities		(155,574	)		(26,371	)		(129,203	)				(165,336	)		(25,127	)		(140,209	)
	Net deferred taxes before valuation allowance		(58,292	)		20,834			(79,126	)				(68,116	)		19,938			(88,054	)
	Valuation allowance		(13,341	)		(2,957	)		(10,384	)				(10,547	)		(2,314	)		(8,233	)
	Net deferred taxes	$	(71,633	)	$	17,877		$	(89,510	)			$	(78,663	)	$	17,624		$	(96,287	)
Schedule of state net operating loss carry forwards	'
		State Net Operating Losses			Gross Valuation Allowance
		(in thousands)
	2014	$	5,427		$	5,401
	2015		8,333			7,980
	2016		11,238			9,728
	2017		12,834			11,092
	Thereafter through 2033		473,034			355,392
Schedule of reconciliation of the Company's unrecognized tax benefits	'
	The reconciliation of the Company's unrecognized tax benefits is as follows (in thousands):
	Gross tax contingencies — January 1, 2011	$	22,310
	Reductions for tax positions taken in prior periods due primarily to statute expiration		(2,706	)
	Reductions for tax positions taken in prior periods due to change in estimate		(7,012	)
	Additions for existing tax positions taken		3,064
	Gross tax contingencies — December 31, 2011		15,656
	Reductions for tax positions taken in prior periods due primarily to statute expiration		(2,516	)
	Additions for existing tax positions taken		750
	Gross tax contingencies — December 31, 2012		13,890
	Reductions for tax positions taken in prior periods due primarily to statute expiration		(2,299	)
	Additions for existing tax positions taken		435
	Gross tax contingencies — December 31, 2013	$	12,026

Segment_Information_Tables

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Information	'
Schedule of selected financial data for the Company's reportable segments	'
		Year Ended December 31, 2011
		Specialty			Outpatient			Other			Total
		Hospitals			Rehabilitation
		(in thousands)
	Net revenue	$	2,095,519		$	708,867		$	121		$	2,804,507
	Adjusted EBITDA		362,334			83,864			(60,237	)		385,961
	Total assets(1):
	Select		2,187,767			486,589			96,382			2,770,738
	Holdings		2,187,767			486,589			97,791			2,772,147
	Capital expenditures		30,464			12,135			3,417			46,016
		Year Ended December 31, 2012
		Specialty			Outpatient			Other			Total
		Hospitals			Rehabilitation
		(in thousands)
	Net revenue	$	2,197,529		$	751,317		$	123		$	2,948,969
	Adjusted EBITDA		381,354			87,024			(62,531	)		405,847
	Total assets(1):
	Select		2,143,906			491,920			124,487			2,760,313
	Holdings		2,143,906			491,920			125,535			2,761,361
	Capital expenditures		50,005			13,209			4,971			68,185
		Year Ended December 31, 2013
		Specialty			Outpatient			Other			Total
		Hospitals			Rehabilitation
		(in thousands)
	Net revenue	$	2,198,121		$	777,177		$	350		$	2,975,648
	Adjusted EBITDA		353,843			90,313			(71,295	)		372,861
	Total assets(1):
	Select		2,205,921			512,539			99,162			2,817,622
	Holdings		2,205,921			512,539			99,162			2,817,622
	Capital expenditures		56,523			14,113			3,024			73,660
	-1
	The specialty hospital segment includes $2.7 million in real estate assets held for sale on December 31, 2011, 2012 and 2013.
Schedule of reconciliation of Adjusted EBITDA to income before income taxes	'
		Year Ended December 31, 2011
		Specialty			Outpatient			Other
		Hospitals			Rehabilitation
								(in thousands)
	Adjusted EBITDA	$	362,334		$	83,864		$	(60,237	)
	Depreciation and amortization		(50,629	)		(16,487	)		(4,401	)
	Stock compensation expense		—			—			(3,725	)
											Holdings			Select
	Income (loss) from operations	$	311,705		$	67,377		$	(68,363	)	$	310,719		$	310,719
	Loss on early retirement of debt											(31,018	)		(20,385	)
	Equity in earnings of unconsolidated subsidiaries											2,923			2,923
	Interest expense, net											(98,894	)		(80,910	)
	Income before income taxes										$	183,730		$	212,347
		Year Ended December 31, 2012
		Specialty			Outpatient			Other
		Hospitals			Rehabilitation
								(in thousands)
	Adjusted EBITDA	$	381,354		$	87,024		$	(62,531	)
	Depreciation and amortization		(46,836	)		(13,208	)		(3,267	)
	Stock compensation expense		—			—			(5,677	)
											Holdings			Select
	Income (loss) from operations	$	334,518		$	73,816		$	(71,475	)	$	336,859		$	336,859
	Loss on early retirement of debt											(6,064	)		(6,064	)
	Equity in earnings of unconsolidated subsidiaries											7,705			7,705
	Interest expense, net											(94,950	)		(83,759	)
	Income before income taxes										$	243,550		$	254,741
		Year Ended December 31, 2013
		Specialty			Outpatient			Other
		Hospitals			Rehabilitation
								(in thousands)
	Adjusted EBITDA	$	353,843		$	90,313		$	(71,295	)
	Depreciation and amortization		(48,621	)		(12,024	)		(3,747	)
	Stock compensation expense		—			—			(7,033	)
											Holdings			Select
	Income (loss) from operations	$	305,222		$	78,289		$	(82,075	)	$	301,436		$	301,436
	Loss on early retirement of debt											(18,747	)		(17,788	)
	Equity in earnings of unconsolidated subsidiaries											2,476			2,476
	Interest expense, net											(87,364	)		(84,954	)
	Income before income taxes										$	197,801		$	201,170

Income_per_Share_Tables

Income per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Income per Share	'
Schedule of computation of basic and diluted income per common share	'
		For the Year Ended December 31,
		2011		2012		2013
		(in thousands, except per share amounts)
	Numerator:
	Net income attributable to Select Medical Holdings Corporation	$	107,846	$	148,230	$	114,390
	Less: Earnings allocated to unvested restricted stockholders		1,205		2,514		2,450
	Net income available to common stockholders	$	106,641	$	145,716	$	111,940
	Denominator:
	Weighted average shares — basic		150,501		138,767		136,879
	Effect of dilutive securities:
	Stock options		224		275		168
	Weighted average shares — diluted		150,725		139,042		137,047
	Basic income per common share:	$	0.71	$	1.05	$	0.82
	Diluted income per common share:	$	0.71	$	1.05	$	0.82
Schedule of anti-dilutive shares excluded from computation	'
		For the Year Ended December 31,
		2011		2012		2013
		(in thousands)
	Stock options		2,414		1,654		1,474

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2013
Related Party Transactions	'
Schedule of future rental commitments under outstanding agreements with the affiliated companies	'
	As of December 31, 2013, future rental commitments under outstanding agreements with the affiliated companies are approximately as follows (in thousands):
	2014	$	3,758
	2015		3,792
	2016		3,828
	2017		3,865
	2018		3,950
	Thereafter		17,047
		$	36,240
Schedule of net operating revenues generated from the provision of contracted services and management fees to related parties	'
		For the Year Ended
		December 31,
		2011		2012		2013
		(in thousands)
	BIR JV, LLP	$	53,309	$	92,205	$	96,465
	Rehabilitation Institute of Denton, LLC		7,292		8,133		7,163
	OHRH, LLC		—		—		2,069
	Global Rehab — Scottsdale, LLC.		—		—		4,129
	Amplion Clinical Communications, Inc.		—		305		1,534
	Other		150		140		310
	Total	$	60,751	$	100,783	$	111,670

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies	'
Schedule of minimum future lease obligations on long-term non-cancelable operating leases	'
	Minimum future lease obligations on long-term non-cancelable operating leases in effect at December 31, 2013 are approximately as follows (in thousands):
	2014	$	125,611
	2015		98,100
	2016		77,724
	2017		63,517
	2018		51,104
	Thereafter		364,253
		$	780,309

Supplemental_Disclosures_of_Ca1

Supplemental Disclosures of Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of non-cash investing and financing activities	'
		Holdings
		For the Year Ended
		December 31,
		2011			2012			2013
		(in thousands)
	Notes issued with acquisitions(1)	$	1,020		$	1,844		$	3,283
	Liabilities assumed with acquisitions(1)		701			107			885
	Contingent consideration related to acquisitions(1)		—			1,500			100
	Notes related to investment in business		—			—			3,399
Select	'
Schedule of non-cash investing and financing activities	'
		Select
		For the Year Ended
		December 31,
		2011			2012			2013
		(in thousands)
	Dividends declared to Holdings by Select(2)	$	(5,240	)	$	(5,240	)	$	—
	Notes issued with acquisitions(1)		1,020			1,844			3,283
	Liabilities assumed with acquisitions(1)		701			107			885
	Contingent consideration related to acquisitions(1)		—			1,500			100
	Notes related to investment in business		—			—			3,399
	-1
	Refer to Footnote 2 — Acquisitions.
	-2
	Recorded in accrued other liabilities on the consolidated balance sheet of Select.

Financial_Information_for_Subs1

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes (Tables)	12 Months Ended
	Dec. 31, 2013
Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes	'
Schedule of Condensed Consolidating Balance Sheet	'
		Select Medical Corporation
		Consolidating Balance Sheet
		December 31, 2013
		Select Medical			Subsidiary			Non-Guarantor			Eliminations			Consolidated
		Corporation (Parent			Guarantors			Subsidiaries
		Company Only)
		(in thousands)
	Assets
	Current Assets:
	Cash and cash equivalents	$	71		$	3,098		$	1,150		$	—		$	4,319
	Accounts receivable, net		—			337,517			54,452			-650	(a)		391,319
	Current deferred tax asset		7,965			5,214			4,445			—			17,624
	Intercompany receivables		—			1,079,736			105,028			-1,184,764	(b)		—
	Other current assets		9,745			26,545			4,850			—			41,140
	Total Current Assets		17,781			1,452,110			169,925			(1,185,414	)		454,402
	Property and equipment, net		15,624			434,040			59,438			—			509,102
	Investment in affiliates		3,059,581			83,012			—			-3,142,593	(c)(d)		—
	Goodwill		—			1,642,633			—			—			1,642,633
	Non-current deferred tax asset		7,662			—			—			-7,662	(e)		—
	Other identifiable intangibles		—			71,907			—			—			71,907
	Other assets		35,274			103,696			608			—			139,578
	Total Assets	$	3,135,922		$	3,787,398		$	229,971		$	(4,335,669	)	$	2,817,622
	Liabilities and Equity
	Current Liabilities:
	Bank overdrafts	$	12,506		$	—		$	—		$	—		$	12,506
	Current portion of long-term debt and notes payable		9,107			7,317			1,141			—			17,565
	Accounts payable		6,749			68,574			12,962			—			88,285
	Intercompany payables		1,184,764			—			—			-1,184,764	(b)		—
	Accrued payroll		1,167			88,599			245			—			90,011
	Accrued vacation		4,619			47,682			7,429			—			59,730
	Accrued interest		11,076			1,221			—			—			12,297
	Accrued other		59,249			23,493			7,729			—			90,471
	Income taxes payable		622			—			—			—			622
	Due to third party payors		—			1			686			-650	(a)		37
	Total Current Liabilities		1,289,859			236,887			30,192			(1,185,414	)		371,524
	Long-term debt, net of current portion		1,006,201			364,060			57,449			—			1,427,710
	Non-current deferred tax liability		—			96,111			7,838			-7,662	(e)		96,287
	Other non-current liabilities		53,628			33,123			5,124			—			91,875
	Total Liabilities		2,349,688			730,181			100,603			(1,193,076	)		1,987,396
	Redeemable non-controlling interests		—			—			11,584			—			11,584
	Stockholder's Equity:
	Common stock		0			—			—			—			0
	Capital in excess of par		869,576			—			—			—			869,576
	Retained earnings		(83,342	)		920,694			21,186			-941,880	(d)		(83,342	)
	Subsidiary investment		—			2,136,523			64,190			-2,200,713	(c)		—
	Total Select Medical Corporation Stockholder's Equity		786,234			3,057,217			85,376			(3,142,593	)		786,234
	Non-controlling interests		—			—			32,408			—			32,408
	Total Equity		786,234			3,057,217			117,784			(3,142,593	)		818,642
	Total Liabilities and Equity	$	3,135,922		$	3,787,398		$	229,971		$	(4,335,669	)	$	2,817,622
	(a)
	Reclass portion of due to third party payor to accounts receivable net in consolidation.
	(b)
	Elimination of intercompany.
	(c)
	Elimination of investments in consolidated subsidiaries.
	(d)
	Elimination of investments in consolidated subsidiaries' earnings.
	(e)
	Reclass of non-current deferred tax assset to report net non-current deferred tax liability in consolidation.
	Select Medical Corporation
	Consolidating Balance Sheet
	December 31, 2012
		Select Medical			Subsidiary			Non-Guarantor			Eliminations			Consolidated
Corporation (Parent		Guarantors			Subsidiaries
Company Only)
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	35,070		$	3,734		$	1,340		$	—		$	40,144
Accounts receivable, net		—			308,043			53,531			-1,645	(a)		359,929
Current deferred tax asset		12,383			1,060			4,434			—			17,877
Prepaid income taxes		3,895			—			—			—			3,895
Intercompany receivables		—			1,021,479			102,694			(1,124,173	)(b)		—
Other current assets		5,600			19,655			6,563			—			31,818
Total Current Assets		56,948			1,353,971			168,562			(1,125,818	)		453,663
Property and equipment, net		16,344			425,677			59,531			—			501,552
Investment in affiliates		2,930,022			82,475			—			(3,012,497	)(c)(d)		—
Goodwill		—			1,640,534			—			—			1,640,534
Other identifiable intangibles		—			71,745			—			—			71,745
Non-current deferred tax asset		5,107			—			—			-5,107	(e)		—
Other assets		28,680			63,447			692			—			92,819
Total Assets	$	3,037,101		$	3,637,849		$	228,785		$	(4,143,422	)	$	2,760,313
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	17,836		$	—		$	—		$	—		$	17,836
Current portion of long-term debt and notes payable		8,916			1,059			1,671			—			11,646
Accounts payable		4,674			72,213			12,660			—			89,547
Intercompany payables		1,124,173			—			—			-1,124,173	(b)		—
Accrued payroll		186			88,096			304			—			88,586
Accrued vacation		4,249			44,508			6,957			—			55,714
Accrued interest		17,955			804			—			—			18,759
Accrued other		55,206			31,343			5,534			—			92,083
Due to third party payors		—			—			2,723			-1,645	(a)		1,078
Total Current Liabilities		1,233,195			238,023			29,849			(1,125,818	)		375,249
Long-term debt, net of current portion		872,671			358,104			60,522			—			1,291,297
Non-current deferred tax liability		—			85,287			9,330			-5,107	(e)		89,510
Other non-current liabilities		49,918			28,808			4,973			—			83,699
Total Liabilities		2,155,784			710,222			104,674			(1,130,925	)		1,839,755
Redeemable non-controlling interests		—			—			10,811			—			10,811
Stockholder's Equity:
Common stock		0			—			—			—			0
Capital in excess of par		859,839			—			—			—			859,839
Retained earnings		21,478			790,692			21,197			-811,889	(d)		21,478
Subsidiary investment		—			2,136,935			63,673			-2,200,608	(c)		—
Total Select Medical Corporation Stockholder's Equity		881,317			2,927,627			84,870			(3,012,497	)		881,317
Non-controlling interests		—			—			28,430			—			28,430
Total Equity		881,317			2,927,627			113,300			(3,012,497	)		909,747
Total Liabilities and Equity	$	3,037,101		$	3,637,849		$	228,785		$	(4,143,422	)	$	2,760,313
(a)
Reclass portion of due to third party payor to accounts receivable net in consolidation.
(b)
Elimination of intercompany.
(c)
Elimination of investments in consolidated subsidiaries.
(d)
Elimination of investments in consolidated subsidiaries' earnings.
(e)
Reclass of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.
Schedule of Condensed Consolidating Statement of Operations	'
		Select Medical Corporation
		Consolidating Statement of Operations
		For the Year Ended December 31, 2013
		Select Medical			Subsidiary			Non-Guarantor			Eliminations			Consolidated
		Corporation (Parent			Guarantors			Subsidiaries
		Company Only)
		(in thousands)
	Net operating revenues	$	350		$	2,553,505		$	421,793		$	—		$	2,975,648
	Costs and expenses:
	Cost of services		1,757			2,135,754			357,965			—			2,495,476
	General and administrative		76,709			212			—			—			76,921
	Bad debt expense		—			31,003			6,420			—			37,423
	Depreciation and amortization		3,746			50,982			9,664			—			64,392
	Total costs and expenses		82,212			2,217,951			374,049			—			2,674,212
	Income (loss) from operations		(81,862	)		335,554			47,744			—			301,436
	Other income and expense:
	Intercompany interest and royalty fees		(1,326	)		1,339			(13	)		—			—
	Intercompany management fees		144,447			(125,361	)		(19,086	)		—			—
	Equity in earnings of unconsolidated subsidiaries		—			2,384			92			—			2,476
	Loss on early retirement of debt		(17,788	)		—			—			—			(17,788	)
	Interest expense		(58,100	)		(22,760	)		(4,094	)		—			(84,954	)
	Income (loss) from operations before income taxes		(14,629	)		191,156			24,643			—			201,170
	Income tax expense (benefit)		(1,238	)		76,870			339			—			75,971
	Equity in earnings of subsidiaries		129,971			15,716			—			-145,687	(a)		—
	Net income		116,580			130,002			24,304			(145,687	)		125,199
	Less: Net income attributable to non-controlling interests		—			—			8,619			—			8,619
	Net income attributable to Select Medical Corporation	$	116,580		$	130,002		$	15,685		$	(145,687	)	$	116,580
	(a)
	Elimination of equity in earnings of subsidiaries.
	Consolidating Statement of Operations
	For the Year Ended December 31, 2012
		Select Medical			Subsidiary			Non-Guarantor			Eliminations			Consolidated
		Corporation (Parent			Guarantors			Subsidiaries
		Company Only)
		(in thousands)
	Net operating revenues	$	123		$	2,549,896		$	398,950		$	—		$	2,948,969
	Costs and expenses:
	Cost of services		2,139			2,099,734			341,677			—			2,443,550
	General and administrative		67,402			(1,208	)		—			—			66,194
	Bad debt expense		—			33,595			5,460			—			39,055
	Depreciation and amortization		3,267			50,734			9,310			—			63,311
	Total costs and expenses		72,808			2,182,855			356,447			—			2,612,110
	Income (loss) from operations		(72,685	)		367,041			42,503			—			336,859
	Other income and expense:
	Intercompany interest and royalty fees		(2,532	)		2,494			38			—			—
	Intercompany management fees		120,276			(102,096	)		(18,180	)		—			—
	Loss on early retirement of debt		(6,064	)		—			—			—			(6,064	)
	Equity in earnings of unconsolidated subsidiaries		—			7,637			68			—			7,705
	Interest expense		(54,167	)		(25,348	)		(4,244	)		—			(83,759	)
	Income (loss) from operations before income taxes		(15,172	)		249,728			20,185			—			254,741
	Income tax expense (benefit)		(8,206	)		101,795			(15	)		—			93,574
	Equity in earnings of subsidiaries		162,470			15,639			—			(178,109	)(a)		—
	Net income		155,504			163,572			20,200			(178,109	)		161,167
	Less: Net income attributable to non-controlling interests		—			—			5,663			—			5,663
	Net income attributable to Select Medical Corporation	$	155,504		$	163,572		$	14,537		$	(178,109	)	$	155,504
	(a)
	Elimination of equity in earnings of subsidiaries.
	Consolidating Statement of Operations
	For the Year Ended December 31, 2011
		Select Medical			Subsidiary			Non-Guarantor			Eliminations			Consolidated
		Corporation (Parent			Guarantors			Subsidiaries
		Company Only)
		(in thousands)
Net operating revenues	$	121		$	2,436,177		$	368,209		$	—		$	2,804,507
Costs and expenses:
Cost of services		1,729			1,996,671			310,170			—			2,308,570
General and administrative		61,995			359			—			—			62,354
Bad debt expense		—			44,300			7,047			—			51,347
Depreciation and amortization		4,115			58,064			9,338			—			71,517
Total costs and expenses		67,839			2,099,394			326,555			—			2,493,788
Income (loss) from operations		(67,718	)		336,783			41,654			—			310,719
Other income and expense:
Intercompany interest and royalty fees		(3,408	)		3,382			26			—			—
Intercompany management fees		120,013			(102,970	)		(17,043	)		—			—
Loss on early retirement of debt		(20,385	)		—			—			—			(20,385	)
Equity in earnings of unconsolidated subsidiaries		—			2,870			53			—			2,923
Interest income		132			122			68			—			322
Interest expense		(41,817	)		(34,612	)		(4,803	)		—			(81,232	)
Income (loss) before income taxes		(13,183	)		205,575			19,955			—			212,347
Income tax expense (benefit)		(12,821	)		92,561			1,244			—			80,984
Equity in earnings of subsidiaries		126,809			13,406			—			-140,215	(a)		—
Net income		126,447			126,420			18,711			(140,215	)		131,363
Less: Net income attributable to non-controlling interests		—			—			4,916			—			4,916
Net income attributable to Select Medical Corporation	$	126,447		$	126,420		$	13,795		$	(140,215	)	$	126,447
(a)
Elimination of equity in earnings of subsidiaries.
Schedule of Condensed Consolidating Statement of Cash Flows	'
	Consolidating Statement of Cash Flows
	For the Year Ended December 31, 2013
		Select Medical			Subsidiary			Non-Guarantor			Eliminations			Consolidated
		Corporation (Parent			Guarantors			Subsidiaries
		Company Only)
		(in thousands)
	Operating activities
	Net income	$	116,580		$	130,002		$	24,304		$	(145,687	)(a)	$	125,199
	Adjustments to reconcile net income to net cash provided by operating activities:
	Depreciation and amortization		3,746			50,982			9,664			—			64,392
	Provision for bad debts		—			31,003			6,420			—			37,423
	Equity in earnings of unconsolidated subsidiaires		—			(2,384	)		(92	)		—			(2,476	)
	Loss on early retirement of debt		17,788			—			—			—			17,788
	Gain from disposal or sale of assets		—			(463	)		(118	)		—			(581	)
	Non-cash stock compensation expense		7,033			—			—			—			7,033
	Amortization of debt discount and issuance costs		8,344			—			—			—			8,344
	Deferred income taxes		7,032			—			—			—			7,032
	Changes in operating assets and liabilities, net of effects from acquisition of businesses:
	Equity in earnings of subsidiaries		(129,971	)		(15,716	)		—			145,687	(a)		—
	Accounts receivable		—			(59,804	)		(7,341	)		—			(67,145	)
	Other current assets		(4,145	)		(5,735	)		1,713			—			(8,167	)
	Other assets		(6,594	)		3,026			84			—			(3,484	)
	Accounts payable		2,075			(3,660	)		302			—			(1,283	)
	Due to third-party payors		—			996			(2,037	)		—			(1,041	)
	Accrued expenses		(4,929	)		20,609			(612	)		—			15,068
	Net cash provided by operating activities		16,959			148,856			32,287			—			198,102
	Investing activities
	Purchases of property and equipment		(3,024	)		(60,532	)		(10,104	)		—			(73,660	)
	Investment in businesses, net of distributions		—			(34,893	)		—			—			(34,893	)
	Acquisition of businesses, net of cash acquired		—			(1,665	)		—			—			(1,665	)
	Proceeds from sale of assets		—			2,456			456			—			2,912
	Net cash used in investing activities		(3,024	)		(94,634	)		(9,648	)		—			(107,306	)
	Financing activities
	Borrowings on revolving credit facility		690,000			—			—			—			690,000
	Payments on revolving credit facility		(800,000	)		—			—			—			(800,000	)
	Borrowings on credit facility term loans, net of discount		298,500			—			—			—			298,500
	Payments on credit facility term loans		(596,720	)		—			—			—			(596,720	)
	Issuance of 6.375% senior notes		600,000			—			—			—			600,000
	Repurchase of 75/8% senior subordinated notes, net of premiums		(70,000	)		—			—			—			(70,000	)
	Borrowings of other debt		8,923			5,303			1,084			—			15,310
	Principal payments on other debt		(7,752	)		(873	)		(2,209	)		—			(10,834	)
	Debt issuance costs		(18,914	)		—			—			—			(18,914	)
	Repayments of bank overdrafts		(5,330	)		—			—			—			(5,330	)
	Equity investment by Holdings		1,525			—			—			—			1,525
	Dividends paid to Holdings		(226,621	)		—			—			—			(226,621	)
	Intercompany		77,455			(59,288	)		(18,167	)		—			—
	Distributions to non-controlling interests		—			—			(3,537	)		—			(3,537	)
	Net cash used in financing activities		(48,934	)		(54,858	)		(22,829	)		—			(126,621	)
	Net decrease in cash and cash equivalents		(34,999	)		(636	)		(190	)		—			(35,825	)
	Cash and cash equivalents at beginning of period		35,070			3,734			1,340			—			40,144
	Cash and cash equivalents at end of period	$	71		$	3,098		$	1,150		$	—		$	4,319
	(a)
	Elimination of equity in earnings of consolidated subsidiaries.
	Consolidating Statement of Cash Flows
	For the Year Ended December 31, 2012
		Select Medical			Subsidiary			Non-Guarantor			Eliminations			Consolidated
		Corporation (Parent			Guarantors			Subsidiaries
		Company Only)
		(in thousands)
	Operating activities
	Net income	$	155,504		$	163,572		$	20,200		$	-178,109	(a)	$	161,167
	Adjustments to reconcile net income to net cash provided by operating activities:
	Depreciation and amortization		3,267			50,734			9,310			—			63,311
Provision for bad debts		—			33,595			5,460			—			39,055
Equity in earnings of unconsolidated subsidiaires		—			(7,637	)		(68	)		—			(7,705	)
Loss on early retirement of debt		6,064			—			—			—			6,064
Loss (gain) from disposal or sale of assets		—			(6,002	)		96			—			(5,906	)
Non-cash stock compensation expense		5,677			—			—			—			5,677
Amortization of debt discount and issuance costs		7,190			—			—			—			7,190
Deferred income taxes		7,909			—			—			—			7,909
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries		(162,470	)		(15,639	)		—			178,109	(a)		—
Accounts receivable		—			29,727			(14,569	)		—			15,158
Other current assets		740			141			(2,488	)		—			(1,607	)
Other assets		2,448			3,268			161			—			5,877
Accounts payable		(2,679	)		(4,040	)		602			—			(6,117	)
Due to third-party payors		—			(15,278	)		10,830			—			(4,448	)
Accrued expenses		25,350			(3,835	)		2,231			—			23,746
Net cash provided by operating activities		49,000			228,606			31,765			—			309,371
Investing activities
Purchases of property and equipment		(5,150	)		(49,160	)		(13,875	)		—			(68,185	)
Investment in businesses, net of distributions		—			(14,689	)		—			—			(14,689	)
Acquisition of businesses, net of cash acquired		—			(6,043	)		—			—			(6,043	)
Proceeds from sale of assets		—			16,511			—			—			16,511
Net cash used in investing activities		(5,150	)		(53,381	)		(13,875	)		—			(72,406	)
Financing activities
Borrowings on revolving credit facility		495,000			—			—			—			495,000
Payments on revolving credit facility		(405,000	)		—			—			—			(405,000	)
Borrowings on 2011 credit facility term loans, net of discount		266,750			—			—			—			266,750
Payments on 2011 credit facility term loans		(9,875	)		—			—			—			(9,875	)
Repurchase of 75/8% senior subordinated notes, net of premiums		(278,495	)		—			—			—			(278,495	)
Borrowings of other debt		8,003			—			278			—			8,281
Principal payments on other debt		(8,049	)		(433	)		(1,813	)		—			(10,295	)
Debt issuance costs		(6,527	)		—			—			—			(6,527	)
Proceeds from bank overdrafts		1,227			—			—			—			1,227
Equity investment by Holdings		1,817			—			—			—			1,817
Dividends paid to Holdings		(268,479	)		—			—			—			(268,479	)
Intercompany		183,421			(171,058	)		(12,363	)		—			—
Distributions to non-controlling interests		—			—			(3,268	)		—			(3,268	)
Net cash used in financing activities		(20,207	)		(171,491	)		(17,166	)		—			(208,864	)
Net increase in cash and cash equivalents		23,643			3,734			724			—			28,101
Cash and cash equivalents at beginning of period		11,427			—			616			—			12,043
Cash and cash equivalents at end of period	$	35,070		$	3,734		$	1,340		$	—		$	40,144
(a)
Elimination of equity in earnings of consolidated subsidiaries.
Consolidating Statement of Cash Flows
For the Year Ended December 31, 2011
	Select Medical			Subsidiary			Non-Guarantor			Eliminations			Consolidated
	Corporation (Parent			Guarantors			Subsidiaries
	Company Only)
	(in thousands)
Operating activities
Net income	$	126,447		$	126,420		$	18,711		$	-140,215	(a)	$	131,363
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		4,115			58,064			9,338			—			71,517
Provision for bad debts		—			44,300			7,047			—			51,347
Equity in earnings of unconsolidated subsidiaries		—			(2,870	)		(53	)		—			(2,923	)
Loss on early retirement of debt		20,385			—			—			—			20,385
Loss (gain) from disposal or sale of assets		13			(5,024	)		45			—			(4,966	)
Non-cash stock compensation expense		3,725			—			—			—			3,725
Amortization of debt discount and issuance costs		6,700			—			—			—			6,700
Deferred income taxes		35,305			—			—			—			35,305
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries		(126,809	)		(13,406	)		—			140,215	(a)		—
Accounts receivable		—			(98,966	)		(12,160	)		—			(111,126	)
Other current assets		(1,780	)		1,165			(586	)		—			(1,201	)
Other assets		(12,069	)		9,683			318			—			(2,068	)
Accounts payable		1,326			16,247			3,056			—			20,629
Due to third-party payors		—			1,408			(1,181	)		—			227
Accrued expenses		14,823			5,522			794			—			21,139
Net cash provided by operating activities		72,181			142,543			25,329			—			240,053
Investing activities
Purchases of property and equipment		(3,413	)		(37,759	)		(4,844	)		—			(46,016	)
Investment in businesses, net of distributions		—			(15,699	)		—			—			(15,699	)
Acquisition of businesses, net of cash acquired		—			(899	)		—			—			(899	)
Proceeds from sale of assets		—			7,879			—			—			7,879
Net cash used in investing activities		(3,413	)		(46,478	)		(4,844	)		—			(54,735	)
Financing activities
Borrowings on revolving credit facility		735,000			—			—			—			735,000
Payments on revolving credit facility		(720,000	)		—			—			—			(720,000	)
Borrowings on 2011 credit facility term loans, net of discount		841,500			—			—			—			841,500
Payments on 2011 credit facility term loans		(4,250	)		—			—			—			(4,250	)
Payments on 2005 credit facility term loans, net of call premium		(484,633	)		—			—			—			(484,633	)
Repurchase of 75/8% senior subordinated notes, net of premiums		(273,941	)		—			—			—			(273,941	)
Borrowings of other debt		6,100			955			—			—			7,055
Principal payments on other debt		(5,662	)		(755	)		(1,082	)		—			(7,499	)
Debt issuance costs		(18,556	)		—			—			—			(18,556	)
Repayments of bank overdrafts		(2,183	)		—			—			—			(2,183	)
Equity investment by Holdings		208			—			—			—			208
Dividends paid to Holdings		(245,729	)		—			—			—			(245,729	)
Intercompany		114,656			(99,832	)		(14,824	)		—			—
Distributions to non-controlling interests		—			—			(4,612	)		—			(4,612	)
Net cash used in financing activities		(57,490	)		(99,632	)		(20,518	)		—			(177,640	)
Net increase (decrease) in cash and cash equivalents		11,278			(3,567	)		(33	)		—			7,678
Cash and cash equivalents at beginning of period		149			3,567			649			—			4,365
Cash and cash equivalents at end of period	$	11,427		$	—		$	616		$	—		$	12,043
(a)
Elimination of equity in earnings of consolidated subsidiaries.

Selected_Quarterly_Financial_D1

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information	'
Schedule of selected unaudited quarterly financial data	'
		Holdings
		First		Second		Third		Fourth
		Quarter		Quarter		Quarter		Quarter
		(in thousands, except per share amounts)
	Year ended December 31, 2012
	Net operating revenues	$	744,021	$	750,193	$	713,669	$	741,086
	Income from operations		91,604		93,513		70,819		80,923
	Net income attributable to Select Medical Holdings Corporation	$	41,542	$	43,172	$	24,110	$	39,406
	Income per common share:
	Basic	$	0.29	$	0.31	$	0.17	$	0.28
	Diluted	$	0.29	$	0.31	$	0.17	$	0.28
		Holdings
		First		Second		Third		Fourth
		Quarter		Quarter		Quarter		Quarter
		(in thousands, except per share amounts)
	Year ended December 31, 2013
	Net operating revenues	$	749,955	$	756,673	$	722,845	$	746,175
	Income from operations		82,530		88,263		62,399		68,244
	Net income attributable to Select Medical Holdings Corporation	$	34,418	$	27,780	$	23,272	$	28,920
	Income per common share:
	Basic	$	0.25	$	0.2	$	0.17	$	0.21
	Diluted	$	0.24	$	0.2	$	0.17	$	0.21
Select	'
Quarterly Financial Information	'
Schedule of selected unaudited quarterly financial data	'
		Select
		First		Second		Third		Fourth
		Quarter		Quarter		Quarter		Quarter
		(in thousands)
	Year ended December 31, 2012
	Net operating revenues	$	744,021	$	750,193	$	713,669	$	741,086
	Income from operations		91,604		93,513		70,819		80,923
	Net income attributable to Select Medical Corporation	$	43,279	$	45,018	$	25,953	$	41,254
		Select
		First		Second		Third		Fourth
		Quarter		Quarter		Quarter		Quarter
		(in thousands)
	Year ended December 31, 2013
	Net operating revenues	$	749,955	$	756,673	$	722,845	$	746,175
	Income from operations		82,530		88,263		62,399		68,244
	Net income attributable to Select Medical Corporation	$	36,608	$	27,780	$	23,272	$	28,920

Organization_and_Significant_A3

Organization and Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	item	item	item
Business Description	'	'	'
Number of specialty hospitals operated by the entity	123	122	119
Number of outpatient clinics operated by the entity	1,006	979	954
Number of states in which the entity had facilities	39	39	39
Accounts Receivable and Allowance for Doubtful Accounts	'	'	'
Deductibles, co-payments and self-insured amounts as a percentage of net accounts receivable balance before doubtful accounts	0.30%	0.20%	'
Minimum period from date of discharge that outstanding governmental accounts are reserved as uncollectible	'365 days	'	'
Minimum period from date of discharge that outstanding non-governmental accounts are reserved as uncollectible	'180 days	'	'

Organization_and_Significant_A4

Organization and Significant Accounting Policies (Details 2)	12 Months Ended
	Dec. 31, 2013
Leasehold improvements | Minimum	'
Property and equipment	'
Estimated useful lives	'5 years
Leasehold improvements | Maximum	'
Property and equipment	'
Estimated useful lives	'15 years
Furniture and equipment | Minimum	'
Property and equipment	'
Estimated useful lives	'3 years
Furniture and equipment | Maximum	'
Property and equipment	'
Estimated useful lives	'20 years
Buildings	'
Property and equipment	'
Estimated useful lives	'40 years
Building Improvements | Minimum	'
Property and equipment	'
Estimated useful lives	'5 years
Building Improvements | Maximum	'
Property and equipment	'
Estimated useful lives	'25 years
Land Improvements | Minimum	'
Property and equipment	'
Estimated useful lives	'2 years
Land Improvements | Maximum	'
Property and equipment	'
Estimated useful lives	'25 years

Organization_and_Significant_A5

Organization and Significant Accounting Policies (Details 3) (USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
		Insurance Risk Programs	Insurance Risk Programs
Intangible Assets	'	'	'
Impairment to goodwill or other recorded intangible assets	$0	'	'
Insurance risk programs	'	'	'
Discount rate for provisions for losses for professional liability (as a percent)	'	3.00%	3.00%
Liability recorded after discounting	'	103.4	92.5
Value of aggregate liability, if the entity did not discount the provisions for losses	'	$106.80	$95.60

Organization_and_Significant_A6

Organization and Significant Accounting Policies (Details 4) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Non-Controlling Interests	'	'	'
Redeemable non-controlling interests	$11,584	$10,811	'
Non-controlling interests	32,408	28,430	'
Net income attributable to non-controlling interests	$8,619	$5,663	$4,916
Net operating revenues | Customer concentration | Medicare program	'	'	'
Revenue recognition	'	'	'
Percentage of concentration risk	46.00%	47.00%	48.00%
Accounts receivable | Customer concentration | Medicare program	'	'	'
Revenue recognition	'	'	'
Percentage of concentration risk	32.00%	29.00%	'

Acquisitions_Details

Acquisitions (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cost of acquired entity	'	'	'
Cash paid net of cash acquired	$1,665,000	$6,043,000	$899,000
Notes issued	3,283,000	1,844,000	1,020,000
Total purchase price	4,948,000	7,887,000	1,919,000
Contingent consideration	100,000	1,500,000	'
Liabilities assumed	885,000	107,000	701,000
Total cost of acquisitions and liabilities assumed	5,933,000	9,494,000	2,620,000
Fair value of assets acquired	'	'	'
Accounts receivable and property and equipment	3,487,000	1,313,000	767,000
Non-controlling interests	347,000	-970,000	-602,000
Cost in excess of fair value of net assets acquired (goodwill)	2,099,000	9,151,000	2,455,000
Other additional information	'	'	'
Non-controlling interests purchased in cash	600,000	100,000	500,000
Regency Hospital Company, L.L.C.	'	'	'
Other additional information	'	'	'
Cash received on settlement of net working capital	'	'	3,900,000
Outpatient rehabilitation business	'	'	'
Cost of acquired entity	'	'	'
Cash paid net of cash acquired	900,000	5,900,000	2,300,000
Notes issued	300,000	1,800,000	1,000,000
Inpatient rehabilitation hospital	'	'	'
Cost of acquired entity	'	'	'
Cash paid net of cash acquired	200,000	'	2,000,000
Notes issued	$3,000,000	'	'
Other additional information	'	'	'
Number of long term acute care hospitals exchanged	'	'	1

Significant_Transactions_Detai

Significant Transactions (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Significant transactions	'	'	'
Investment in cash	$34,893,000	$14,689,000	$15,699,000
Baylor Health Care System	'	'	'
Significant transactions	'	'	'
Gain on contribution of property to equity method investment	'	'	1,200,000
Investment in cash	'	7,800,000	13,500,000
Purchase of partnership units	'	'	7,600,000
Working capital investments	'	'	$5,900,000
Percentage of ownership	49.00%	'	'

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property and equipment	'	'	'
Property and equipment, gross	$866,295,000	$818,224,000	'
Less: accumulated depreciation	357,193,000	316,672,000	'
Total property and equipment	509,102,000	501,552,000	'
Depreciation expense	63,900,000	62,500,000	69,800,000
Land	'	'	'
Property and equipment	'	'	'
Property and equipment, gross	68,492,000	68,573,000	'
Leasehold improvements	'	'	'
Property and equipment	'	'	'
Property and equipment, gross	146,117,000	128,468,000	'
Buildings	'	'	'
Property and equipment	'	'	'
Property and equipment, gross	368,968,000	352,677,000	'
Furniture and equipment	'	'	'
Property and equipment	'	'	'
Property and equipment, gross	256,079,000	246,858,000	'
Construction-in-progress	'	'	'
Property and equipment	'	'	'
Property and equipment, gross	$26,639,000	$21,648,000	'

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified				Trademarks	Trademarks	Certificates of need	Certificates of need	Accreditations	Accreditations
Indefinite-lived intangible assets:	'	'	'	'	'	'	'	'	'
Gross Carrying Amount of Goodwill	$1,642,633	$1,640,534	$1,631,716	'	'	'	'	'	'
Gross Carrying Amount	$1,714,540	$1,712,279	'	$57,709	$57,709	$12,115	$11,914	$2,083	$2,122
Weighted average time until next renewal	'	'	'	'6 years 6 months	'	'	'	'1 year 6 months	'

Intangible_Assets_Details_2

Intangible Assets (Details 2) (Non-compete agreements, Outpatient rehabilitation division of HealthSouth Corporation, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011
Non-compete agreements | Outpatient rehabilitation division of HealthSouth Corporation	'	'
Finite-lived intangible assets	'	'
Amortization expense	$340	$1,306

Intangible_Assets_Details_3

Intangible Assets (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Goodwill	'	'
Balance at the beginning of the period	$1,640,534	$1,631,716
Goodwill acquired during year	2,232	9,151
Other	'	-333
Purchase price adjustment	-133	'
Balance at the end of the period	1,642,633	1,640,534
Specialty Hospitals	'	'
Goodwill	'	'
Balance at the beginning of the period	1,333,220	1,333,553
Goodwill acquired during year	1,395	'
Other	'	-333
Balance at the end of the period	1,334,615	1,333,220
Outpatient Rehabilitation	'	'
Goodwill	'	'
Balance at the beginning of the period	307,314	298,163
Goodwill acquired during year	837	9,151
Purchase price adjustment	-133	'
Balance at the end of the period	$308,018	$307,314

LongTerm_Debt_and_Notes_Payabl2

Long-Term Debt and Notes Payable (Details) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

28-May-13

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jun. 01, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Select

Select

Select

7 5/8% senior subordinated notes

7 5/8% senior subordinated notes

7 5/8% senior subordinated notes

7 5/8% senior subordinated notes

6.375% senior notes

6.375% senior notes

6.375% senior notes

6.375% senior notes

6.375% senior notes

Senior secured credit facility

Senior secured credit facility

Senior secured credit facility

Senior secured credit facility

Senior secured credit facility

Senior secured credit facility

Senior secured credit facility

Senior secured credit facility

Term loans

Term loans

Term loans

Term loans

Series B Term Loan

Series B Term Loan

Series B Term Loan

Series C Term Loan

Series C Term Loan

Series C Term Loan

Series C Term Loan

Senior floating rate notes

Other

Other

Other

Other

Letters of credit

Revolving loan

Revolving loan

Revolving loan

Revolving loan

Revolving loan

Revolving loan

Revolving credit facility that matures on March 1, 2018

Revolving credit facility that matures on June 1, 2016

10% senior subordinated notes

10% senior subordinated notes

Select

Select

Select

Select

Select

Select

Select

Select

Select

Select

Select

Select

Select

Select

Select

Select

Adjusted LIBO

Alternate base rate

Select

Adjusted LIBO

Alternate base rate

Select

Select

Select

Select

Select

Adjusted LIBO

Alternate base rate

Select

Select

Select

Select

Prior to June 1, 2016

Maximum

Leverage ratio greater than 3.75 to 1.00

Leverage ratio less than or equal to 3.75 to 1.00 but greater than 3.25 to 1.00

Leverage ratio equal to 3.91 to 1.00

Maximum

Maximum

Minimum

Minimum

Prior to June 1, 2016

Leverage ratio greater than 3.75 to 1.00

Leverage ratio less than or equal to 3.25 to 1.00

Adjusted LIBO

Long-term debt and notes payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate of debt (as a percent)

'

'

'

'

'

'

7.63%

7.63%

7.63%

7.63%

6.38%

6.38%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

10.00%

Total debt

$1,445,275,000

$1,470,243,000

'

$1,445,275,000

$1,302,943,000

'

$70,000,000

'

$70,000,000

'

$600,000,000

$600,000,000

'

'

'

'

'

'

'

'

'

'

'

$807,815,000

$1,096,641,000

$807,815,000

$1,096,641,000

'

'

$295,900,000

'

'

$511,900,000

'

$167,300,000

$17,460,000

$6,302,000

$17,460,000

$6,302,000

'

$20,000,000

$130,000,000

'

'

$20,000,000

$130,000,000

'

'

'

'

Less: current maturities

17,565,000

11,646,000

'

17,565,000

11,646,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total long-term debt

1,427,710,000

1,458,597,000

'

1,427,710,000

1,291,297,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unamortized discounts

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,300,000

14,200,000

6,300,000

14,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,150,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000,000

'

293,300,000

6,700,000

'

'

Loss on early retirement of debt

18,747,000

6,064,000

31,018,000

17,788,000

6,064,000

20,385,000

-6,100,000

'

-6,100,000

20,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31,000,000

'

Aggregate principal amount

'

'

'

'

'

'

'

'

'

'

'

'

600,000,000

'

'

'

'

'

'

'

'

'

'

'

'

814,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Periodic payment in equal quarterly installments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Variable rate basis

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Adjusted LIBO

'Alternate base rate

'

'Adjusted LIBO

'Alternate base rate

'

'

'

'

'

'

'

'

'

'

'Adjusted LIBO

'Alternate base rate

'

'

'

'

'

'

Interest rate margin (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.25%

2.25%

'

3.00%

2.00%

'

1.00%

'

'

'

'

'

'

'

'

3.75%

2.75%

'

'

'

'

'

'

Availability under revolving loan facility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

237,700,000

'

'

'

'

'

Outstanding letters of credit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

42,300,000

'

'

'

'

'

'

'

'

'

'

Pro forma ratio of total indebtedness to Consolidated EBITDA

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.91

'

3.75

3.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of net cash proceeds received from non-ordinary course asset sales or other dispositions, or as a result of a casualty or condemnation to be used for prepayment of debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of net proceeds received from the issuance of debt obligations other than certain permitted debt obligations to be used for prepayment of debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of excess cash flow to be used for prepayment of debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

25.00%

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Prepayment of debt required unless a specified leverage ratio is met

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

34,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual capital expenditure permitted under the covenants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

125,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of the amount permitted for capital expenditures in previous fiscal year which can carry-over

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of principal amount at which notes may be required to be repurchased in event of change of control by the entity

'

'

'

'

'

'

'

'

'

'

'

101.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of the principal amount of the debt instrument which the entity may redeem with the proceeds from certain equity offerings

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of the principal amount representing the redemption price of notes which may be redeemed with proceeds from certain equity offerings

'

'

'

'

'

'

'

'

'

'

'

'

'

106.38%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maturities of Long-Term Debt and Notes Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2014

17,565,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2015

10,183,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2016

296,232,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2017

4,075,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2018

515,820,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2019 and beyond

601,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal amount of debt repurchased and retired

'

'

'

'

'

'

'

'

$275,000,000

$266,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$150,000,000

'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stockholders' Equity	'	'	'
Maximum amount authorized to be repurchased under the common stock repurchase program	$350	'	'
Number of shares repurchased under the program	1,115,691	5,725,782	9,858,907
Value of shares repurchased under the program	$10	$46.80	$72.70
Shares of restricted stock granted	952,500	761,500	565,000
Shares of common stock related to the exercise of stock options issued	166,600	301,208	53,932
Shares of common stock forfeited	331,697	15,860	10,860

Stock_Option_and_Restricted_St2

Stock Option and Restricted Stock Plans (Details) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Aug. 03, 2011

13-May-11

Mar. 03, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Aug. 12, 2009

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Aug. 12, 2009

Options

Options

Options

Options

Options

Options

Plans

Plans

Plans

Plans

Plans

Plans

Director Plan

Director Plan

Director Plan

Director Plan

Director Plan

Director Plan

Director Plan

Director Plan

Options

Options

Options

Options

Options

Options

Options

Options

Options

Options

Options

Options

Options

Restricted stock awards

Minimum

Minimum

Maximum

Maximum

Minimum

Minimum

Maximum

Maximum

Stock option and restricted stock plans

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,000

'

'

'

'

150,000

Vesting period

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expiration term

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected volatility (as a percent)

'

'

'

'

'

'

'

'

36.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividend yield (as a percent)

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected life

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk free rate (as a percent)

'

'

'

'

'

'

'

'

3.30%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value of Common Stock (in dollars per share)

'

'

'

$7.14

$9

$7.66

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted Average Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at the beginning of the period (in dollars per share)

'

'

'

'

'

'

'

'

'

$8.40

$8.16

$3.33

$3.33

$10

$10

$7.62

$8.69

'

$3.33

$3.33

$10

$10

'

Granted (in dollars per share)

'

'

'

$7.14

$9

$7.66

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercised (in dollars per share)

'

'

'

'

'

'

'

'

'

$9.15

$6.07

$7.14

$3.33

$10

$10

$5.47

'

'

$3.33

'

$8.33

'

'

Canceled (in dollars per share)

'

'

'

'

'

'

'

'

'

$9.13

$8.18

$8.33

$7.66

$10

$10

'

'

'

'

'

'

'

'

Balance at the end of the period (in dollars per share)

'

'

'

'

'

'

'

'

'

$8.22

$8.40

$3.33

$3.33

$10

$10

$8.69

$8.69

'

$3.33

$3.33

$10

$10

'

Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at the beginning of the period (in shares)

'

'

'

'

'

'

'

'

'

2,423,000

2,730,000

'

'

'

'

63,000

42,000

'

'

'

'

'

'

Granted (in shares)

'

'

'

10,000

20,000

88,000

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercised (in shares)

-166,600

-301,208

-53,932

'

'

'

'

'

'

-167,000

-280,000

'

'

'

'

-21,000

'

'

'

'

'

'

'

Canceled (in shares)

'

'

'

'

'

'

'

'

'

-316,000

-27,000

'

'

'

'

'

'

'

'

'

'

'

'

Balance at the end of the period (in shares)

'

'

'

'

'

'

'

'

'

1,940,000

2,423,000

'

'

'

'

42,000

42,000

'

'

'

'

'

'

Stock_Option_and_Restricted_St3

Stock Option and Restricted Stock Plans (Details 2) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013
$ 3.00 - 4.00 | Plans	'
Additional information with respect to the outstanding options	'
Exercise price, low end of range (in dollars per share)	$3
Exercise price, high end of range (in dollars per share)	$4
Number Outstanding (in shares)	220
Weighted Average Remaining Contractual Life	'1 year 1 month 24 days
Number Exercisable (in shares)	220
$ 6.00 - 7.00 | Plans	'
Additional information with respect to the outstanding options	'
Exercise price, low end of range (in dollars per share)	$6
Exercise price, high end of range (in dollars per share)	$7
Number Outstanding (in shares)	9
Weighted Average Remaining Contractual Life	'6 years 7 months 10 days
Number Exercisable (in shares)	3
$ 7.01 - 8.00 | Plans	'
Additional information with respect to the outstanding options	'
Exercise price, low end of range (in dollars per share)	$7.01
Exercise price, high end of range (in dollars per share)	$8
Number Outstanding (in shares)	75
Weighted Average Remaining Contractual Life	'7 years 2 months 12 days
Number Exercisable (in shares)	28
$ 8.01 - 9.00 | Plans	'
Additional information with respect to the outstanding options	'
Exercise price, low end of range (in dollars per share)	$8.01
Exercise price, high end of range (in dollars per share)	$9
Number Outstanding (in shares)	585
Weighted Average Remaining Contractual Life	'3 years 3 months 22 days
Number Exercisable (in shares)	557
$ 9.01 - 10.00 | Plans	'
Additional information with respect to the outstanding options	'
Exercise price, low end of range (in dollars per share)	$9.01
Exercise price, high end of range (in dollars per share)	$10
Number Outstanding (in shares)	1,051
Weighted Average Remaining Contractual Life	'5 years 6 months 4 days
Number Exercisable (in shares)	848
Exercise price range six | Director Plan	'
Additional information with respect to the outstanding options	'
Exercise price, low end of range (in dollars per share)	$3
Exercise price, high end of range (in dollars per share)	$4
Number Outstanding (in shares)	6
Weighted Average Remaining Contractual Life	'1 year 7 months 10 days
Number Exercisable (in shares)	6
Exercise price range seven | Director Plan	'
Additional information with respect to the outstanding options	'
Exercise price, low end of range (in dollars per share)	$8
Exercise price, high end of range (in dollars per share)	$9
Number Outstanding (in shares)	9
Weighted Average Remaining Contractual Life	'3 years 4 months 13 days
Number Exercisable (in shares)	9
Exercise price range eight | Director Plan	'
Additional information with respect to the outstanding options	'
Exercise price, low end of range (in dollars per share)	$9.01
Exercise price, high end of range (in dollars per share)	$10
Number Outstanding (in shares)	27
Weighted Average Remaining Contractual Life	'5 years 1 month 13 days
Number Exercisable (in shares)	25

Stock_Option_and_Restricted_St4

Stock Option and Restricted Stock Plans (Details 3) (USD $)

12 Months Ended

0 Months Ended

Share data in Thousands, except Per Share data, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Oct. 30, 2013

Aug. 07, 2013

1-May-13

Feb. 20, 2013

Jan. 02, 2013

Oct. 30, 2012

Aug. 07, 2012

2-May-12

Mar. 26, 2012

Dec. 15, 2011

Nov. 03, 2011

Aug. 03, 2011

Dec. 31, 2013

Options

Options

Options

Options

Restricted stock awards

Restricted stock awards

Restricted stock awards

Restricted stock awards

Restricted stock awards

Restricted stock awards

Restricted stock awards

Restricted stock awards

Restricted stock awards

Restricted stock awards

Restricted stock awards

Restricted stock awards

Restricted stock awards

Plans

Plans

Plans

Director Plan

Stock option and restricted stock plans

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average remaining contractual term for all outstanding options

'4 years 5 months 1 day

'

'

'4 years 2 months 26 days

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average remaining contractual term of exercisable options

'4 years 1 month 10 days

'

'

'4 years 1 month 28 days

'

'

'

'

'

'

'

'

'

'

'

'

'

Total intrinsic value of options exercised (in dollars)

$200,000

$1,100,000

$200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of options outstanding (in dollars)

6,600,000

'

'

122,700

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of options exercisable (in dollars)

5,800,000

'

'

118,800

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Shares Issued

'

'

'

'

760

38

115

35

5

530

38

129

65

350

190

25

'

Fair Value of Common Stock (in dollars per share)

'

'

'

'

$8.50

$8.89

$8.06

$8.80

$9.90

$10.75

$11.84

$8.67

$8.33

$8.57

$8.61

$7.14

'

Stock compensation expense for each of the next five years, based on restricted stock awards granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,740,000

2015

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,057,000

2016

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,061,000

2017

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

581,000

2018

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$40,000

Stock_Option_and_Restricted_St5

Stock Option and Restricted Stock Plans (Details 4) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock compensation expense:	'	'	'
Total	$7,033	$5,677	$3,725
Included in general and administrative	'	'	'
Stock compensation expense:	'	'	'
Total	5,276	3,538	1,996
Included in cost of services	'	'	'
Stock compensation expense:	'	'	'
Total	$1,757	$2,139	$1,729

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current:	'	'	'
Federal	$55,847	$70,159	$29,991
State and local	11,913	11,589	5,672
Total current	67,760	81,748	35,663
Deferred	7,032	7,909	35,305
Total income tax provision	74,792	89,657	70,968
Differences between the expected income tax provision and income taxes computed at the federal statutory rate	'	'	'
Expected federal tax rate (as a percent)	35.00%	35.00%	35.00%
State and local taxes, net of federal benefit (as a percent)	4.60%	4.20%	4.50%
Other permanent differences (as a percent)	1.10%	0.60%	1.00%
Valuation allowance (as a percent)	-0.70%	-0.60%	-0.50%
Uncertain tax positions (as a percent)	-0.60%	-0.50%	-3.60%
IRS audit settlements (as a percent)	'	-0.60%	'
Non-controlling interest (as a percent)	-1.70%	-0.90%	-1.10%
Sale of entities (as a percent)	'	'	3.10%
Other (as a percent)	0.10%	-0.40%	0.20%
Total (as a percent)	37.80%	36.80%	38.60%
Select	'	'	'
Current:	'	'	'
Federal	57,026	74,076	40,007
State and local	11,913	11,589	5,672
Total current	68,939	85,665	45,679
Deferred	7,032	7,909	35,305
Total income tax provision	$75,971	$93,574	$80,984
Differences between the expected income tax provision and income taxes computed at the federal statutory rate	'	'	'
Expected federal tax rate (as a percent)	35.00%	35.00%	35.00%
State and local taxes, net of federal benefit (as a percent)	4.50%	4.00%	3.90%
Other permanent differences (as a percent)	1.10%	0.60%	0.90%
Valuation allowance (as a percent)	-0.60%	-0.60%	-0.40%
Uncertain tax positions (as a percent)	-0.60%	-0.50%	-3.10%
IRS audit settlements (as a percent)	'	-0.50%	'
Non-controlling interest (as a percent)	-1.70%	-0.90%	-0.90%
Sale of entities (as a percent)	'	'	2.70%
Other (as a percent)	0.10%	-0.40%	'
Total (as a percent)	37.80%	36.70%	38.10%

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets	'	'
Allowance for doubtful accounts, Total	$1,484	$1,496
Allowance for doubtful accounts, Current	1,484	1,496
Compensation and benefit related accruals, Total	45,147	45,784
Compensation and benefit related accruals, Current	35,706	38,254
Compensation and benefit related accruals, Non-Current	9,441	7,530
Professional malpractice liability insurance, Total	20,333	17,005
Professional malpractice liability insurance, Current	6,382	5,003
Professional malpractice liability insurance, Non-Current	13,951	12,002
Restructuring reserve, Total	441	679
Restructuring reserve, Current	441	679
Net operating loss carryforwards, Total	22,686	24,543
Net operating loss carryforwards, Current	422	777
Net operating loss carryforwards, Non-Current	22,264	23,766
Other, Total	630	1,025
Other, Current	630	996
Other, Non-Current	'	29
Stock options, Total	4,392	4,089
Stock options, Non-Current	4,392	4,089
Uncertain tax positions, Total	2,107	2,661
Uncertain tax positions, Non-Current	2,107	2,661
Total deferred tax assets, Total	97,220	97,282
Total deferred tax assets, Current	45,065	47,205
Total deferred tax assets, Non-Current	52,155	50,077
Deferred tax liabilities	'	'
Deferred income, Total	-31,832	-33,188
Deferred income, Current	-24,897	-26,253
Deferred income, Non-Current	-6,935	-6,935
Other, Total	-2,620	-1,311
Other, Current	-230	-118
Other, Non-Current	-2,390	-1,193
Depreciation and amortization, Total	-130,884	-121,075
Depreciation and amortization, Non-Current	-130,884	-121,075
Total deferred tax liabilities, Total	-165,336	-155,574
Total deferred tax liabilities, Current	-25,127	-26,371
Total deferred tax liabilities, Non-Current	-140,209	-129,203
Net deferred taxes before valuation allowance, Total	-68,116	-58,292
Net deferred taxes before valuation allowance, Current	19,938	20,834
Net deferred taxes before valuation allowance, Non-Current	-88,054	-79,126
Valuation allowance, Total	-10,547	-13,341
Valuation allowance, Current	-2,314	-2,957
Valuation allowance, Non-Current	-8,233	-10,384
Net deferred taxes, Total	-78,663	-71,633
Net deferred taxes, Current	17,624	17,877
Net deferred taxes, Non-Current	($96,287)	($89,510)
Additional information related to valuation allowance	'	'
Period of review for assessment of deferred tax assets	'3 years	'

Income_Taxes_Details_3

Income Taxes (Details 3) (State, USD $)	Dec. 31, 2013
State	'
Net operating loss carry forwards	'
Net operating losses	$512,300,000
State Net Operating Losses	'
2014	5,427,000
2015	8,333,000
2016	11,238,000
2017	12,834,000
Thereafter through 2033	473,034,000
Gross Valuation Allowance	'
2014	5,401,000
2015	7,980,000
2016	9,728,000
2017	11,092,000
Thereafter through 20xx	$355,392,000

Income_Taxes_Details_4

Income Taxes (Details 4) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of the Company's unrecognized tax benefits	'	'	'
Gross tax contingencies at the beginning of the period	$13,890,000	$15,656,000	$22,310,000
Reductions for tax positions taken in prior periods due primarily to statute expiration	-2,299,000	-2,516,000	-2,706,000
Reductions for tax positions taken in prior periods due to change in estimate	'	'	-7,012,000
Additions for existing tax positions taken	435,000	750,000	3,064,000
Gross tax contingencies at the end of the period	12,026,000	13,890,000	15,656,000
Income tax benefits recognized based on new information discovered	'	'	7,000,000
Unrecognized tax benefits, if fully recognized, would affect effective income tax rate	12,000,000	13,900,000	'
Accrued interest related to income taxes	1,600,000	1,500,000	'
Interest recognized	$500,000	$500,000	$400,000

Retirement_Savings_Plan_Detail

Retirement Savings Plan (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Retirement savings plan	'	'	'
Matching contribution by the employer (as a percent)	25.00%	'	'
Matching contribution of the employees (as a percent)	6.00%	'	'
Vesting period	'3 years	'	'
Expense incurred	$8.70	$8.20	$7.60
Employees who are not classified as HCE's | Maximum	'	'	'
Retirement savings plan	'	'	'
Contribution by employees (as a percent)	30.00%	'	'
HCE | Maximum	'	'	'
Retirement savings plan	'	'	'
Contribution by employees (as a percent)	6.00%	'	'

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of selected financial data	'	'	'	'	'	'	'	'	'	'	'
Net revenue	$746,175,000	$722,845,000	$756,673,000	$749,955,000	$741,086,000	$713,669,000	$750,193,000	$744,021,000	$2,975,648,000	$2,948,969,000	$2,804,507,000
Adjusted EBITDA	'	'	'	'	'	'	'	'	372,861,000	405,847,000	385,961,000
Total assets:	2,817,622,000	'	'	'	2,761,361,000	'	'	'	2,817,622,000	2,761,361,000	2,772,147,000
Capital expenditures	'	'	'	'	'	'	'	'	73,660,000	68,185,000	46,016,000
Select	'	'	'	'	'	'	'	'	'	'	'
Summary of selected financial data	'	'	'	'	'	'	'	'	'	'	'
Net revenue	746,175,000	722,845,000	756,673,000	749,955,000	741,086,000	713,669,000	750,193,000	744,021,000	2,975,648,000	2,948,969,000	2,804,507,000
Total assets:	2,817,622,000	'	'	'	2,760,313,000	'	'	'	2,817,622,000	2,760,313,000	2,770,738,000
Capital expenditures	'	'	'	'	'	'	'	'	73,660,000	68,185,000	46,016,000
Specialty Hospitals	'	'	'	'	'	'	'	'	'	'	'
Summary of selected financial data	'	'	'	'	'	'	'	'	'	'	'
Real estate assets held for sale	2,700,000	'	'	'	2,700,000	'	'	'	2,700,000	2,700,000	2,700,000
Operating Segments | Specialty Hospitals	'	'	'	'	'	'	'	'	'	'	'
Summary of selected financial data	'	'	'	'	'	'	'	'	'	'	'
Net revenue	'	'	'	'	'	'	'	'	2,198,121,000	2,197,529,000	2,095,519,000
Adjusted EBITDA	'	'	'	'	'	'	'	'	353,843,000	381,354,000	362,334,000
Total assets:	2,205,921,000	'	'	'	2,143,906,000	'	'	'	2,205,921,000	2,143,906,000	2,187,767,000
Capital expenditures	'	'	'	'	'	'	'	'	56,523,000	50,005,000	30,464,000
Operating Segments | Specialty Hospitals | Select	'	'	'	'	'	'	'	'	'	'	'
Summary of selected financial data	'	'	'	'	'	'	'	'	'	'	'
Total assets:	2,205,921,000	'	'	'	2,143,906,000	'	'	'	2,205,921,000	2,143,906,000	2,187,767,000
Operating Segments | Outpatient Rehabilitation	'	'	'	'	'	'	'	'	'	'	'
Segment information	'	'	'	'	'	'	'	'	'	'	'
Number of operating segments	'	'	'	'	'	'	'	'	2	'	'
Summary of selected financial data	'	'	'	'	'	'	'	'	'	'	'
Net revenue	'	'	'	'	'	'	'	'	777,177,000	751,317,000	708,867,000
Adjusted EBITDA	'	'	'	'	'	'	'	'	90,313,000	87,024,000	83,864,000
Total assets:	512,539,000	'	'	'	491,920,000	'	'	'	512,539,000	491,920,000	486,589,000
Capital expenditures	'	'	'	'	'	'	'	'	14,113,000	13,209,000	12,135,000
Operating Segments | Outpatient Rehabilitation | Select	'	'	'	'	'	'	'	'	'	'	'
Summary of selected financial data	'	'	'	'	'	'	'	'	'	'	'
Total assets:	512,539,000	'	'	'	491,920,000	'	'	'	512,539,000	491,920,000	486,589,000
Other	'	'	'	'	'	'	'	'	'	'	'
Summary of selected financial data	'	'	'	'	'	'	'	'	'	'	'
Net revenue	'	'	'	'	'	'	'	'	350,000	123,000	121,000
Adjusted EBITDA	'	'	'	'	'	'	'	'	-71,295,000	-62,531,000	-60,237,000
Total assets:	99,162,000	'	'	'	125,535,000	'	'	'	99,162,000	125,535,000	97,791,000
Capital expenditures	'	'	'	'	'	'	'	'	3,024,000	4,971,000	3,417,000
Other | Select	'	'	'	'	'	'	'	'	'	'	'
Summary of selected financial data	'	'	'	'	'	'	'	'	'	'	'
Total assets:	$99,162,000	'	'	'	$124,487,000	'	'	'	$99,162,000	$124,487,000	$96,382,000

Segment_Information_Details_2

Segment Information (Details 2) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment information	'	'	'	'	'	'	'	'	'	'	'
Adjusted EBITDA	'	'	'	'	'	'	'	'	$372,861	$405,847	$385,961
Depreciation and amortization	'	'	'	'	'	'	'	'	-64,392	-63,311	-71,517
Stock compensation expense	'	'	'	'	'	'	'	'	-7,033	-5,677	-3,725
Income from operations	68,244	62,399	88,263	82,530	80,923	70,819	93,513	91,604	301,436	336,859	310,719
Loss on early retirement of debt	'	'	'	'	'	'	'	'	-18,747	-6,064	-31,018
Equity in earnings of unconsolidated subsidiaries	'	'	'	'	'	'	'	'	2,476	7,705	2,923
Interest expense, net	'	'	'	'	'	'	'	'	-87,364	-94,950	-98,894
Income before income taxes	'	'	'	'	'	'	'	'	197,801	243,550	183,730
Select	'	'	'	'	'	'	'	'	'	'	'
Segment information	'	'	'	'	'	'	'	'	'	'	'
Depreciation and amortization	'	'	'	'	'	'	'	'	-64,392	-63,311	-71,517
Income from operations	68,244	62,399	88,263	82,530	80,923	70,819	93,513	91,604	301,436	336,859	310,719
Loss on early retirement of debt	'	'	'	'	'	'	'	'	-17,788	-6,064	-20,385
Equity in earnings of unconsolidated subsidiaries	'	'	'	'	'	'	'	'	2,476	7,705	2,923
Interest expense, net	'	'	'	'	'	'	'	'	-84,954	-83,759	-80,910
Income before income taxes	'	'	'	'	'	'	'	'	201,170	254,741	212,347
Operating Segments | Specialty Hospitals	'	'	'	'	'	'	'	'	'	'	'
Segment information	'	'	'	'	'	'	'	'	'	'	'
Adjusted EBITDA	'	'	'	'	'	'	'	'	353,843	381,354	362,334
Depreciation and amortization	'	'	'	'	'	'	'	'	-48,621	-46,836	-50,629
Income from operations	'	'	'	'	'	'	'	'	305,222	334,518	311,705
Operating Segments | Outpatient Rehabilitation	'	'	'	'	'	'	'	'	'	'	'
Segment information	'	'	'	'	'	'	'	'	'	'	'
Adjusted EBITDA	'	'	'	'	'	'	'	'	90,313	87,024	83,864
Depreciation and amortization	'	'	'	'	'	'	'	'	-12,024	-13,208	-16,487
Income from operations	'	'	'	'	'	'	'	'	78,289	73,816	67,377
Other	'	'	'	'	'	'	'	'	'	'	'
Segment information	'	'	'	'	'	'	'	'	'	'	'
Adjusted EBITDA	'	'	'	'	'	'	'	'	-71,295	-62,531	-60,237
Depreciation and amortization	'	'	'	'	'	'	'	'	-3,747	-3,267	-4,401
Stock compensation expense	'	'	'	'	'	'	'	'	-7,033	-5,677	-3,725
Income from operations	'	'	'	'	'	'	'	'	($82,075)	($71,475)	($68,363)

Income_per_Share_Details

Income per Share (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income per Share	'	'	'	'	'	'	'	'	'	'	'
Contractual dividends	'	'	'	'	'	'	'	'	$0	$0	$0
Numerator:	'	'	'	'	'	'	'	'	'	'	'
Net income attributable to Select Medical Holdings Corporation	28,920	23,272	27,780	34,418	39,406	24,110	43,172	41,542	114,390	148,230	107,846
Less: Earnings allocated to unvested restricted stockholders	'	'	'	'	'	'	'	'	2,450	2,514	1,205
Net income available to common stockholders	'	'	'	'	'	'	'	'	$111,940	$145,716	$106,641
Denominator:	'	'	'	'	'	'	'	'	'	'	'
Weighted average shares - basic	'	'	'	'	'	'	'	'	136,879	138,767	150,501
Effect of dilutive securities: Stock options (in shares)	'	'	'	'	'	'	'	'	168	275	224
Weighted average shares - diluted	'	'	'	'	'	'	'	'	137,047	139,042	150,725
Income per common share	'	'	'	'	'	'	'	'	'	'	'
Basic income per common share: (in dollars per share)	$0.21	$0.17	$0.20	$0.25	$0.28	$0.17	$0.31	$0.29	$0.82	$1.05	$0.71
Diluted income per common share: (in dollars per share)	$0.21	$0.17	$0.20	$0.24	$0.28	$0.17	$0.31	$0.29	$0.82	$1.05	$0.71
Anti-dilutive securities excluded from computation of earnings per share	'	'	'	'	'	'	'	'	'	'	'
Stock options (in shares)	'	'	'	'	'	'	'	'	1,474	1,654	2,414

Fair_Value_Details

Fair Value (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Fair Value	'	'
Carrying value	$1,445,275,000	$1,470,243,000
Select	'	'
Fair Value	'	'
Carrying value	1,445,275,000	1,302,943,000
Senior secured credit facility | Select	'	'
Fair Value	'	'
Carrying value	827,800,000	1,226,600,000
Fair value	828,300,000	1,216,200,000
6.375% senior notes	'	'
Fair Value	'	'
Carrying value	600,000,000	'
Interest rate of debt (as a percent)	6.38%	'
6.375% senior notes | Select	'	'
Fair Value	'	'
Carrying value	600,000,000	'
Fair value	$586,500,000	'
Interest rate of debt (as a percent)	6.38%	'

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Related party transactions	'	'	'
Net operating revenues from contracted services and management fees to related parties	$111,670,000	$100,783,000	$60,751,000
Future rental commitments under outstanding agreements	'	'	'
2014	125,611,000	'	'
2015	98,100,000	'	'
2016	77,724,000	'	'
2017	63,517,000	'	'
2018	51,104,000	'	'
Thereafter	364,253,000	'	'
Total	780,309,000	'	'
Affiliated companies	'	'	'
Related party transactions	'	'	'
Payments for office rent, leasehold improvements and miscellaneous expenses	4,200,000	4,000,000	4,000,000
Future rental commitments under outstanding agreements	'	'	'
2014	3,758,000	'	'
2015	3,792,000	'	'
2016	3,828,000	'	'
2017	3,865,000	'	'
2018	3,950,000	'	'
Thereafter	17,047,000	'	'
Total	36,240,000	'	'
BIR JV, LLP	'	'	'
Related party transactions	'	'	'
Net operating revenues from contracted services and management fees to related parties	96,465,000	92,205,000	53,309,000
Rehabilitation Institute of Denton, LLC	'	'	'
Related party transactions	'	'	'
Net operating revenues from contracted services and management fees to related parties	7,163,000	8,133,000	7,292,000
OHRH, LLC	'	'	'
Related party transactions	'	'	'
Net operating revenues from contracted services and management fees to related parties	2,069,000	'	'
Global Rehab - Scottsdale, LLC	'	'	'
Related party transactions	'	'	'
Net operating revenues from contracted services and management fees to related parties	4,129,000	'	'
Amplion Clinical Communications, Inc	'	'	'
Related party transactions	'	'	'
Net operating revenues from contracted services and management fees to related parties	1,534,000	305,000	'
Other	'	'	'
Related party transactions	'	'	'
Net operating revenues from contracted services and management fees to related parties	$310,000	$140,000	$150,000

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Future rental commitments under outstanding agreements	'	'	'
2014	$125,611,000	'	'
2015	98,100,000	'	'
2016	77,724,000	'	'
2017	63,517,000	'	'
2018	51,104,000	'	'
Thereafter	364,253,000	'	'
Total	780,309,000	'	'
Total rent expense for operating leases	164,600,000	168,300,000	163,900,000
Property rent expense to unrelated parties	119,500,000	118,100,000	114,800,000
Construction Commitments	'	'	'
Outstanding commitments under construction contracts	$22,800,000	'	'

Commitments_and_Contingencies_2

Commitments and Contingencies (Details 2) (Naming, promotional and sponsorship agreement, Subsidiary, USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Naming, promotional and sponsorship agreement | Subsidiary	'
Commitments and Contingencies	'
Amount expected to be paid in next year	$2.90
Increase in successive annual payment (as a percent)	0.023

Commitments_and_Contingencies_3

Commitments and Contingencies (Details 3) (USD $)	0 Months Ended		1 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Mar. 29, 2013	Jan. 08, 2013	Jan. 31, 2014	Dec. 31, 2013	Dec. 31, 2013
	SSH-Evansville	SSH-Evansville	SSH-Evansville	Professional liability claims	General liability claims
	Amended complaint	Amended complaint	Amended complaint
		item	item
Commitments and Contingencies	'	'	'	'	'
Self insurance retention per occurrence	'	'	'	$2	$2
Number of case managers identified as plaintiff	'	2	'	'	'
Number of physicians named as defendants	'	2	'	'	'
Number of days the deadlines have been stayed from the Magistrate judge	'90 days	'	'	'	'
Period after which patients were readmitted to short-stay acute care hospitals to enable billing for two admissions	'	'	'9 days	'	'
Number of admissions into hospitals	'	'	2	'	'

Supplemental_Disclosures_of_Ca2

Supplemental Disclosures of Cash Flow Information (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Notes issued with acquisitions	$3,283	$1,844	$1,020
Liabilities assumed with acquisitions	885	107	701
Contingent consideration related to acquisitions	100	1,500	'
Notes related to investment in business	3,399	'	'
Select	'	'	'
Dividends declared to Holdings	'	-5,240	-5,240
Notes issued with acquisitions	3,283	1,844	1,020
Liabilities assumed with acquisitions	885	107	701
Contingent consideration related to acquisitions	100	1,500	'
Notes related to investment in business	$3,399	'	'

Subsequent_Events_Details

Subsequent Events (Details) (Subsequent Event, Select, USD $)	0 Months Ended
	Feb. 19, 2014
Subsequent Event | Select	'
Subsequent Event	'
Cash dividend declared (in dollars per share)	$0.10

Financial_Information_for_Subs2

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes (Details) (6.375% senior notes)	Dec. 31, 2013
Financial information for subsidiary guarantors and non-guarantor subsidiaries under select's 6.375% senior notes	'
Interest rate of debt (as a percent)	6.38%
Select	'
Financial information for subsidiary guarantors and non-guarantor subsidiaries under select's 6.375% senior notes	'
Interest rate of debt (as a percent)	6.38%

Financial_Information_for_Subs3

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
In Thousands, unless otherwise specified
Current Assets:	'	'	'	'
Cash and cash equivalents	$4,319	$40,144	$12,043	$4,365
Accounts receivable, net	391,319	359,929	'	'
Current deferred tax asset	17,624	17,877	'	'
Prepaid income taxes	'	3,895	'	'
Other current assets	41,140	31,818	'	'
Total Current Assets	454,402	453,663	'	'
Property and equipment, net	509,102	501,552	'	'
Goodwill	1,642,633	1,640,534	1,631,716	'
Other identifiable intangibles	71,907	71,745	'	'
Other assets	139,578	93,867	'	'
Total Assets	2,817,622	2,761,361	2,772,147	'
Current Liabilities:	'	'	'	'
Bank overdrafts	12,506	17,836	'	'
Current portion of long-term debt and notes payable	17,565	11,646	'	'
Accounts payable	88,285	89,547	'	'
Accrued payroll	90,011	88,586	'	'
Accrued vacation	59,730	55,714	'	'
Accrued interest	12,297	22,016	'	'
Accrued other	90,471	86,843	'	'
Income taxes payable	622	'	'	'
Due to third party payors	37	1,078	'	'
Total Current Liabilities	371,524	373,266	'	'
Long-term debt, net of current portion	1,427,710	1,458,597	'	'
Non-current deferred tax liability	96,287	89,510	'	'
Other non-current liabilities	91,875	83,699	'	'
Total Liabilities	1,987,396	2,005,072	'	'
Redeemable non-controlling interest	11,584	10,811	'	'
Stockholder's Equity:	'	'	'	'
Common stock	140	141	'	'
Capital in excess of par	474,729	473,697	'	'
Retained earnings	311,365	243,210	'	'
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	786,234	717,048	'	'
Non-controlling interests	32,408	28,430	'	'
Total Equity	818,642	745,478	846,338	807,176
Total Liabilities and Equity	2,817,622	2,761,361	'	'
Select Medical Corporation	'	'	'	'
Current Assets:	'	'	'	'
Cash and cash equivalents	4,319	40,144	12,043	4,365
Accounts receivable, net	391,319	359,929	'	'
Current deferred tax asset	17,624	17,877	'	'
Prepaid income taxes	'	3,895	'	'
Other current assets	41,140	31,818	'	'
Total Current Assets	454,402	453,663	'	'
Property and equipment, net	509,102	501,552	'	'
Goodwill	1,642,633	1,640,534	'	'
Other identifiable intangibles	71,907	71,745	'	'
Other assets	139,578	92,819	'	'
Total Assets	2,817,622	2,760,313	2,770,738	'
Current Liabilities:	'	'	'	'
Bank overdrafts	12,506	17,836	'	'
Current portion of long-term debt and notes payable	17,565	11,646	'	'
Accounts payable	88,285	89,547	'	'
Accrued payroll	90,011	88,586	'	'
Accrued vacation	59,730	55,714	'	'
Accrued interest	12,297	18,759	'	'
Accrued other	90,471	92,083	'	'
Income taxes payable	622	'	'	'
Due to third party payors	37	1,078	'	'
Total Current Liabilities	371,524	375,249	'	'
Long-term debt, net of current portion	1,427,710	1,291,297	'	'
Non-current deferred tax liability	96,287	89,510	'	'
Other non-current liabilities	91,875	83,699	'	'
Total Liabilities	1,987,396	1,839,755	'	'
Redeemable non-controlling interest	11,584	10,811	'	'
Stockholder's Equity:	'	'	'	'
Common stock	0	0	'	'
Capital in excess of par	869,576	859,839	'	'
Retained earnings	-83,342	21,478	'	'
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	786,234	881,317	'	'
Non-controlling interests	32,408	28,430	'	'
Total Equity	818,642	909,747	1,010,105	1,107,890
Total Liabilities and Equity	2,817,622	2,760,313	'	'
Select Medical Corporation | Reportable legal entities | Select Medical Corporation (Parent Company Only)	'	'	'	'
Current Assets:	'	'	'	'
Cash and cash equivalents	71	35,070	11,427	149
Current deferred tax asset	7,965	12,383	'	'
Prepaid income taxes	'	3,895	'	'
Other current assets	9,745	5,600	'	'
Total Current Assets	17,781	56,948	'	'
Property and equipment, net	15,624	16,344	'	'
Investment in affiliates	3,059,581	2,930,022	'	'
Non-current deferred tax asset	7,662	5,107	'	'
Other assets	35,274	28,680	'	'
Total Assets	3,135,922	3,037,101	'	'
Current Liabilities:	'	'	'	'
Bank overdrafts	12,506	17,836	'	'
Current portion of long-term debt and notes payable	9,107	8,916	'	'
Accounts payable	6,749	4,674	'	'
Intercompany payables	1,184,764	1,124,173	'	'
Accrued payroll	1,167	186	'	'
Accrued vacation	4,619	4,249	'	'
Accrued interest	11,076	17,955	'	'
Accrued other	59,249	55,206	'	'
Income taxes payable	622	'	'	'
Total Current Liabilities	1,289,859	1,233,195	'	'
Long-term debt, net of current portion	1,006,201	872,671	'	'
Other non-current liabilities	53,628	49,918	'	'
Total Liabilities	2,349,688	2,155,784	'	'
Stockholder's Equity:	'	'	'	'
Common stock	0	0	'	'
Capital in excess of par	869,576	859,839	'	'
Retained earnings	-83,342	21,478	'	'
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	786,234	881,317	'	'
Total Equity	786,234	881,317	'	'
Total Liabilities and Equity	3,135,922	3,037,101	'	'
Select Medical Corporation | Reportable legal entities | Subsidiary Guarantors	'	'	'	'
Current Assets:	'	'	'	'
Cash and cash equivalents	3,098	3,734	'	3,567
Accounts receivable, net	337,517	308,043	'	'
Current deferred tax asset	5,214	1,060	'	'
Intercompany receivables	1,079,736	1,021,479	'	'
Other current assets	26,545	19,655	'	'
Total Current Assets	1,452,110	1,353,971	'	'
Property and equipment, net	434,040	425,677	'	'
Investment in affiliates	83,012	82,475	'	'
Goodwill	1,642,633	1,640,534	'	'
Other identifiable intangibles	71,907	71,745	'	'
Other assets	103,696	63,447	'	'
Total Assets	3,787,398	3,637,849	'	'
Current Liabilities:	'	'	'	'
Current portion of long-term debt and notes payable	7,317	1,059	'	'
Accounts payable	68,574	72,213	'	'
Accrued payroll	88,599	88,096	'	'
Accrued vacation	47,682	44,508	'	'
Accrued interest	1,221	804	'	'
Accrued other	23,493	31,343	'	'
Due to third party payors	1	'	'	'
Total Current Liabilities	236,887	238,023	'	'
Long-term debt, net of current portion	364,060	358,104	'	'
Non-current deferred tax liability	96,111	85,287	'	'
Other non-current liabilities	33,123	28,808	'	'
Total Liabilities	730,181	710,222	'	'
Stockholder's Equity:	'	'	'	'
Retained earnings	920,694	790,692	'	'
Subsidiary investment	2,136,523	2,136,935	'	'
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	3,057,217	2,927,627	'	'
Total Equity	3,057,217	2,927,627	'	'
Total Liabilities and Equity	3,787,398	3,637,849	'	'
Select Medical Corporation | Reportable legal entities | Non-Guarantor Subsidiaries	'	'	'	'
Current Assets:	'	'	'	'
Cash and cash equivalents	1,150	1,340	616	649
Accounts receivable, net	54,452	53,531	'	'
Current deferred tax asset	4,445	4,434	'	'
Intercompany receivables	105,028	102,694	'	'
Other current assets	4,850	6,563	'	'
Total Current Assets	169,925	168,562	'	'
Property and equipment, net	59,438	59,531	'	'
Other assets	608	692	'	'
Total Assets	229,971	228,785	'	'
Current Liabilities:	'	'	'	'
Current portion of long-term debt and notes payable	1,141	1,671	'	'
Accounts payable	12,962	12,660	'	'
Accrued payroll	245	304	'	'
Accrued vacation	7,429	6,957	'	'
Accrued other	7,729	5,534	'	'
Due to third party payors	686	2,723	'	'
Total Current Liabilities	30,192	29,849	'	'
Long-term debt, net of current portion	57,449	60,522	'	'
Non-current deferred tax liability	7,838	9,330	'	'
Other non-current liabilities	5,124	4,973	'	'
Total Liabilities	100,603	104,674	'	'
Redeemable non-controlling interest	11,584	10,811	'	'
Stockholder's Equity:	'	'	'	'
Retained earnings	21,186	21,197	'	'
Subsidiary investment	64,190	63,673	'	'
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	85,376	84,870	'	'
Non-controlling interests	32,408	28,430	'	'
Total Equity	117,784	113,300	'	'
Total Liabilities and Equity	229,971	228,785	'	'
Select Medical Corporation | Eliminations	'	'	'	'
Current Assets:	'	'	'	'
Accounts receivable, net	-650	-1,645	'	'
Intercompany receivables	-1,184,764	-1,124,173	'	'
Total Current Assets	-1,185,414	-1,125,818	'	'
Investment in affiliates	-3,142,593	-3,012,497	'	'
Non-current deferred tax asset	-7,662	-5,107	'	'
Total Assets	-4,335,669	-4,143,422	'	'
Current Liabilities:	'	'	'	'
Intercompany payables	-1,184,764	-1,124,173	'	'
Due to third party payors	-650	-1,645	'	'
Total Current Liabilities	-1,185,414	-1,125,818	'	'
Non-current deferred tax liability	-7,662	-5,107	'	'
Total Liabilities	-1,193,076	-1,130,925	'	'
Stockholder's Equity:	'	'	'	'
Retained earnings	-941,880	-811,889	'	'
Subsidiary investment	-2,200,713	-2,200,608	'	'
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	-3,142,593	-3,012,497	'	'
Total Equity	-3,142,593	-3,012,497	'	'
Total Liabilities and Equity	($4,335,669)	($4,143,422)	'	'

Financial_Information_for_Subs4

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes (Details 3) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Condensed Consolidating Statement of Operations	'	'	'	'	'	'	'	'	'	'	'
Net operating revenues	$746,175	$722,845	$756,673	$749,955	$741,086	$713,669	$750,193	$744,021	$2,975,648	$2,948,969	$2,804,507
Costs and expenses:	'	'	'	'	'	'	'	'	'	'	'
Cost of services	'	'	'	'	'	'	'	'	2,495,476	2,443,550	2,308,570
General and administrative	'	'	'	'	'	'	'	'	76,921	66,194	62,354
Bad debt expense	'	'	'	'	'	'	'	'	37,423	39,055	51,347
Depreciation and amortization	'	'	'	'	'	'	'	'	64,392	63,311	71,517
Total costs and expenses	'	'	'	'	'	'	'	'	2,674,212	2,612,110	2,493,788
Income from operations	68,244	62,399	88,263	82,530	80,923	70,819	93,513	91,604	301,436	336,859	310,719
Other income and expense:	'	'	'	'	'	'	'	'	'	'	'
Equity in earnings (losses) of unconsolidated subsidiaries	'	'	'	'	'	'	'	'	2,476	7,705	2,923
Loss on early retirement of debt	'	'	'	'	'	'	'	'	-18,747	-6,064	-31,018
Interest income	'	'	'	'	'	'	'	'	'	'	322
Interest expense	'	'	'	'	'	'	'	'	-87,364	-94,950	-99,216
Income before income taxes	'	'	'	'	'	'	'	'	197,801	243,550	183,730
Income tax expense (benefit)	'	'	'	'	'	'	'	'	74,792	89,657	70,968
Net income	'	'	'	'	'	'	'	'	123,009	153,893	112,762
Less: Net income attributable to non-controlling interests	'	'	'	'	'	'	'	'	8,619	5,663	4,916
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	28,920	23,272	27,780	34,418	39,406	24,110	43,172	41,542	114,390	148,230	107,846
Select Medical Corporation	'	'	'	'	'	'	'	'	'	'	'
Condensed Consolidating Statement of Operations	'	'	'	'	'	'	'	'	'	'	'
Net operating revenues	746,175	722,845	756,673	749,955	741,086	713,669	750,193	744,021	2,975,648	2,948,969	2,804,507
Costs and expenses:	'	'	'	'	'	'	'	'	'	'	'
Cost of services	'	'	'	'	'	'	'	'	2,495,476	2,443,550	2,308,570
General and administrative	'	'	'	'	'	'	'	'	76,921	66,194	62,354
Bad debt expense	'	'	'	'	'	'	'	'	37,423	39,055	51,347
Depreciation and amortization	'	'	'	'	'	'	'	'	64,392	63,311	71,517
Total costs and expenses	'	'	'	'	'	'	'	'	2,674,212	2,612,110	2,493,788
Income from operations	68,244	62,399	88,263	82,530	80,923	70,819	93,513	91,604	301,436	336,859	310,719
Other income and expense:	'	'	'	'	'	'	'	'	'	'	'
Equity in earnings (losses) of unconsolidated subsidiaries	'	'	'	'	'	'	'	'	2,476	7,705	2,923
Loss on early retirement of debt	'	'	'	'	'	'	'	'	-17,788	-6,064	-20,385
Interest income	'	'	'	'	'	'	'	'	'	'	322
Interest expense	'	'	'	'	'	'	'	'	-84,954	-83,759	-81,232
Income before income taxes	'	'	'	'	'	'	'	'	201,170	254,741	212,347
Income tax expense (benefit)	'	'	'	'	'	'	'	'	75,971	93,574	80,984
Net income	'	'	'	'	'	'	'	'	125,199	161,167	131,363
Less: Net income attributable to non-controlling interests	'	'	'	'	'	'	'	'	8,619	5,663	4,916
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	28,920	23,272	27,780	36,608	41,254	25,953	45,018	43,279	116,580	155,504	126,447
Select Medical Corporation | Reportable legal entities | Select Medical Corporation (Parent Company Only)	'	'	'	'	'	'	'	'	'	'	'
Condensed Consolidating Statement of Operations	'	'	'	'	'	'	'	'	'	'	'
Net operating revenues	'	'	'	'	'	'	'	'	350	123	121
Costs and expenses:	'	'	'	'	'	'	'	'	'	'	'
Cost of services	'	'	'	'	'	'	'	'	1,757	2,139	1,729
General and administrative	'	'	'	'	'	'	'	'	76,709	67,402	61,995
Depreciation and amortization	'	'	'	'	'	'	'	'	3,746	3,267	4,115
Total costs and expenses	'	'	'	'	'	'	'	'	82,212	72,808	67,839
Income from operations	'	'	'	'	'	'	'	'	-81,862	-72,685	-67,718
Other income and expense:	'	'	'	'	'	'	'	'	'	'	'
Intercompany interest and royalty fees	'	'	'	'	'	'	'	'	-1,326	-2,532	-3,408
Intercompany management fees	'	'	'	'	'	'	'	'	144,447	120,276	120,013
Loss on early retirement of debt	'	'	'	'	'	'	'	'	-17,788	-6,064	-20,385
Interest income	'	'	'	'	'	'	'	'	'	'	132
Interest expense	'	'	'	'	'	'	'	'	-58,100	-54,167	-41,817
Income before income taxes	'	'	'	'	'	'	'	'	-14,629	-15,172	-13,183
Income tax expense (benefit)	'	'	'	'	'	'	'	'	-1,238	-8,206	-12,821
Equity in earnings of subsidiaries	'	'	'	'	'	'	'	'	129,971	162,470	126,809
Net income	'	'	'	'	'	'	'	'	116,580	155,504	126,447
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	'	'	'	'	'	'	'	'	116,580	155,504	126,447
Select Medical Corporation | Reportable legal entities | Subsidiary Guarantors	'	'	'	'	'	'	'	'	'	'	'
Condensed Consolidating Statement of Operations	'	'	'	'	'	'	'	'	'	'	'
Net operating revenues	'	'	'	'	'	'	'	'	2,553,505	2,549,896	2,436,177
Costs and expenses:	'	'	'	'	'	'	'	'	'	'	'
Cost of services	'	'	'	'	'	'	'	'	2,135,754	2,099,734	1,996,671
General and administrative	'	'	'	'	'	'	'	'	212	-1,208	359
Bad debt expense	'	'	'	'	'	'	'	'	31,003	33,595	44,300
Depreciation and amortization	'	'	'	'	'	'	'	'	50,982	50,734	58,064
Total costs and expenses	'	'	'	'	'	'	'	'	2,217,951	2,182,855	2,099,394
Income from operations	'	'	'	'	'	'	'	'	335,554	367,041	336,783
Other income and expense:	'	'	'	'	'	'	'	'	'	'	'
Intercompany interest and royalty fees	'	'	'	'	'	'	'	'	1,339	2,494	3,382
Intercompany management fees	'	'	'	'	'	'	'	'	-125,361	-102,096	-102,970
Equity in earnings (losses) of unconsolidated subsidiaries	'	'	'	'	'	'	'	'	2,384	7,637	2,870
Interest income	'	'	'	'	'	'	'	'	'	'	122
Interest expense	'	'	'	'	'	'	'	'	-22,760	-25,348	-34,612
Income before income taxes	'	'	'	'	'	'	'	'	191,156	249,728	205,575
Income tax expense (benefit)	'	'	'	'	'	'	'	'	76,870	101,795	92,561
Equity in earnings of subsidiaries	'	'	'	'	'	'	'	'	15,716	15,639	13,406
Net income	'	'	'	'	'	'	'	'	130,002	163,572	126,420
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	'	'	'	'	'	'	'	'	130,002	163,572	126,420
Select Medical Corporation | Reportable legal entities | Non-Guarantor Subsidiaries	'	'	'	'	'	'	'	'	'	'	'
Condensed Consolidating Statement of Operations	'	'	'	'	'	'	'	'	'	'	'
Net operating revenues	'	'	'	'	'	'	'	'	421,793	398,950	368,209
Costs and expenses:	'	'	'	'	'	'	'	'	'	'	'
Cost of services	'	'	'	'	'	'	'	'	357,965	341,677	310,170
Bad debt expense	'	'	'	'	'	'	'	'	6,420	5,460	7,047
Depreciation and amortization	'	'	'	'	'	'	'	'	9,664	9,310	9,338
Total costs and expenses	'	'	'	'	'	'	'	'	374,049	356,447	326,555
Income from operations	'	'	'	'	'	'	'	'	47,744	42,503	41,654
Other income and expense:	'	'	'	'	'	'	'	'	'	'	'
Intercompany interest and royalty fees	'	'	'	'	'	'	'	'	-13	38	26
Intercompany management fees	'	'	'	'	'	'	'	'	-19,086	-18,180	-17,043
Equity in earnings (losses) of unconsolidated subsidiaries	'	'	'	'	'	'	'	'	92	68	53
Interest income	'	'	'	'	'	'	'	'	'	'	68
Interest expense	'	'	'	'	'	'	'	'	-4,094	-4,244	-4,803
Income before income taxes	'	'	'	'	'	'	'	'	24,643	20,185	19,955
Income tax expense (benefit)	'	'	'	'	'	'	'	'	339	-15	1,244
Net income	'	'	'	'	'	'	'	'	24,304	20,200	18,711
Less: Net income attributable to non-controlling interests	'	'	'	'	'	'	'	'	8,619	5,663	4,916
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	'	'	'	'	'	'	'	'	15,685	14,537	13,795
Select Medical Corporation | Eliminations	'	'	'	'	'	'	'	'	'	'	'
Other income and expense:	'	'	'	'	'	'	'	'	'	'	'
Equity in earnings of subsidiaries	'	'	'	'	'	'	'	'	-145,687	-178,109	-140,215
Net income	'	'	'	'	'	'	'	'	-145,687	-178,109	-140,215
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	'	'	'	'	'	'	'	'	($145,687)	($178,109)	($140,215)

Financial_Information_for_Subs5

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 6.375% Senior Notes (Details 4) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Operating activities	'	'	'
Net income	$123,009	$153,893	$112,762
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Depreciation and amortization	64,392	63,311	71,517
Provision for bad debts	37,423	39,055	51,347
Equity in earnings of unconsolidated subsidiaries	-2,476	-7,705	-2,923
Loss on early retirement of debt	18,747	6,064	31,018
Loss (gain) from disposal or sale of assets	-581	-5,906	-4,966
Non-cash stock compensation expense	7,033	5,677	3,725
Amortization of debt discount and issuance costs	8,433	7,566	8,007
Deferred income taxes	7,032	7,909	35,305
Changes in operating assets and liabilities, net of effects from acquisition of businesses:	'	'	'
Accounts receivable	-67,145	15,158	-111,126
Other current assets	-8,167	-1,607	-1,201
Other assets	-3,484	5,862	-2,081
Accounts payable	-1,283	-6,117	20,629
Due to third-party payors	-1,041	-4,448	227
Accrued expenses	10,631	19,970	4,888
Net cash provided by operating activities	192,523	298,682	217,128
Investing activities	'	'	'
Purchases of property and equipment	-73,660	-68,185	-46,016
Investment in businesses, net of distributions	-34,893	-14,689	-15,699
Acquisition of businesses, net of cash acquired	-1,665	-6,043	-899
Proceeds from sale of assets	2,912	16,511	7,879
Net cash used in investing activities	-107,306	-72,406	-54,735
Financing activities	'	'	'
Borrowings on revolving credit facility	690,000	495,000	735,000
Payments on revolving credit facility	-800,000	-405,000	-720,000
Borrowings on credit facility term loans, net of discount	298,500	266,750	841,500
Payments on credit facility term loans	-596,720	-9,875	-4,250
Payments on 2005 credit facility term loans, net of call premium	'	'	-484,633
Repurchase of 7 5/8% senior subordinated notes, net of premiums	-70,000	-278,495	-273,941
Borrowings of other debt	15,310	8,281	7,055
Principal payments on other debt	-10,834	-10,295	-7,499
Debt issuance costs	-18,914	-6,527	-18,556
Repayments of bank overdrafts	-5,330	1,227	-2,183
Dividends paid to Holdings	-41,961	-210,888	'
Distributions to non-controlling interests	-3,537	-3,268	-4,612
Net cash used in financing activities	-121,042	-198,175	-154,715
Net increase (decrease) in cash and cash equivalents	-35,825	28,101	7,678
Cash and cash equivalents at beginning of period	40,144	12,043	4,365
Cash and cash equivalents at end of period	4,319	40,144	12,043
Select Medical Corporation	'	'	'
Operating activities	'	'	'
Net income	125,199	161,167	131,363
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Depreciation and amortization	64,392	63,311	71,517
Provision for bad debts	37,423	39,055	51,347
Equity in earnings of unconsolidated subsidiaries	-2,476	-7,705	-2,923
Loss on early retirement of debt	17,788	6,064	20,385
Loss (gain) from disposal or sale of assets	-581	-5,906	-4,966
Non-cash stock compensation expense	7,033	5,677	3,725
Amortization of debt discount and issuance costs	8,344	7,190	6,700
Deferred income taxes	7,032	7,909	35,305
Changes in operating assets and liabilities, net of effects from acquisition of businesses:	'	'	'
Accounts receivable	-67,145	15,158	-111,126
Other current assets	-8,167	-1,607	-1,201
Other assets	-3,484	5,877	-2,068
Accounts payable	-1,283	-6,117	20,629
Due to third-party payors	-1,041	-4,448	227
Accrued expenses	15,068	23,746	21,139
Net cash provided by operating activities	198,102	309,371	240,053
Investing activities	'	'	'
Purchases of property and equipment	-73,660	-68,185	-46,016
Investment in businesses, net of distributions	-34,893	-14,689	-15,699
Acquisition of businesses, net of cash acquired	-1,665	-6,043	-899
Proceeds from sale of assets	2,912	16,511	7,879
Net cash used in investing activities	-107,306	-72,406	-54,735
Financing activities	'	'	'
Borrowings on revolving credit facility	690,000	495,000	735,000
Payments on revolving credit facility	-800,000	-405,000	-720,000
Borrowings on credit facility term loans, net of discount	298,500	266,750	841,500
Payments on credit facility term loans	-596,720	-9,875	-4,250
Payments on 2005 credit facility term loans, net of call premium	'	'	-484,633
Issuance of 6.375% senior notes	600,000	'	'
Repurchase of 7 5/8% senior subordinated notes, net of premiums	-70,000	-278,495	-273,941
Borrowings of other debt	15,310	8,281	7,055
Principal payments on other debt	-10,834	-10,295	-7,499
Debt issuance costs	-18,914	-6,527	-18,556
Repayments of bank overdrafts	-5,330	1,227	-2,183
Equity investment by Holdings	1,525	1,817	208
Dividends paid to Holdings	-226,621	-268,479	-245,729
Distributions to non-controlling interests	-3,537	-3,268	-4,612
Net cash used in financing activities	-126,621	-208,864	-177,640
Net increase (decrease) in cash and cash equivalents	-35,825	28,101	7,678
Cash and cash equivalents at beginning of period	40,144	12,043	4,365
Cash and cash equivalents at end of period	4,319	40,144	12,043
Select Medical Corporation | Reportable legal entities | Select Medical Corporation (Parent Company Only)	'	'	'
Operating activities	'	'	'
Net income	116,580	155,504	126,447
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Depreciation and amortization	3,746	3,267	4,115
Loss on early retirement of debt	17,788	6,064	20,385
Loss (gain) from disposal or sale of assets	'	'	13
Non-cash stock compensation expense	7,033	5,677	3,725
Amortization of debt discount and issuance costs	8,344	7,190	6,700
Deferred income taxes	7,032	7,909	35,305
Changes in operating assets and liabilities, net of effects from acquisition of businesses:	'	'	'
Equity in earnings of subsidiaries	-129,971	-162,470	-126,809
Other current assets	-4,145	740	-1,780
Other assets	-6,594	2,448	-12,069
Accounts payable	2,075	-2,679	1,326
Accrued expenses	-4,929	25,350	14,823
Net cash provided by operating activities	16,959	49,000	72,181
Investing activities	'	'	'
Purchases of property and equipment	-3,024	-5,150	-3,413
Net cash used in investing activities	-3,024	-5,150	-3,413
Financing activities	'	'	'
Borrowings on revolving credit facility	690,000	495,000	735,000
Payments on revolving credit facility	-800,000	-405,000	-720,000
Borrowings on credit facility term loans, net of discount	298,500	266,750	841,500
Payments on credit facility term loans	-596,720	-9,875	-4,250
Payments on 2005 credit facility term loans, net of call premium	'	'	-484,633
Issuance of 6.375% senior notes	600,000	'	'
Repurchase of 7 5/8% senior subordinated notes, net of premiums	-70,000	-278,495	-273,941
Borrowings of other debt	8,923	8,003	6,100
Principal payments on other debt	-7,752	-8,049	-5,662
Debt issuance costs	-18,914	-6,527	-18,556
Repayments of bank overdrafts	-5,330	1,227	-2,183
Equity investment by Holdings	1,525	1,817	208
Dividends paid to Holdings	-226,621	-268,479	-245,729
Intercompany	77,455	183,421	114,656
Net cash used in financing activities	-48,934	-20,207	-57,490
Net increase (decrease) in cash and cash equivalents	-34,999	23,643	11,278
Cash and cash equivalents at beginning of period	35,070	11,427	149
Cash and cash equivalents at end of period	71	35,070	11,427
Select Medical Corporation | Reportable legal entities | Subsidiary Guarantors	'	'	'
Operating activities	'	'	'
Net income	130,002	163,572	126,420
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Depreciation and amortization	50,982	50,734	58,064
Provision for bad debts	31,003	33,595	44,300
Equity in earnings of unconsolidated subsidiaries	-2,384	-7,637	-2,870
Loss (gain) from disposal or sale of assets	-463	-6,002	-5,024
Changes in operating assets and liabilities, net of effects from acquisition of businesses:	'	'	'
Equity in earnings of subsidiaries	-15,716	-15,639	-13,406
Accounts receivable	-59,804	29,727	-98,966
Other current assets	-5,735	141	1,165
Other assets	3,026	3,268	9,683
Accounts payable	-3,660	-4,040	16,247
Due to third-party payors	996	-15,278	1,408
Accrued expenses	20,609	-3,835	5,522
Net cash provided by operating activities	148,856	228,606	142,543
Investing activities	'	'	'
Purchases of property and equipment	-60,532	-49,160	-37,759
Investment in businesses, net of distributions	-34,893	-14,689	-15,699
Acquisition of businesses, net of cash acquired	-1,665	-6,043	-899
Proceeds from sale of assets	2,456	16,511	7,879
Net cash used in investing activities	-94,634	-53,381	-46,478
Financing activities	'	'	'
Borrowings of other debt	5,303	'	955
Principal payments on other debt	-873	-433	-755
Intercompany	-59,288	-171,058	-99,832
Net cash used in financing activities	-54,858	-171,491	-99,632
Net increase (decrease) in cash and cash equivalents	-636	3,734	-3,567
Cash and cash equivalents at beginning of period	3,734	'	3,567
Cash and cash equivalents at end of period	3,098	3,734	'
Select Medical Corporation | Reportable legal entities | Non-Guarantor Subsidiaries	'	'	'
Operating activities	'	'	'
Net income	24,304	20,200	18,711
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Depreciation and amortization	9,664	9,310	9,338
Provision for bad debts	6,420	5,460	7,047
Equity in earnings of unconsolidated subsidiaries	-92	-68	-53
Loss (gain) from disposal or sale of assets	-118	96	45
Changes in operating assets and liabilities, net of effects from acquisition of businesses:	'	'	'
Accounts receivable	-7,341	-14,569	-12,160
Other current assets	1,713	-2,488	-586
Other assets	84	161	318
Accounts payable	302	602	3,056
Due to third-party payors	-2,037	10,830	-1,181
Accrued expenses	-612	2,231	794
Net cash provided by operating activities	32,287	31,765	25,329
Investing activities	'	'	'
Purchases of property and equipment	-10,104	-13,875	-4,844
Proceeds from sale of assets	456	'	'
Net cash used in investing activities	-9,648	-13,875	-4,844
Financing activities	'	'	'
Borrowings of other debt	1,084	278	'
Principal payments on other debt	-2,209	-1,813	-1,082
Intercompany	-18,167	-12,363	-14,824
Distributions to non-controlling interests	-3,537	-3,268	-4,612
Net cash used in financing activities	-22,829	-17,166	-20,518
Net increase (decrease) in cash and cash equivalents	-190	724	-33
Cash and cash equivalents at beginning of period	1,340	616	649
Cash and cash equivalents at end of period	1,150	1,340	616
Select Medical Corporation | Eliminations	'	'	'
Operating activities	'	'	'
Net income	-145,687	-178,109	-140,215
Changes in operating assets and liabilities, net of effects from acquisition of businesses:	'	'	'
Equity in earnings of subsidiaries	$145,687	$178,109	$140,215

Selected_Quarterly_Financial_D2

Selected Quarterly Financial Data (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Selected quarterly financial data (unaudited)	'	'	'	'	'	'	'	'	'	'	'
Net operating revenues	$746,175	$722,845	$756,673	$749,955	$741,086	$713,669	$750,193	$744,021	$2,975,648	$2,948,969	$2,804,507
Income from operations	68,244	62,399	88,263	82,530	80,923	70,819	93,513	91,604	301,436	336,859	310,719
Net income attributable to Select Medical Holdings Corporation	28,920	23,272	27,780	34,418	39,406	24,110	43,172	41,542	114,390	148,230	107,846
Income per common share:	'	'	'	'	'	'	'	'	'	'	'
Basic (in dollars per share)	$0.21	$0.17	$0.20	$0.25	$0.28	$0.17	$0.31	$0.29	$0.82	$1.05	$0.71
Diluted (in dollars per share)	$0.21	$0.17	$0.20	$0.24	$0.28	$0.17	$0.31	$0.29	$0.82	$1.05	$0.71
Select	'	'	'	'	'	'	'	'	'	'	'
Selected quarterly financial data (unaudited)	'	'	'	'	'	'	'	'	'	'	'
Net operating revenues	746,175	722,845	756,673	749,955	741,086	713,669	750,193	744,021	2,975,648	2,948,969	2,804,507
Income from operations	68,244	62,399	88,263	82,530	80,923	70,819	93,513	91,604	301,436	336,859	310,719
Net income attributable to Select Medical Holdings Corporation	$28,920	$23,272	$27,780	$36,608	$41,254	$25,953	$45,018	$43,279	$116,580	$155,504	$126,447

Schedule_II_Valuation_and_Qual1

Schedule II - Valuation and Qualifying Accounts (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance for Doubtful Accounts	'	'	'
Changes in valuation and qualifying accounts	'	'	'
Balance at Beginning of Year	$41,854	$47,469	$44,416
Charged to Cost and Expenses	37,423	39,055	51,347
Acquisitions	'	'	108
Deductions	-38,462	-44,670	-48,402
Balance at End of Year	40,815	41,854	47,469
Income Tax Valuation Allowance	'	'	'
Changes in valuation and qualifying accounts	'	'	'
Balance at Beginning of Year	13,341	15,733	16,622
Charged to Cost and Expenses	-2,794	-2,392	-889
Balance at End of Year	$10,547	$13,341	$15,733